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Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and 
mortality in the United States. Dietary habits may have an impact on COPD through anti-
inflammatory mechanisms. For this cross-sectional secondary data analysis study, the 
advanced model of the epidemiology triangle was used as a guide to assess the 
association between total daily flavonoid intake and COPD diagnosis, COPD severity, 
systemic inflammation, and comorbidity burden. Data from over 5,100 male and female 
participants aged 30 and older were obtained from the 2007-2010 National Health and 
Nutrition Examination Survey. The prevalence of COPD was 5.2% according to 
spirometry data. Multiple logistic regression analysis showed that a 1% increase in total 
daily flavonoid intake resulted in a 5.9% decrease (95% CI [0.940, 0.943]) in the odds of 
having COPD after controlling for age, BMI, dietary fiber intake, education level, gender, 
race/ethnicity, and smoking status. After controlling for the same variables, multiple 
linear regression analyses showed that a 1% increase in total daily flavonoid intake 
among those with COPD resulted in a .00001 (95% CI [.001, .002], p < .001) increase in 
the percentage of the predicted FEV1 and a 0.076% decrease in C-reactive protein (95% 
CI [-.078, -.074], p < .001). A one-way ANOVA showed that total daily flavonoid intake 
was significantly (p < .001) different for each comorbidity burden level, and those with 2 
or 3 comorbid diseases had significantly (p < .001) lower flavonoid intake than those 
with 1 or no comorbid diseases. These findings expand the knowledge of this topic and 
may effect positive social change by informing public health policies and interventions 
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Chapter 1: Introduction to the Study  
Chronic obstructive pulmonary disease (COPD) is a major public health concern, 
given its severe impact on morbidity and mortality in the United States and around the 
world. Ranked as the third leading cause of death in the United States, COPD is 
responsible for millions of hospitalizations each year (American Lung Association 
[ALA], 2014; Centers for Disease Control and Prevention [CDC], 2012a). Worldwide, 
COPD is likely to rank as the fifth leading cause of disease burden and the third leading 
cause of mortality by 2020 (Vestbo et al., 2013).  
As with many chronic diseases, individual behavior, including dietary habits, can 
influence COPD. Both healthy and unhealthy dietary habits appear to affect COPD. 
Healthy diets appear to decrease the risk of COPD, COPD severity, and comorbidity, 
while unhealthy diets seem to have the opposite effect (Annesi-Maesano & Roche, 2014; 
Mekary, 2015; Okubo et al., 2014; Root, Houser, Anderson, & Dawson, 2014; Shaheen et 
al., 2010; Varraso, Fung, Hu, Willett, & Camargo, 2007). Despite an apparent 
relationship between diet and COPD, it is unclear which specific components of a diet are 
the causative agents for these effects. Polyphenolic compounds known as flavonoids are a 
potential candidate responsible for the observed decreased risk of COPD attributed to 
diets high in fruits and vegetables (Celik & Topcu, 2006; Tabak, Arts, Smit, Heederik, & 
Kromhout, 2001). However, more research is needed in this area to elucidate this 
potential relationship between increased dietary intake of flavonoids and decreased 
COPD risk. Results from such research could be used by public health advocates to 
2 
 
develop interventions aimed towards reducing the disease burden of COPD, which would 
have positive implications for social change.  
This chapter includes an overview of the key components in this study. The 
introduction to the study includes a background review, the research problem, the study 
purpose, and the research questions. Additional facets of the study development, design, 
and impact presented in this chapter include the theoretical framework, nature of the 
study, definitions, assumptions, scope and delimitations, limitations, and significance.  
Background 
COPD disease is characterized as a progressive decrease in key measures of lung 
function, such as maximum expiratory flow and forced expiratory volume in the first 
second (FEV1), and includes an enhanced inflammatory response (Zhou et al., 2014). A 
diagnosis of COPD occurs most accurately using spirometry and assessing results related 
to forced vital capacity (FVC) and FEV1. Specifically, COPD involves having a ratio of 
FEV1 / FVC < 0.70 (Global Initiative for Chronic Obstructive Lung Disease [GOLD], 
2015). As COPD progresses, increases in disease severity include incremental increases 
in airflow limitation. Increases in airflow limitation decrease the FEV1 that an individual 
can produce. The four stages of COPD severity reflect the percentage of the predicted 
normal FEV1 (FEV1% predicted). FEV1% predicted values that are less than or equal to 
80% indicate mild COPD or Stage I, values of 50–79% indicate moderate COPD or Stage 
II, values of 30–49% indicate severe COPD or Stage III, and values less than 30% 
indicate very severe COPD or Stage IV (GOLD, 2015). 
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A sustained inflammatory response to tissue damage caused by repetitive 
inhalation of pollutants, such as cigarette smoke, ultimately drives COPD. During this 
process, cellular lung damage triggers the recruitment of inflammatory cells, which in 
turn signal the release of cytokines (Rovina, Koutsoukou, & Koulouris, 2013). 
Eventually, the release of more cytokines causes more tissue damage, which ultimately 
sustains a cycle of inflammation and cellular damage even after exposure to noxious 
particles and gases has ended (Lago et al., 2014; Rovina et al., 2013; Simpson et al., 
2013; Tuder & Petrache, 2012; Zuo et al., 2014). The clinical manifestations of COPD 
include chronic bronchitis and emphysema. Chronic bronchitis involves inflammation 
and remodeling within the large bronchial airways, and emphysema involves the distal 
airways and the loss of surface area and elasticity due to inflammatory processes, which 
limit gas exchange (Rovina et al., 2013; Tuder & Petrache, 2012).  
Beyond acute local inflammation within the lungs, research has indicated that an 
association may exist between COPD and systemic inflammation. In fact, an association 
does exist between COPD and increased serum levels of circulating inflammatory 
mediators such as C-reactive protein (CRP), interleukins 6 (IL-6) and 8 (IL-8), tumor 
necrosis factor-alpha (TNF-α), and fibrinogen (Agustí et al., 2012). Furthermore, an 
association exists between these inflammatory mediators and an increased risk of major 
comorbidities, such as hypertension, cardiovascular disease, ischemic heart disease, 
myocardial infarction, heart failure, diabetes, lung cancer, and pneumonia (Miller et al., 
2013; Thomsen, Dahl, Lange, Vestbo, & Nordestgaard, 2012). An association also exists 
between an increased accumulation of comorbidities and poor health outcomes, such as 
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increased mortality among people with COPD (Miller et al., 2013). Therefore, systemic 
inflammation has serious implications for compounded morbidity and mortality risk 
among COPD patients.  
Tobacco smoke is the predominant cause of COPD, and other causes can include 
prolonged exposure to air pollutants and alpha-1 antitrypsin (A1AT) deficiency (National 
Heart, Lung, and Blood Institute, 2013). A1AT is a circulating antiprotease produced by 
the liver that acts to protect lung tissue from damage associated with inflammation; a 
deficiency in the production of A1AT, caused by a rare genetic condition, can induce 
COPD (Caroll, 2014). The absence of functional A1AT ultimately leaves the lungs 
vulnerable to an insufficient inhibition of serine protease activity and repetitive 
uncontrolled proteolytic attack, which leads to alveolar destruction among those less than 
40 years old, regardless of environmental exposures, such as tobacco smoke (Olfert, 
Malek, Eagan, Wagner, & Wagner, 2014).  
Researchers have linked body mass index (BMI) to the onset and progression of 
COPD. For example, an association exists between a low BMI and a greater risk of 
COPD (Beiko, Paoletti, Strange, & Kumbhare, 2015; Zhou et al., 2013). An association 
also exists between lower BMI and greater severity of COPD (Mitra et al., 2013; 
Vanfleteren et al., 2013). Researchers still do not have a strong understanding of the 
primary underlying mechanism or cause for this association, but the association between 
BMI and COPD is likely due to losses in muscle mass from restricted physical activity 
and cachexia resulting from the limitations of a compromised respiratory system 
(Baarends, Schols, Mostert, & Wouters, 1997; Emtner, Hallin, Arnardottir, & Janson, 
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2015; Engelen, Schols, Does, & Wouters, 2000; Remels, Gosker, Langen, & Schols, 
2013).  
Like BMI, an association also exists between diet and COPD; however, the 
association with diet appears to be more than just a physiological response to the onset 
and progression of COPD. Ample evidence supports the premise that diet might affect 
COPD outcomes. For example, results from prospective studies have indicated that an 
association exists between a healthy diet rich in fruits and vegetables and a reduced risk 
of COPD (Mekary, 2015; Varraso, Willett, & Camargo, 2010). Researchers have also 
found an association between healthy diets and a reduced risk of a range of chronic 
comorbid diseases, including those linked to chronic systemic inflammation (Boeing et 
al., 2012; Chiuve et al., 2012; Li et al., 2014). Conversely, unhealthy diets rich in 
processed and cured meats are associated with increased COPD severity, decreased 
pulmonary lung function, and hospital readmission for COPD (De Batlle, Mendez, et al., 
2012; Mekary, 2015; Okubo et al., 2014; Root et al., 2014; Varraso & Camargo, 2014).  
Although researchers have linked dietary habits with COPD and its associated 
severity, systemic inflammation, and comorbidity, literature regarding the identification 
of a specific dietary constituent or component responsible for this observed effect is 
lacking. Some researchers have pointed to potential associations with select compounds, 
such as fiber and antioxidant micronutrients (Annesi-Maesano & Roche, 2014; Fonseca 
Wald, Borst, Gosker, & Schols, 2014). In fact, researchers have found that diets high in 
fiber intake have a protective effect against systemic inflammation (Esmaillzadeh & 
Azadbakht, 2012; Grooms, Ommerborn, Pham, Djousse, & Clark, 2013). Furthermore, 
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dietary fiber intake is associated with reduced COPD risk, better lung function, and fewer 
COPD symptoms (Butler, Koh, Lee, Yu, & London, 2004; Kan, Stevens, Heiss, Rose, & 
London, 2008; Van den Borst et al., 2012). The associations observed between dietary 
fiber and COPD are consistent with associations between fruit and vegetable intake and 
COPD. These similarities could arise because fruits and vegetables are sources of fiber, 
and there may be some overlapping or shared nutrients among these dietary components 
(Bentley et al., 2012; Boeing et al., 2012). However, there is no definitive consensus 
regarding any one nutrient or class of nutrients that fully explains the association between 
diet and COPD, although the class of dietary compounds known as flavonoids may be 
partly responsible for the protective effects observed between diet and COPD outcomes. 
These polyphenolic compounds are cytoprotective and exist in many dietary plants, 
including fruits and vegetables.  
The anti-inflammatory properties of flavonoids are attributed to their ability to 
attenuate inflammatory response by inhibiting the recruitment of inflammatory mediators, 
such as TNF-α, matrix-metalloproteinases 9, IL-8, and others (Kim et al., 2015; Li et al., 
2012). Researchers of multiple in vitro studies have pointed to specific mechanisms that 
may account for this effect (Esposito, Chen, Grace, Komarnytsky, & Lila, 2014; 
Ferlazzo, Visalli, Smeriglio, Cirmi, & Enrico, 2015; Flores et al., 2012; Ganesan et al., 
2010; Kim et al., 2011; Li et al., 2012; Lixuan et al., 2010; Weseler et al., 2009). 
Likewise, animal studies have also shown benefits associated with increased dietary 
flavonoid intake, including a reduced risk of COPD outcomes (Bao et al., 2013; Ganesan 
et al., 2010; Guan et al., 2012; Huang, Zhong, & Wu, 2015; Yang, Luo, et al., 2012). 
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Cross-sectional studies in humans involving Turkish and Dutch participants have also 
shown that dietary intake of flavonoids are positively associated with lung function and 
inversely associated with COPD symptoms, including coughing and breathlessness (Celik 
& Topcu, 2006; Tabak et al., 2001). However, researchers have conducted very few 
human studies examining the potential relationship between dietary flavonoid intake and 
COPD outcomes. Of the studies conducted in this regard, most have involved the 
participants from only one country, gender, or age group, while COPD outcome variables 
from large-scale studies have only included measures of lung function and COPD 
symptoms (Butland, Fehily, & Elwood, 2000; Butler et al., 2004; Garcia-Larsen, Amigo, 
Bustos, Bakolis, & Rona, 2015; Landberg et al., 2011; Tabak et al., 2001). Researchers 
have not yet explored the potential relationship between dietary flavonoid intake and 
COPD, COPD severity, systemic inflammation, and comorbidity using a large national 
sample of the U.S. population aged 30 years and older. In this study, I addressed this gap 
in the literature while also reinforcing findings noted in existing research. 
Problem Statement 
Few interventions are available to target the underlying factors contributing to the 
pathogenesis and pathophysiology of COPD. Anti-inflammatory treatments for COPD 
are limited, and health care providers treat many patients with inhaled corticosteroids 
(ICSs) or oral corticosteroids (Barnes, 2013). However, some COPD patients respond 
poorly to ICSs or oral corticosteroids, even at high doses (Barnes, 2013). Inhaled 
corticosteroids do not have a significant effect on the prevalence, progression, or 
mortality of COPD, despite minor reductions in COPD exacerbations (Li et al., 2012; 
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Yang, Clarke, Sim, & Fong, 2012). Specifically, ICSs do not reduce systematic 
inflammation, inflammatory cell counts, or inflammatory mediators in COPD patients 
(Singanayagam, Chalmers, Akram, & Hill, 2011). Therefore, I sought to explore 
alternative public health interventions to curtail the prevalence, progression, and 
morbidity of COPD.  
Diet affects the risk of COPD and COPD outcomes. Flavonoids may have at least 
a partial role in this effect due to their anti-inflammatory properties (Celik & Topcu, 
2006; Kim et al., 2015; Li et al., 2012; Tabak et al., 2001). Increased dietary intake of 
flavonoids may play a protective role in the development and progression of COPD and 
may represent a viable therapeutic option for COPD patients. However, researchers do 
not fully understand, and must further elucidate, the relationship between flavonoids and 
COPD in humans. Determining if an association exists between flavonoid intake and 
COPD diagnosis, COPD severity, systemic inflammation, or comorbidity burden would 
represent a major step forward in that regard.  
Purpose of the Study 
The purpose of this quantitative study was to explore the possible relationship 
between dietary flavonoid intake and COPD outcomes, systemic inflammation, and 
comorbidity among adults aged 30 years and older in the United States. The independent 
variable was total daily flavonoid intake, and the dependent variables were COPD 
diagnosis, FEV1% predicted, CRP serum level, and comorbidity burden. The CRP level 
and the number of comorbidities were suitable dependent variables because they are 
measures of systemic inflammation that served as indicators of COPD morbidity (Agustí 
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et al., 2012; Miller et al., 2013). In particular, comorbidities related to systemic 
inflammation among those with COPD include cardiovascular disease, hypertension, and 
type 2 diabetes (Miller et al., 2013). Covariates included age, gender, race or ethnicity, 
smoking status, education level, annual income group, BMI, and dietary fiber intake, as 
research has indicated that these are associated with the independent variable and study 
outcomes, and they might have confounded results (ALA, 2014; Beiko et al., 2015; 
Eisner et al., 2009; Fonseca Wald et al., 2014; Hooper et al., 2012; Marott & Lange, 
2013; Pistelli et al., 2012; Sebastian, Enns, Goldman, Steinfeldt, & Moshfegh, 2016; 
Zhou et al., 2013). This exploration of flavonoid intake and the development and 
progression of COPD using a nationally representative sample was necessary to gain a 
better understanding of the relationship between flavonoid intake and COPD in the 
United States.  
Research Questions and Hypotheses  
Research Question 1 (RQ1): What is the relationship between total daily 
flavonoid intake and COPD among adults? 
H01: There is no statistically significant association between total daily flavonoid 
intake and spirometry-diagnosed COPD among adult participants of the 2007–2010 
National Health and Nutrition Examination Survey (NHANES) after adjusting for 
relevant confounders. 
H11: There is a statistically significant association between total daily flavonoid 
intake and spirometry-diagnosed COPD among adult participants of the 2007–2010 
NHANES after adjusting for relevant confounders. 
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Research Question 2 (RQ2): What is the relationship between total daily 
flavonoid intake and COPD severity among adults? 
H02: There is no statistically significant association between total daily flavonoid 
intake and FEV1% predicted among adult participants of the 2007–2010 NHANES after 
adjusting for relevant confounders. 
H12: There is a statistically significant association between total daily flavonoid 
intake and FEV1% predicted among adult participants of the 2007–2010 NHANES, after 
adjusting for relevant confounders. 
Research Question 3 (RQ3): What is the relationship between total daily 
flavonoid intake and systemic inflammation among adults with COPD? 
H03: There is no statistically significant association between total daily flavonoid 
intake and the CRP serum levels among adult participants of the 2007–2010 NHANES 
with COPD after adjusting for relevant confounders. 
H13: There is a statistically significant association between total daily flavonoid 
intake and the CRP serum levels among adult participants of the 2007–2010 NHANES 
with COPD after adjusting for relevant confounders. 
Research Question 4 (RQ4): What is the relationship between total daily 
flavonoid intake and comorbidity burden among adults with COPD?  
H04: There is no statistically significant association between total daily flavonoid 
intake and comorbidity burden among adult participants of the 2007–2010 NHANES 
with COPD after adjusting for relevant confounders. 
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H14: There is a statistically significant association between total daily flavonoid 
intake and comorbidity burden among adult participants of the 2007–2010 NHANES 
with COPD after adjusting for relevant confounders. 
Theoretical Framework 
The advanced model of the epidemiology triangle served as the theoretical 
foundation and framework for this research study. The advanced model of the 
epidemiology triangle includes three key components that influence the occurrence of 
disease over time: causative factors, the group or population and their characteristics, and 
the environment and behavior (Merrill, 2009). The advanced model of the epidemiology 
triangle serves to encourage researchers to look beyond just causative factors, and to 
include other elements such as the environmental and behavioral factors that may work 
synergistically to bring about the occurrence of disease (Merrill, 2009). The 
environmental and behavioral components of the model in this study consisted of 
available food choices and dietary behavior. Applying this model to the current study 
supported the theoretical premise that changes in dietary behavior may affect the 
occurrence of COPD. The research questions and associated variables of this study 
aligned with the advanced model of the epidemiology triangle to facilitate my exploration 
of a potential relationship between flavonoid intake and COPD. For example, causative 
factors of the model were the variable for smoking status, and the population’s 
characteristics included socioeconomic and demographic variables, such as age, annual 
income group, education, gender, and race or ethnicity. Additionally, the variables for 
dietary fiber intake and total daily flavonoid intake indirectly represented the 
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environmental component of the model, as the environment often influences the 
availability of certain foods and dietary habits (Blitstein, Snider, & Evans, 2012; 
Gustafson, Christian, Lewis, Moore, & Jilcott, 2013; Swinburn et al., 2011). The research 
questions for this study were suitable for determining the relationship between these 
variables because they related to key components of the model. The study variables and 
research questions were suitable given the theory that changes in key components of the 
advanced model of the epidemiology triangle affect disease outcomes. Detailed 
information regarding this theoretical framework appears in Chapter 2. 
Nature of the Study 
In this study, I used a quantitative methodology and a cross-sectional approach. 
Quantitative research is suitable for assessing differences in prevalence and frequency of 
outcomes among groups, which was a key focus in this study as I attempted to address 
the research questions. Therefore, nationally representative retrospective data from 
publicly available datasets were suitable for determining if a relationship or an 
association exists between flavonoid intake and COPD outcomes. This quantitative 
analysis helped to determine if flavonoids might play a role in the development of COPD, 
COPD severity, systemic inflammation, and comorbidity. 
Definitions 
Body mass index (BMI): Body mass index provides a measure of nutritional status 
and body fat of an individual (National Heart, Lung, and Blood Institute [NHLBI], 2012). 
Values for BMI can serve as a guide to determine if people are underweight, normal 
weight, overweight, or obese. Calculating BMI involves using an individual’s weight in 
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kilograms and dividing that value by their height in meters squared (NHLBI, 2012). In 
this study, I included the BMI values obtained for participants in the 2007–2010 
NHANES. 
Cardiovascular disease: Cardiovascular disease is a term used to encapsulate 
several diseases and problems with the heart, blood vessels, and arteries often related to 
the process of atherosclerosis, which includes the build-up of plaque within arterial walls 
(ALA, 2014). Cardiovascular disease typically manifests as an occurrence of a heart 
attack or stroke (ALA, 2014). Many people with cardiovascular disease have not yet 
experienced an occurrence of a heart attack or stroke but are at increased risk for such an 
outcome. In this study, a self-reported physician diagnosis of an occurrence of stroke, 
heart attack, or congestive heart failure determined the presence of cardiovascular 
disease. 
Chronic obstructive pulmonary disease (COPD): Chronic obstructive pulmonary 
disease is a progressive disease that consists of airflow obstruction with an FEV1 / FVC 
ratio of < 70% that is not fully reversible (Drummond, Buist, Crapo, Wise, & Rennard, 
2014; Morrow et al., 2015). In the United States, the term COPD includes chronic 
bronchitis and emphysema, with most people diagnosed with COPD having both 
conditions (NHLBI, 2013). The presence of COPD among participants within the current 
study was determined using spirometry values. Those having a postbronchodilator FEV1 / 
FVC ratio of < 70% were confirmed as having COPD. 
Comorbidity: Comorbidity, also referred to as multimorbidity, refers to a person 
having more than one disease during a specific period (Valderas, Starfield, Sibbald, 
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Salisbury, & Roland, 2009). In most cases, comorbid diseases are long-term chronic 
conditions (Valderas et al., 2009). The comorbid diseases of interest in this study were 
cardiovascular disease, type 2 diabetes, and hypertension. Participants’ self-reported 
physician diagnosis determined the presence of each of these comorbid diseases. 
C-reactive protein (CRP): C-reactive protein is a protein produced in the liver as 
a response to inflammation within the body (MedlinePlus, 2015). C-reactive protein is a 
measure of systemic inflammation because circulating levels of this protein increase in 
the presence of inflammation. Values for CRP came from a laboratory analysis of blood 
samples from participants of the 2007–2010 NHANES. These CRP values were suitable 
for assessing systemic inflammation among participants in the study.  
Diabetes: Diabetes is a condition that entails having too much glucose present in 
the blood, which can cause nerve damage, blood vessel damage, and complications such 
as heart disease, stroke, blindness, and kidney disease (National Institutes of Health 
[NIH], 2014). There are two types of diabetes, often referred to as type 1 and type 2. 
Type 1 diabetes is as an inability to produce enough insulin to allow glucose to 
disseminate to cells within the body, while type 2 diabetes refers to insulin resistance by 
fat, muscle, and liver cells that can no longer use insulin (NIH, 2014). For this study, 
references to diabetes denote type 2 diabetes. Participant self-reported data determined 
the presence of diabetes.  
Dietary fiber: Dietary fiber refers to the undigested components of carbohydrates 
derived from plant-based foods, such as fruits, vegetables, grains, beans, and nuts (Hoy & 
Goldman, 2014). Dietary fiber provides bulk in an individual’s diet and contributes to the 
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feeling of satiety, which promotes gastrointestinal function, assists in managing weight, 
and reduces risk of chronic diseases (Hoy & Goldman, 2014). The measurement of 
dietary fiber intake for the foods and proportions consumed by participants of the 2007–
2010 NHANES was in grams, as determined by responses to 24-hour dietary recalls. The 
current study included the values obtained for dietary fiber intake during the 2007–2010 
NHANES. 
Flavonoids: Flavonoids are a diverse and ubiquitous group of polyphenolic 
metabolites found primarily in plant-based foods (Kozlowska & Szostak-Wegierek, 
2014). The major sources of dietary flavonoids are fruit, vegetables, nuts, and beverages 
such as tea (Corcoran, McKay, & Blumberg, 2012). Furthermore, flavonoids have 
antioxidant and anti-inflammatory properties (Kozlowska & Szostak-Wegierek, 2014). 
The flavonoid content values for foods reported in the 2007–2010 NHANES 24-hour 
dietary recalls came from the U.S. Department of Agriculture (USDA), which maintains 
a publicly available database of flavonoid content, and these values were suitable for use 
in the current study. Additional information appears in Chapter 3. 
Hypertension: Another common term for hypertension is high blood pressure. 
Hypertension or high blood pressure is a disease characterized as having a systolic blood 
pressure of at least 140 mm/Hg with a diastolic blood pressure of at least 90 mm/Hg 
(AHA, 2015). Hypertension increases the risk for adverse cardiac events due to vascular 
weakness, vascular scarring, and increased possibility of blood clots, plaque build-up, 
tissue and organ damage, and strain on the circulatory system (AHA, 2015). Self-
reporting indicated the presence of hypertension among participants for the current study. 
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Spirometry: Spirometry is a diagnostic test using a device called a spirometer that 
measures the amount of air an individual can exhale forcibly based on measures of FEV 
and FVC. The FEV1 / FVC spirometry value for an individual without obstructive disease 
is a ratio of ≥ 70%, and those with obstructive disease have a ratio of < 70% (GOLD, 
2015). FEV1 values are indicative COPD severity, with severity increasing as FEV1 
decreases. Additional information appears in Chapter 3. 
Total energy intake: Total energy intake refers to the total amount of calories 
consumed by an individual in a day (Evans, Jacques, Dallal, Sacheck, & Must, 2015). 
Responses to two 24-hour dietary recalls served to indicate total energy intake for the 
foods and proportions consumed by participants of the 2007–2010 NHANES. An average 
of the values obtained from each 24-hour dietary recall provided an estimate of total 
energy intake for participants in the current study. 
Assumptions 
In this secondary analysis of data from the NHANES, I assumed that all data 
came from a sample that was representative of adults in the United States. I also assumed 
that the collection of all study data, such as self-reports, CRP, spirometry values, and 
anthropometric values, involved using established guidelines and lacked measurement 
error. Further, I assumed that the average of two 24-hour dietary recalls, obtained as a 
part of the NHANES, was representative of a study participant’s typical dietary intake. It 
was not possible to rule out the chance that study participants may have altered their 
dietary habits in previous years, which may have had an impact on observed effects 
within the study. However, research has shown the use of multiple 24-hour dietary recalls 
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to be an acceptable method to determine average dietary patterns (Carroll et al., 2012; 
Freedman et al., 2011; Schatzkin et al., 2003). Further details appear in Chapter 3. 
Scope and Delimitations 
The scope of this study entailed obtaining information related to the association 
between total daily flavonoid intake and COPD among a representative sample of U.S. 
adults aged 30 and older. The scope included secondary data from the 2007–2010 
NHANES that I used to examine potential associations between flavonoid intake and 
COPD diagnosis, severity, systemic inflammation, and comorbidity. Potential 
confounders included age, annual income group, BMI, dietary fiber intake, education 
level, gender, race or ethnicity, and smoking status. I excluded individuals from the study 
who were missing spirometry measures and those who answered affirmatively to having 
asthma. Other participants were excluded from additional analyses related to COPD 
severity, systemic inflammation, and comorbidity burden if they had missing data, self-
reported responses of unknown, or refused to answer a question. A power calculation 
analysis for the study sample size appears in Chapter 3. A final boundary for the scope of 
this study was the statistical analyses I performed. Identifying the statistical analyses for 
this study a priori ensured that I could achieve my aims in this study without deviating 
from the intended scope. 
Limitations 
This study was subject to several limitations related to secondary data analysis 
and study design. The first limitation was my use of secondary data from a previously 
collected survey. Because the use of previously collected data does not allow an 
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opportunity to check the accuracy of the data, there may have been an increased 
likelihood of statistical error during secondary data analysis. However, CDC researchers 
have refined and validated the NHANES data collection methods and techniques over the 
course of decades (CDC, 2015a). Using data from an identifiable and reputable source 
such as the CDC minimized the chance for errors in data collection and subsequent 
statistical errors during analysis. Another key limitation of this study was the lack of 
long-term dietary information due to limitations of the 24-hour dietary recall instrument 
and the cross-sectional nature of the study design. It remains unknown whether dietary 
intake reported in the 24-hour dietary recall is reflective of dietary habits prior to the 
onset of COPD or if dietary changes took place after diagnosis, potentially even due to 
the diagnosis. However, the lack of long-term dietary data is an acceptable limitation 
because researchers have shown that long-term dietary habits are consistent with findings 
from 24-hour dietary recalls (Bertoia et al., 2015). Another limitation of the study was the 
lack of data for other measures of systemic inflammation in the NHANES, such as IL-6, 
IL-8, and TNF-α. However, the use of CRP is an acceptable measure of systemic 
inflammation among those with COPD (Baldrick et al., 2012). Finally, the cross-sectional 
design of this study limited my ability to establish causality between the independent 
variable and the dependent variables. However, this was an acceptable limitation because 
my aim was to pursue an understanding of potential associations between variables rather 
than to establish causation. 
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Significance of the Study 
Researchers have not conducted studies in the United States using a nationally 
representative population to assess the potential relationship between total dietary 
flavonoid intake and COPD, COPD severity, systemic inflammation, and comorbidity. 
Results from this study add to the current literature regarding this topic and provide 
further evidence of an association between diet and COPD. The results of this study have 
the potential to reinforce broader recommendations for maintaining a healthy diet high in 
fruits and vegetables, which supports a healthy lifestyle overall.  
There are numerous health benefits associated with the consumption of fruits and 
vegetables through anti-inflammatory and antioxidant interactions. For example, 
evidence indicates that diets high in fruits and vegetables are associated with a decreased 
risk of cancer, coronary heart disease, hypertension, stroke, dementia, certain eye 
diseases, and osteoporosis (Boeing et al., 2012). Americans fail to eat the amounts of 
fruits and vegetables necessary to maintain good health (Slavin & Lloyd, 2012). 
Therefore, the results obtained from this study support previous research related to the 
consumption of greater quantities of fruits and vegetables. Given the lack of anti-
inflammatory treatments addressing the underlying systemic inflammatory processes of 
COPD, the results of this research study have implications for managing flavonoid intake 
among COPD patients. Results from this study have additional implications for managing 




The increasing prevalence of COPD and associated morbidity and mortality 
represents a significant public health concern. The literature has indicated that diet might 
affect COPD; however, researchers do not understand the underlying cause of the effect. 
Micronutrients within certain foods may be responsible for the associations observed 
between diet and COPD. Given their anti-inflammatory and antioxidant properties, 
flavonoids were a viable target for further research to elucidate the relationship between 
diet and COPD, and my primary aim in this study was to determine the relationship 
between total daily flavonoid intake and COPD.  
The variables in this study aligned with the advanced model of the epidemiology 
triangle, which I used to assess the relationship between causative factors, the group or 
population and its characteristics, and environmental and behavioral components. For 
example, the environmental and behavioral components in this study were represented by 
the independent variable, total daily flavonoid intake. The study design included a cross-
sectional approach and a quantitative research methodology to analyze secondary data 
from the 2007–2010 NHANES. The scope of the study included examining potential 
associations between total daily flavonoid intake and COPD outcomes among a 
nationally representative sample of adults aged 30 years and older in the United States. 
The design of this study included several key assumptions and specific 
limitations; however, despite the limitations, the study contributes to the literature 
surrounding this topic. Key assumptions for this study included the expectation that data 
collected in the NHANES came from a nationally representative population, were 
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collected following accepted guidelines, and were free of measurement error. The 
limitations of the study did not inhibit my analysis of data or my ability to draw 
conclusions from the results, as the scope and design of the study minimized the impact 
of study limitations. The outcome of this study expands the current knowledge and 
understanding of the role that flavonoids may play in the development and progression of 
chronic diseases, such as COPD. Furthermore, the study results could influence policy 
decisions related to public health interventions, which may effect positive social change. 
Chapter 2 includes an overview of the literature search strategy and the theoretical 
framework for this study, and a review of the relevant literature related to flavonoid 
intake and COPD. Chapter 3 includes an outline of the research methodology, inclusive 
of the study variables and planned statistical procedures. Chapter 4 contains an in-depth 
review of the dataset preparation and statistical results from this study. Finally, the 
dissertation concludes with Chapter 5, which contains a discussion of relevant study 





Chapter 2: Literature Review 
Introduction 
COPD is a progressive disease consisting of emphysema, which involves damage 
to alveoli over time, and chronic bronchitis, which involves inflammation of the airways 
manifested by a long-term cough with mucus (Medline, 2014). COPD is characterized by 
a persistent and progressive reduction or obstruction in airflow due to prolonged and 
repetitive exposure to noxious gases or particles (NHLBI, 2013). Ultimately, exposure to 
these noxious gases or particles results in loss of airway and alveoli elasticity, destruction 
of the walls between alveoli, and overproduction of mucus within the airways (NHLBI, 
2013). COPD is also associated with a heightened chronic inflammatory response in the 
airways, exacerbation of symptoms, and development of comorbidities contributing to the 
level of severity within patients (GOLD, 2015). Common symptoms associated with 
COPD include dyspnea, chronic cough, and mucus production (Wheaton, Cunningham, 
Ford, & Craft, 2015). These symptoms are consistent with an inflammatory response and 
are consistent with the understanding that COPD is an inflammatory-based lung disease 
(Augusti et al., 2012). 
Oxidative stress and the persistent inflammation of the airways is one of the 
primary mechanisms involved in the pathophysiology of COPD (Augusti et al., 2012). 
Anti-inflammatory treatments for COPD are limited, and many patients are often treated 
with an ICS or oral corticosteroids; however, most COPD patients respond very poorly to 
these treatments (Barnes, 2013; Yang et al., 2012). Specifically, ICSs do not reduce 
systematic inflammation, inflammatory cell counts, or inflammatory mediator levels in 
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COPD patients (Singanayagam, Chalmers, Akram, & Hill, 2011). Therefore, alternative 
interventions are needed to provide anti-inflammatory relief in the management of 
COPD. There is a growing body of research indicating that dietary habits may influence 
the prevalence and severity of COPD through anti-inflammatory mechanisms. For 
instance, a higher intake of fruit and vegetables is associated with a decrease risk of 
COPD and improve lung function (Keranis et al., 2010; Boeing et al., 2012). There has 
been some speculation that flavonoids may be responsible for these beneficial outcomes 
related to COPD. 
Flavonoids are polyphenolic compounds known to have anti-inflammatory and 
anti-oxidant properties, and are abundant in fruits, vegetables, and nuts (Lago et al., 
2014). Researchers of in vitro studies have pointed to several mechanisms related to 
molecular signaling pathways that reduce the accumulation of inflammatory cells and the 
gene and protein expression of inflammatory mediators (Flores et al., 2012; Kim et al., 
2011; Li et al., 2012). Researchers conducting animal studies have demonstrated that 
some flavonoids, such as apple polyphenol and liqueritin apioside derived from licorice, 
reduced cigarette-induced lung inflammation and reversed oxidative stress in the lungs 
(Bao et al., 2013; Guan et al., 2012). Researchers of animal studies have also 
demonstrated the ability of flavonoids to inhibit the activation of inflammation-regulatory 
transcription factors in the expression of inflammation-mediating genes (Kim et al., 
2015). Results from studies with humans are supportive of findings from in vitro and 
animal studies (Celik & Topcu, 2006; Tabak et al., 2001; Siedlinski, Boer, Smit, Postma, 
& Boezen, 2012). Specifically, researchers have found that human dietary flavonoid 
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intake has a positive association with lung function in the general population and also is 
associated with a decreased occurrence of COPD and COPD symptoms (Celik & Topcu, 
2006; Tabak et al., 2001; Siedlinski, Boer, Smit, Postma, & Boezen, 2012). However, no 
studies have been conducted in the United States using a nationally representative 
population to test this association. 
My aim in this research was to explore the potential associations between dietary 
flavonoid intake and COPD in the U.S. population. Such a large-scale study of flavonoid 
intake should help to elucidate the role of these compounds in the health of the nation 
with regard to COPD. Furthermore, this study may also have implications for further 
understanding the impact that dietary flavonoid intake may have on other inflammatory-
based diseases, such as cardiovascular disease, diabetes, and hypertension. 
In this chapter, I present the literature search strategy, theoretical framework, and 
literature findings relevant to this study. The literature search strategy section of the 
chapter provides a description of the research databases, key search terms, and techniques 
I used to identify relevant literature. The theoretical framework section of the chapter 
highlights the application of the advanced model of the epidemiology triangle and how it 
informed my understanding of the potential relationship between variables in this study. 
The literature review section includes a discussion that highlights the existing gaps in the 
scientific understanding of the association between flavonoids and COPD. 
Literature Search Strategy 
I obtained the literature I summarize in this chapter from systematic searches for 
peer reviewed articles in PubMed, Google Scholar, and the CINAHL and MEDLINE 
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databases, which I accessed via the Walden University Library. Key search terms were 
selected to target articles relating to the independent and dependent variables. Search 
terms included COPD GOLD, COPD cost, COPD NHANES, COPD burden, COPD 
comorbidity, COPD prevalence, COPD flavonoids, diet COPD, fruits vegetables COPD, 
polyphenols COPD, flavonoids emphysema, flavonoids bronchitis, flavonoids 
inflammation COPD, flavonoids antioxidant COPD, flavonoids respiratory disease, 
flavonoids pulmonary, flavonoids lung, flavonoids lung function, flavonoids NHANES, 
and flavonoids airways. I conducted multiple searches using various combinations of 
these search terms. The initial search was restricted to English-language articles 
published between 2012 and 2016 that reported results from studies exploring COPD and 
flavonoid intake in the U.S. population. The scope of the initial search was then expanded 
to include results reported from studies using populations foreign to the United States, 
because I found that seminal research on this topic was conducted outside of the United 
States. 
After organizing the studies I found in the database searchers, I first examining 
human experimental and observational studies. Next, I reviewed in vitro studies of 
potential molecular mechanisms to support a biological basis for a potential association 
between flavonoid intake and COPD. Finally, I reviewed animal studies in the same 
regard. Full-text copies of the articles selected for this review were obtained directly from 
the publishing journal’s website or the Walden University Library. 
I identified additional articles by reviewing the list of references cited by authors 
of the articles from the initial searches, and by using Google Scholar’s option to review 
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“related articles.” Of these additional articles, only those articles that appeared relevant to 
the topic or seminal to the body of literature were included for review and synthesis. Full-
text copies of these articles were obtained as previously described.  
Theoretical Framework 
The advanced model of the epidemiology triangle includes three primary 
components that directly influence the occurrence of disease (Merrill, 2009). These 
components include causative factors, the group or population and its characteristics, and 
various facets of the environment, such as behavior, culture, physiological factors, and 
ecological elements (Merrill, 2009). The model posits that these components interact over 
time to determine the occurrence of chronic disease. As it relates to this study, causative 
factors in the occurrence of COPD included cigarette smoke, long-term environmental 
exposure to lung irritants, and A1AT deficiency. The study participants represented the 
group or population implicated in the occurrence of COPD, and the environment 
consisted of dietary behavior in the consumption of foods containing flavonoids, such as 
fruits and vegetables. The combination of these components over time can be used to 
describe the impact of flavonoid intake on the prevalence, severity, and morbidity of 
COPD. Theoretically, if the environmental component of the model was manipulated 
with regard to the quantity of flavonoid intake, then the occurrence of COPD may be 
impacted. 
Researchers applying the advanced model of the epidemiology triangle, as it 
relates to diet and COPD, have consistently acknowledged that cigarette smoke is not the 
only contributor to risk of COPD. For example, in a study of dietary antioxidants and the 
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risk of COPD, researchers examined multiple factors that served as proxies for 
environmental components of the advanced epidemiologic triangle, such as income level, 
education, and body mass index (Joshi, Kim, & Lee, 2015). Results of this study 
indicated that each of these environmental components were significant risk factors for 
COPD, but the risk of COPD was reduced as antioxidant consumption increased (Joshi et 
al., 2015). The strength and utility of the theoretical model was evident in how it allowed 
Joshi et al. (2015) to recognize the importance of examining multiple factors of the 
environment and how these environmental factors interacted with dietary antioxidants to 
impact the risk of COPD. Another strength of this model is that it allows researchers the 
flexibility to see how multiple components of the model interact to impact disease 
outcome. For example, results from researchers examining the relationship between 
causative factors, such as smoking, and environmental factors, like diet, have indicated 
that the combination of smoking and poor diet results in a higher risk of COPD as 
compared to individual factors alone (Bentley et al., 2012; Hanson, Root, Houser, 
Anderson, & Dawson, 2014; Rutten, Wouters, & Rennard, 2013). By linking causative 
factors and environmental factors, researchers could identify specific segments of the 
population most at risk for COPD, such as those who smoke and consume an unhealthy 
diet (Bentley et al., 2012; Hanson et al., 2014; Rutten et al., 2013). When examining the 
component of time in relation smoking duration and diet, researchers have found that 
those with longer smoking duration and diets low in fruits and vegetables have an 
increased risk of developing negative COPD outcomes (Bentley et al., 2012; Lange, 
Sparrow, Vokonas, & Litonjua, 2012). Ultimately, the greatest utility of this model is that 
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it allows for flexibility in the combination and pairing of the model’s components to 
assess the risk of disease outcome. Therefore, I deemed this model appropriate to serve as 
the theoretical lens through which I designed this study and analyzed its results. 
Literature Review Related to Key Variables/Concepts 
COPD Burden 
COPD is a major cause of illness and death in the United States. COPD is the 
sixth leading contributor to the total number of years lived with disability by people in 
the United States (Murray et al., 2013). COPD is also considered the primary contributor 
to mortality by chronic lower respiratory diseases and is ranked as the third leading cause 
of mortality in the United States, resulting in 134,676 deaths in 2010 (ALA, 2014; CDC, 
2012a). COPD became the third leading cause of death in the United States in 2008, 
which was more than 10 years sooner than projected by the Global Burden of Disease 
Study (Miniño, Xu, & Kochanek, 2010; Lopez et al., 2006). Additionally, COPD is the 
only leading cause of death among the top five causes that showed an increasing rate 
between 2010 and 2011 (Hoyert & Xu, 2012). The increasing morbidity and mortality of 
COPD in the United States is reflected as an increasing economic burden. It is estimated 
that the annual COPD-attributable cost to the United States is $36 billion, with 
projections for increases reaching $49 billion by 2020 (Ford et al., 2015). Given the 
disease and economic burden of COPD, it is important to fully understand its prevalence.  
Prevalence. The worldwide prevalence of COPD is not easily determined, given 
the lack of diagnostic testing and limited access to multiple regions and countries around 
the world. A leading estimate of COPD prevalence indicates that approximately 210 
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million people worldwide have COPD (Cruz, 2007). Most COPD-related deaths around 
the world are concentrated in low- and middle-income countries (World Health 
Organization [WHO], 2015). More than 3 million people died in 2012 due to COPD, 
which represents 6% of all deaths occurring around the world that year (WHO, 2015). 
Worldwide, COPD now affects men and women equally due to increased smoking 
among women in high-income countries and indoor pollution from the use of biomass 
fuel in low-income countries (WHO, 2015). Overall, the distribution of COPD in the 
global population, as it relates to age, gender, and exposure to noxious gases appears to 
be consistent with findings in the United States (Wheaton et al., 2015).  
In 2013, an estimated 15.7 million Americans reported being told by a physician 
or another healthcare provider that they had COPD (Wheaton et al., 2015). It is estimated 
that an additional 24 million people are undiagnosed and living with COPD as of 2011 
(ALA, 2014). According to self-reported diagnosis, the age-adjusted prevalence 
distribution is as low as 2.6% among individuals ages 18-36, and increases with each 
older age group to as high as 12.3% among those age 75 or greater (Wheaton et al., 
2015). Prevalence estimates according to clinical diagnosis using spirometry testing were 
14% overall for those aged 40-79 years, with higher prevalence rates among older age 
groups (Tilert, Dillon, Paulose-Ram, Hnizdo, & Doney, 2013). Given the linear 
distribution of prevalence across age groups, there appears to be a relationship between 
age and prevalence of COPD. Gender and smoking status also appear to be risk factors 
for COPD, as 2013 data from the Behavioral Risk Factor Surveillance System has 
indicated. For example, women have a higher prevalence of COPD than men at 6.6% 
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among women as compared to 5.4% among men (Wheaton et al., 2015). Additionally, 
COPD is found to be more common among those who are current smokers at 14.3% than 
among those who are former smokers or have never smoked at 7% and 2.8%, 
respectively (Wheaton et al., 2015). It is also important to note that 38% of adults with 
COPD are current smokers even though continued smoking contributes to increased 
mortality (Wheaton et al., 2015).  
Economic impact. Given the significant prevalence of COPD in the United 
States, the corresponding economic impact is substantial. As with most chronic diseases, 
the economic burden is not limited to only direct costs, but also includes indirect costs. In 
2010, the total estimated economic costs of COPD were $49.9 billion, with 
approximately $30 billion attributed to direct costs and $20 billion resulting from indirect 
costs (Boccia, Villari, & Ricciardi, 2015).  
Indirect costs include those costs associated with the morbidity and mortality 
caused by COPD, which includes the disabling effects of COPD, such as low 
productivity and missed days from work. Approximately 13%-18% of people with COPD 
have limitations in their ability to work or the type of work they perform (Patel, Nagar, & 
Dalal, 2014). Overall, the workforce participation range for those with COPD is 56%-
69%, as compared to 65%-77% for those without COPD (Patel et al., 2014). For those 
with COPD who can work, they are limited in the number of working days they can 
contribute due to the limitations of their illness. For example, the number of restricted 
activity days for those with COPD ranged from 27 to 63 days annually (Patel et al., 
2014). Additionally, the number of sick days per year ranged from 1.3 to 19.4, and the 
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number of bed confinement days was estimated to range from 13 to 32 days per year 
(Patel et al., 2014). Overall, COPD represents a significant burden for employers and 
employees due to lost productivity and loss of income, respectively (Patel et al., 2014). In 
1990, COPD was ranked as the twelfth leading cause of disability-adjusted life years 
(DALY) lost, accounting for 2.1% of all DAYLs worldwide (GOLD, 2015). Given the 
recent increase in prevalence, COPD is projected to become the seventh most prominent 
cause of DALYs lost worldwide in 2030 (GOLD, 2015). While indirect costs pose a 
considerable impact on the U.S. economy, it is the smallest contributor to the overall 
economic costs for COPD. 
Direct costs for COPD include those health care costs related to diagnosis, 
treatment, prevention, and rehabilitation in the form of physician services, 
hospitalizations, medications, and home healthcare. Of the overall direct costs for COPD 
in the United States, $13.2 billion are associated with hospital care, $5.5 billion result 
from physician services, $5.8 billion are associated with prescription drugs, $1.3 billion 
are associated with home healthcare, and $3.7 billion result from nursing home care 
(Blanchette, Dalal, & Mapel, 2012). There is a significant correlation between direct 
costs and severity of COPD, including the number of comorbid diseases associated with 
COPD (Emre et al., 2014; GOLD, 2015; Lazic et al., 2012; Vestbo et al., 2013). 
According to GOLD guidelines, COPD is divided into four stages of increasing severity 
(Vestbo et al., 2013). COPD Stages I, II, III, and IV correspond to a disease severity of 
mild, moderate, severe, and very severe, respectively (Vestbo et al., 2013). The total 
direct costs incurred for COPD increases as the stage of severity increases among COPD 
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patients. For example, Stage I patients incur the lowest direct annual cost of $1681, Stage 
II patients incur $5,037 in annual direct costs, and Stage III patients incur $10,812 in 
direct annual costs (Guarascio, et al., 2013). The economic burden of COPD will 
continue to increase as new diagnoses are made and the disease advances among those 
who already have the disease.  
Leading Causes 
COPD is primarily caused by exposure to tobacco smoke, which includes primary 
and second-hand smoke (NHLBI, 2013). Additionally, smoking is the cause of 80% of all 
deaths from COPD (Warren, Alberg, Kraft, & Cummings, 2014). Approximately 18 of 
every 100 people in the United States smoke cigarettes, and this proportion represents 
approximately 42.1 million people in the United States (Jamal et al., 2014). Cigarette 
smoke causes airway inflammation and oxidative stress (GOLD, 2015). Airway 
inflammation is a key characteristic of COPD and specifically involves neutrophilic 
airway inflammation (Simpson et al., 2013). As exposure to cigarette smoke through 
primary or second-hand smoke accumulates, it contributes to chronic inflammation and 
oxidative stress within the lungs, which are processes central to the pathogenesis of 
COPD (GOLD, 2015). The inflammation and oxidative stress initiated by exposure to 
cigarette smoke in the lungs is characterized as persistent and not fully reversible even 
after smoking cessation is initiated (Simpson et al., 2013; Zuo et al., 2014). With 
cigarette smoke established as the primary risk factor for developing COPD, it is 
important to note that approximately 25% to 33% of COPD patients are non-smokers 
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(Zeng & Zhong, 2012). Therefore, other causes of COPD must be considered aside from 
just smoking. 
Other causes of COPD include chronic exposure to noxious gases and pollutants, 
such as occupational dusts and gases and indoor pollution originating from the 
combustion of biomass fuel for cooking and heating (GOLD, 2015). Occupational 
exposures linked to the development of COPD include coal mine dust, breathable silica, 
agricultural dusts, metal fumes, specific flavoring chemicals, and second-hand smoke 
(Minov et al., 2014; Rose, 2013). Additionally, researchers conducting cross-sectional 
and longitudinal studies have demonstrated that occupational exposure to gases, dust, and 
fumes among those who have never smoked is independently and significantly associated 
with an increased risk of COPD (Hagstad et al., 2015;Torén, & Järvholm, 2014). During 
occupational exposure to dusts and chemicals, pro-inflammatory mediators, such as 
macrophages, are activated and subsequently stimulate other pro-inflammatory factors, 
such as nitric oxide, reactive oxygen species, and TNF-α (Gasparotto et al., 2013). With 
repetitive and prolonged exposure to dust and chemicals, the combination of 
inflammation and oxidative stress seems to be the contributing factor in the pathogenesis 
of COPD (Gasparotto et al., 2013). Ultimately, prolonged occupational exposure to 
noxious gases and dust limit lung function, obstruct airways, and lead to respiratory 
complications and diseases, including COPD (GOLD, 2015). 
Exposure to indoor pollution resulting from the use of biomass fuel was also 
found to be significantly associated with the development of COPD, particularly among 
women living in low to middle-income countries (Cheng et al., 2015; Da Silva et al., 
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2012; Diette et al., 2012; WHO, 2015). Fuels for combustion, such as firewood, charcoal, 
crop residues, and animal dung constitute biomass fuels (Cheng et al., 2015). The burning 
of biomass for fuel produces smoke containing fine particulate matter (PM) of less than 
2.5 μm in aerodynamic diameter (Da Silva et al., 2012). Exposure to biomass smoke 
(BMS) is significantly associated with an amplified prevalence of respiratory symptoms, 
reductions in pulmonary function, and onset of COPD (Da Silva et al., 2012). 
Furthermore, these effects are significantly correlated with the length and intensity of the 
exposure to BMS (Da Silva et al., 2012). Ultimately, BMS contributes to the 
pathogenesis of COPD by instigating an increase in acute inflammation and oxidative 
stress within the lungs while also increasing overall systemic inflammation (Silva, 
Oyarzun, & Olloquequi, 2015). As such, women exposed to BMS have higher alveolar 
levels of leukocytes and macrophages along with higher saliva and mucus levels of 
interleukin (IL)-6, IL-8, and TNF-α than women who do not utilize biomass as fuel 
(Banerjee, Mondal, Das, & Ray, 2012; Mondal, Bhattacharya, & Ray, 2011). 
Another important factor in the development of COPD is a rare genetic deficiency 
known as A1AT deficiency (NHLBI, 2013). A1AT is the only known genetic disorder 
that leads to COPD (Bhattacharjee, 2013). A1AT is considered a rare disorder, as it 
affects 1 in 1,500 to 3,500 people of European descent, and is uncommon among people 
with Asian ancestry (NIH, 2015). A1AT is a circulating antiprotease produced by the 
liver and acts to protect lung tissue from damage associated with inflammation (Caroll, 
2014). Low levels of A1AT in serum and lungs characterize deficiency in the production 
of this antiprotease, with a high risk for the development of emphysema approximately 
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between ages 30 and 59 (Bhattacharjee, 2013). A1AT deficiency ultimately causes an 
elastase imbalance through an inability to fully inhibit neutrophil elastase, which 
contributes to the development of severe COPD conditions, such as emphysema 
(Bhattacharjee, 2013). For example, in response to cigarette smoke, neutrophil elastase 
attack the alveolar wall matrix along with other proteases, which results in the release of 
elastin fragments and chemo-attractants, causing oxidative stress that intensifies 
inflammation and lung damage in emphysema (Bhattacharjee, 2013; Hoenderdos & 
Condliffe, 2013; Zuou et al., 2014). Therefore, as with the other causes of COPD, A1AT 
also contributes to underlying chronic inflammation and oxidative stress that brings about 
the onset of COPD. 
Effects of Diet on COPD 
Researchers have identified diet and nutrition as significant factors in the 
prevention, development, and progression of a wide array of chronic diseases, including 
hypertension, congestive heart disease, stroke, and cancer (Boeing et al., 2012; Chiuve et 
al., 2012; Li et al., 2014). Therefore, although exposure to tobacco smoke, air pollution, 
and genetic disorders are primary risk factors for COPD, it is important to explore the 
role that diet plays in the development and progression of this disease. In general, the 
literature demonstrates that diets high in fruit, vegetables, whole-meal cereals, and fish 
are associated with a reduced risk of COPD, while diets rich in cured and red meats, 
refined grains, and desserts are associated with an increased risk of COPD (Mekary, 
2015; Okubo et al., 2014; Root et al., 2014; Shaheen et al., 2010; Varraso et al., 2007). 
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An overall healthy diet has a positive effect on lung function in terms of airflow 
rate and lung capacity, as measured by FEV1 and FVC, respectively. For example, 
findings from a prospective cohort study of 15,567 Americans indicated that a healthy 
diet, according to the overall healthy eating index 2005 (HEI-2005), was positively 
associated with FEV1/ FVC ratio at visit 1 (β = .101) and visit 2 (β = .140) between 
quintiles of the HEI-2005 (Root et al., 2014). These findings are meaningful because each 
quintile decrease in HEI-2005 corresponded to the approximate equivalent of three years 
of decline in FEV1/ FVC found with age. The HEI-2005 is an index developed by the 
USDA to assess compliance with the 2005 Dietary Guidelines for Americans, which 
emphasizes an ideal healthy diet and provides standard scoring that measures compliance 
with each HEI-2005 dietary component (Guenther et al., 2006). The dietary components 
of the HEI-2005 included total fruit, vegetables, grains, whole fruit, and other items, such 
as legumes, beans, meats, oils, alcoholic beverages, and saturated fat (Guenther et al., 
2006). When examining the component HEI-2005 scores, Root et al. (2014) found that 
several dietary constituents were positively associated with lung function, such as, animal 
protein (β = .132 and .093) and dietary fiber (β = .129). Likewise, in a prospective cohort 
study of 73,228 female nurses and 47,026 male health professionals in the United States, 
researchers found that a higher Alternate Healthy Eating Index 2010 (AHEI-2010) score 
was inversely associated with risk of COPD, which provided further evidence of the 
positive effects of a healthy diet (Mekary, 2015). Higher AHEI-2010 scores are indicative 
of diets high in grains, polyunsaturated fatty acids, nuts, long chain omega-3 fats, and 
limited consumption of red meat, and processed meat (Mekary, 2015). A higher AHEI-
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2010 score was associated with lower risk of COPD (RR = 0.67, 95% CI [0.53-0.85]) 
when comparing the top and bottom quintiles (Mekary, 2015). The AHEI-2010 was an 
update to the HEI-2005 to align with the 2010 Dietary Guidelines for Americans. 
Updates made in the AHEI-2010 included the replacement of dark green and orange 
vegetables and legumes with greens and beans (Guenther et al., 2013). Additionally, fatty 
acids replaced oils and saturated fats while refined grains replaced total grains. Also, 
seafood and plant proteins were added to reflect subgroup choices for proteins (Guenther 
et al., 2013). Despite minor changes in the HEI from 2005 to 2010, results from the 
studies mentioned above indicate that a healthier diet is associated with better COPD 
outcomes (Roote et al., 2014; Mekary, 2015).  
A healthy diet is typically characterized as having a high intake of fruits, 
vegetables, and whole grains while maintaining a low intake of processed meats (Mekary, 
2015). However, it is important to note that the dietary intake of animal protein is 
associated with some health benefits relevant to COPD. In fact, animal protein was found 
by Root et al. (2014) to be positively associated with lung function, but the reference to 
animal protein in the study by Root et al. did not include processed meats and is 
consistent with findings by Mekary (2015). This distinction between animal protein and 
processed meats is noteworthy because other researchers demonstrated that diets high in 
processed meats have negative associations with a lung function (Okubo et al., 2014; 
Varraso, & Camargo, 2014). For example, a cross-sectional analysis of 1551 males and 
1391 females from the United Kingdom demonstrated that diets high in processed meat 
consumption showed a high correlation with lower FEV1 in men and women (Okubo et 
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al., 2014). However, this finding was more pronounced among men, with the difference 
in FEV1 between the first and fifth quintile of consumption at -170 mL (95% CI [−250, 
−80]; Okubo et al., 2014). Also, increased intake of cured meats among those with COPD 
impacts the rate of COPD-related hospitalizations (De Batlle, Mendez et al., 2012). For 
instance, researchers who conducted a prospective cohort study in Spain found that after 
adjusting for age, FEV1, and total caloric intake, a high intake of cured meat was 
associated with an increased risk (adjusted HR 2.02, 95% CI 1.31–3.12, p = 0.001) of 
hospital readmission for COPD (De Batlle, Mendez et al., 2012).  
Of the many components that make up a healthy diet, fiber intake seems to have 
generated the most interest among researchers. Fiber is negatively associated with COPD 
outcome and lung function (Lyden et al., 2015; Varraso et al., 2010). For example, 
researchers who conducted a prospective case-control study of 111,580 U.S. women and 
men found that total fiber intake was negatively associated with a risk (RR = 0.67, 95% 
CI [0.50-0.90], p = 0.03) of new COPD diagnosis for those with the highest intake of 
fiber versus those with the lowest intake (Varraso et al., 2010). Likewise, researchers 
who conducted a cross-sectional study using data from 1,929 participants in the 2009-
2010 NHANES dataset found that after adjusting for age, BMI, height, and smoking 
status, subjects in the highest quartile of fiber intake had values for FEV1 of 212 mL and 
FVC of 291 mL higher than the lowest quartile of fiber intake (Lyden et al., 2015). These 
results show that dietary fiber was associated with lung function in this study, which may 
have implications for the development and progression of COPD. However, this study 
was limited by the cross-sectional nature of the design and the reliance on participant 
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memory for reporting dietary intake and frequency patterns (Lyden et al., 2015). A 
systematic review conducted to assess the relationship between dietary fiber and COPD 
was supportive of the findings by Varasso et al. (2010) and Lyden et al. (2015). However, 
the review incorporated only nine articles, of which four reported on dietary fiber and 
five reported on fatty acids (Fonseca Wald et al., 2014). Based on these articles, the 
researchers ultimately concluded that greater intake of dietary fiber was consistently 
found to be associated with a reduced risk of COPD, healthier lung function, and 
attenuated respiratory symptoms (Fonseca Wald et al., 2014).  
Several studies with contrary results must also be considered. For example, 
researchers who conducted a prospective Korean study of 325 COPD patients and 6,781 
at risk participants found that dietary fiber intake was not significantly associated with 
COPD risk as a function of overall daily nutrients intake among men and women (Joshi 
et al., 2015). However, this study was limited by using a simplified clinical definition of 
COPD instead of a clinical diagnosis, which may have resulted in non-differential 
misclassification of COPD cases versus non-cases (Joshi et al., 2015). Additionally, 
dietary intake relied on participant recall of food frequency and portion, which could 
have resulted in biased responses (Joshi et al., 2015). Researchers conducted a Japanese 
case-control study of 278 COPD patients and 340 controls to assess the potential 
relationship between intake of fruit and vegetables and risk of COPD (Hirayama et al., 
2009). Despite finding high levels of insoluble fiber and total dietary fiber intake in this 
population, researchers found no significant association linking dietary fiber intake and 
risk of COPD (Hirayama et al., 2009). However, tt is important to note that this study 
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also relied on participant recall of past dietary patterns and proportions, which could be 
subject to recall bias. Additionally, the researchers admitted that their study was also 
subject to selection bias, as participation in the study was voluntary (Hirayama et al., 
2009).  
Given the findings regarding fiber intake and COPD, it is of interest to explore 
specific sources of fiber that have a significant association with COPD. Fruits and 
vegetables are the main sources of soluble and insoluble fiber and are found to have a 
strong association with a reduced risk of COPD (Bentley et al., 2012; Boeing et al., 
2012). For example, while the study by Hirayama et al. (2009) did not identify a 
significant association between total dietary fiber intake and reduced risk of COPD, a 
trend was identified linking higher total daily vegetable intake with COPD risk (ptrend = 
0.037). The prevalence of dyspnea, a common symptom of COPD, was also found to be 
lower among individuals with higher vegetable consumption (OR = 0.49, 95% CI [0.27-
0.88]; Hirayama, 2009). A prospective randomized controlled study of 120 participants 
with COPD was conducted to determine if a diet high in fruits and vegetables impacted 
lung function decline over 3 years (Keranis et al., 2010). Significantly lower FEV1 (p = 
0.03) was found among participants assigned to the high fruit and vegetable diet 
intervention as compared to participants assigned to the control group (Keranis et al., 
2010). Moreover, participants in the intervention group exhibited a significant lower 
average annual risk of COPD exacerbation as compared to participants in the control 
group (Keranis e al., 2010). When examining specific components of a healthy diet, it 
becomes apparent that certain components may be more strongly related to COPD risk 
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than others. Researchers studying the association between fruits and vegetables and 
COPD have focused on specific micronutrients found in fruits and vegetables (Baldrick et 
al., 2012; Hanson et al., 2013; Joshi et al., 2015; Rezaeetalab & Dalili, 2014). The 
micronutrients found in fruits and vegetables like antioxidants, such as vitamins A, C, D, 
E, and others, are speculated to be responsible for the positive associations observed 
between pulmonary function and COPD exacerbation (Keranis et al., 2010; Hirayama et 
al., 2009). Furthermore, researchers have demonstrated that vitamin A, C, D, and E are 
all independently associated with COPD (Annesi-Maesano & Roche, 2014; Hanson et al., 
2013). 
Researchers assessing biomarkers in humans have indicated that a relationship 
may exist between antioxidants and COPD outcome and severity (Lin, Wu, Chen, Hseih, 
& Yeh, 2010; Pirabbasi et al., 2012). For instance, researchers who conducted a case-
control study of 34 COPD patients and 43 controls in Taiwan demonstrated that plasma 
levels of vitamin antioxidants and total carotenoids were lower among those with COPD 
as compared to those without (Lin et al., 2010). Similar findings were observed in a 
cross-sectional study that explored the association between antioxidants, oxidative stress 
status, and lung function in 149 male COPD subjects in Malaysia (Pirabbasi et al., 2012). 
Serum vitamin C was below 0.4mg/dl in 86% of participants. Total antioxidant capacity 
was significantly (p = <0.05) lower among those with very severe COPD as compared to 
those with less severe stages of the disease (Pirabbasi et al., 2012). Additionally, low 
levels of vitamin A (p=0.012) and vitamin C (p = 0.007) were observed among those 
who were undernourished (Pirabbasi et al., 2012). Also, FVC percent predicted and 
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consumption of β-carotene were significant predictors (R2 = 0.104, p = 0.002) of total 
antioxidant capacity (Pirabbasi et al., 2012).  
Antioxidants may be protective against declines in lung function and risk of 
COPD, given their ability to attenuate oxidative stress caused by chronic inflammation 
within the lungs (Domej, Oettl, & Renner, 2014; Fischer, Voynow, & Ghio, 2015; 
Hanson et al., 2013; Rezaeetalab & Dalili, 2014). For example, post hoc analysis of a 
randomized double-blind placebo-controlled study involving 38,597 female participants 
throughout a 10-year follow-up period revealed a 10% reduced risk of COPD (HR = 0.90, 
95% CI [0.81-0.99], p = 0.029) among those randomized to the vitamin E intervention as 
compared to placebo (Agler, Kurth, Gaziano, Buring, & Cassano, 2011). Likewise, 
researchers who conducted a prospective Korean study of 325 COPD patients and 6,781 
at risk subjects found a negative association between risk of COPD and dietary intake of 
antioxidant vitamins when comparing the first quintile of intake to the fifth quintile (Joshi 
et al., 2015). The vitamins found to have significant negative association with COPD 
included vitamins C and E, especially among males (Joshi et al., 2015). Findings from 
this study also showed a significant positive association between intake of vitamin C and 
FEV1 (p = 0.04) and FVC (p = 0.03; Joshi et al., 2015). Furthermore, a positive 
association was also observed between vitamin E intake and FEV1 (p = 0.03) and FVC (p 
= 0.04; Joshi et al., 2015).  
Comparable findings regarding the protective association of micronutrients have 
also been observed among smokers. For example, researchers who conducted a 
prospective cohort study of 1,443 adults in the United States found that higher intake of 
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vitamin C and fruit and vegetables among smokers resulted in an 8 mL (p < 0.0001) and 
24 mL (p = 0.003) slower degree of annual deterioration in FEV1, respectively (Bentley 
et al., 2012). Researchers who conducted a prospective cohort study found that vitamin D 
may also reduce the rate of decline in FEV1 (Lange et al., 2012). Longitudinal analysis 
from this study revealed that rates of decline in FEV1 were significantly higher (p = 
0.023) among those with vitamin D deficiency when compared to those who had 
sufficient levels of vitamin D (Lange et al., 2012). Furthermore, a cross-sectional analysis 
of 626 male veterans from Massachusetts showed that lung function, measured by FEV1, 
FVC, and FEV1/FVC, was significantly (p ≤ 0.0002) lower among those who were 
vitamin D deficient (Lange et al., 2012). Analogous results were reported by researchers 
who conducted a cross-sectional population-based study of 1002 women in the United 
States to determine if an association exists between serum carotenoids and reduced lung 
function in older women (Semba et al., 2012). Findings showed that higher serum α- and 
β-carotene concentrations were positively associated with FEV1 (p < 0.05) and FVC (p < 
0.05), respectively (Semba et al., 2012). Additionally, total serum carotenoids were also 
significantly associated with FEV1 (p = 0.08) and FVC (p = 0.06; Semba et al., 2012).  
Many of the antioxidant-associated health benefits reported in the literature are 
attributed to the ability of these micronutrients to attenuate oxidative stress within the 
lungs (Domej et al., 2013; Hanson et al., 2013; Rezaeetalab & Dalili, 2014). Oxidative 
stress has a direct relationship with COPD through various mechanisms; however, the 
foremost mechanism is the amplified expression of pro-inflammatory genes that 
perpetuate long-lasting inflammation (Domej et al., 2013). Because chronic inflammation 
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is the central component in the pathogenesis of COPD, it is of interest to also explore the 
impact of diet on inflammation.  
Diet and inflammation. Diet has been implicated as a modulator of systemic 
inflammation. For example, dietary fiber may explain some of the variations in the 
distribution of systemic inflammation among those identifying as Hispanic, African 
American, and non-Hispanic White (Young & Hopkins, 2014; Young & Hopkins, 
2013a). This explanation is relevant to COPD because prospective research has 
demonstrated that between 50% and 70% of people who develop COPD and lung cancer 
have elevated systemic inflammation (Young & Hopkins, 2013b). Because Hispanic 
people have the highest intake of fiber while exhibiting the lowest rates of COPD, the 
association of fiber intake and systemic inflammation may hold some significance in 
assessing COPD risk (Young & Hopkins, 2013a).  
Researchers conducting cross-sectional studies have provided supporting 
information that demonstrates a significant association between higher levels of fiber 
intake and lower systemic inflammation (Esmaillzadeh & Azadbakht, 2012; Grooms et 
al., 2013). For example, researchers examining data from the 1999-2010 NHANES found 
that high fiber intake among the highest quintile, as compared with the lowest, was 
associated with lower systemic inflammation, obesity, and metabolic syndrome (Grooms 
et al., 2013). These associations remained significant after adjusting for confounding 
variables (Grooms et al., 2013). The strongest significant association (risk ratio = 0.66, 
95% CI [0.61-0.72] was found between high fiber consumption and lower systemic 
inflammation (Grooms et al., 2013). Likewise, in an Iranian cross-sectional study of 486 
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women, researchers found that high intake of fiber consisting of lentils, peas, chickpeas, 
various beans, and chickling vetch was inversely associated with serum concentrations of 
inflammatory biomarkers (Esmaillzadeh & Azadbakht, 2012). The researchers measured 
the consumption of the aforementioned foods, as these represent the main sources of fiber 
in the Iranian population (Esmaillzadeh & Azadbakht, 2012). Results from adjusted 
analyses indicated that the percentage difference found between the lowest and highest 
tertile was −39.2% (p < 0.001) for CRP, −15.9% (p = 0.04) for TNF-α, and −39.5% (p < 
0.01) for IL-6 (Esmaillzadeh & Azadbakht, 2012).  
Researchers have reported contradictory results when assessing the association 
between increasing fruit and vegetable intake and measures of oxidative stress and 
COPD-related inflammation (Baldrick et al., 2012). In a randomized controlled trial 
involving 454 UK participants, Baldrick et al. (2012) found no significant changes in 
systemic inflammation, measured by CRP, or systemic oxidative stress, measured by 8-
isoprostane, among those who received a 12-week intervention requiring intake of five or 
more servings of fruits and vegetables each day (Baldrick et al., 2012). However, this 
study was limited by a short intervention period, which prohibits generalizing results 
beyond short-term fruits and vegetables intake. Furthermore, the short intervention period 
may be responsible for yielding results that conflict with the findings of Keranis et al. 
(2010), as they utilized a 3-year intervention in their study.  
Fiber and antioxidants are the dietary constituents most widely implicated in the 
literature as having an associated with COPD (Fonseca Wald et al., 2014). The focus on 
these dietary components might be partially explained by the interrelatedness of fruit and 
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vegetables as good sources of fiber and antioxidant micronutrients (Annesi-Maesano & 
Roche, 2014). Overall, the beneficial effects of the foods found in a healthy diet may be 
attributable to more specific micronutrients, such as antioxidants in the form of vitamin 
A, C, D, and E (Hanson et al., 2013; Rezaeetalab & Dalili, 2014). In addition to these 
micronutrients, flavonoids have been proposed as one of the most potent compounds that 
may be responsible for the beneficial associations between diet and COPD (Lago et al., 
2012). 
Flavonoids 
Flavonoids are polyphenolic compounds that are ubiquitous in plant-based foods 
and are primarily abundant in fruits, vegetables, and teas (Birt & Jeffery, 2013). There are 
more than 5,000 unique flavonoid compounds, and they have been categorized into six 
major subclasses:  Flavones, flavonols, flavan-3-ols (flavanols), flavanones, 
anthocyanidins, and isoflavones (Corcoran et al., 2012). All flavonoids share the same 
fifteen carbon skeleton C6–C3–C6 chemical structure, with different substitutions that 
make up the various subclasses (Rodgriguea-Mateos et al., 2012). Figure 1 shows the 
basic three-ring chemical structure consisting of two benzene rings (A and B) that are 
linked by a third ring (C), which is a heterocyclic pyran ring (Kumar & Pandey, 2013a). 
The subgroups of flavonoids vary according to the level of oxidation and pattern of C 
ring substitutions, while specific compounds within a subgroup differ in the pattern of the 
A and B ring substitutions (Middelton Jr., 1998). The activities of various flavonoids are 
structure dependent with regard to their specific subgroup, the degree of hydroxylation, 
conjugations, and degree of polymerization (Kumar & Pandey, 2013a). Some flavonoids, 
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such as flavones and flavonols, occur naturally as aglycones; however, the majority of 
flavonoids are found stored within plants as glycosides (Corcoran et al., 2012). 
Flavonoids that occur as glycosides are characterized as being bound to one or 
more sugar molecules of the plants in which they are stored, and they are more stable 
than the flavonoids occurring as non-sugar aglycones (Corcoran et al., 2012). However, 
aglycones can be easily absorbed by the small intestine while flavonoid glycosides often 
require hydrolysis to convert into flavonoid aglycones before being absorbed in the small 
intestine (Corcoran et al., 2012; Kumar & Pandey, 2013a; Németh et al., 2003). After 
absorption takes place, the flavonoids are then conjugated in the liver or metabolized into 
smaller phenolic compounds. Given the liver conjugation reactions, no free flavonoid 
aglycones are found in plasma or urine, with the exception of catechins (Hollman, 2004). 
 
Figure 1. Basic flavonoid structure. Adapted from “Chemistry and biological activities of 
flavonoids: An overview,” by S. Kumar and A. Pandey, 2013, The Scientific World 
Journal, 2013 (pp. 2). Copyright 2013 by Shashank Kumar and Abhay K. Pandey. 
Reproduced with permission. 
 
The bioavailability of flavonoids has been noted as poor, with only less than 10% 
of the consumed flavonoids found to reach peak concentrations in circulation at 
nanomolar or low micromolar range within a few hours (Corcoran et al., 2012). The 
flavonoid subgroups that appear to have the most bioavailability are isoflavones, while 
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flavan-3-ols and anthocyanidins are the most poorly absorbed (Barnes et al., 2011; 
Kumar & Pandey, 2013a; Manach, Williamson, Morand, Scalbert, & Remesy, 2005). 
However, it is important to note that the bioavailability of flavonoids is not fully 
understood and further studies are needed to understand the factors that influence the 
process in vivo. Bioavailability can be influenced by various factors, including the 
presence of fiber, macronutrients, micronutrients, gastrointestinal transit time, gut 
microbiota, sugar moiety of flavonoid glycosides, dimerization, and food matrix (Corcora 
et al., 2012; Kumar & Pandey, 2013a). For example, if enzymes found in the small 
intestine do not hydrolyze flavonoids bound to dietary fiber, then their bioavailability 
may be extended and later degraded by colonic microbiota (Perez-Jimenez et al., 2009). 
Additionally, the homogenization and processing of some foods have been found to 
enhance bioavailability of flavonoids. For example, the flavonone naringenin is better 
absorbed from tomato-based products instead of fresh fruit (Porrini & Riso, 2008). 
Furthermore, the flavonoid content from green tea is absorbed rapidly after ingestion, as 
indicated by a significant rise in the level of plasma antioxidant status (Benzie, Szeto, 
Strain, & Tomlinson, 1999). Also, plasma concentrations of catechins have been found to 
reach levels of 637.1 μg/L (p < 0.001) following a meal with wine, fruit, and vegetables 
(Ruidavets et al., 2000). Such findings provide an indication that dietary intake of 
flavonoids can lead to increased serum levels of these compounds to a point at where 
they can execute a wide range of pharmacological effects. For instance, flavonoids have 
been documented to mediate antioxidant effects, chelate metals, and induce protective 
enzyme systems (Kumar & Pandey, 2013a). Additionally, flavonoids have been reported 
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to exhibit anti-proliferative, anti-tumor, anti-inflammatory, and pro-apoptic properties 
(Buer, Imin, & Djordjevic, 2010).  
Dietary intake of flavonoids. Understanding the dietary flavonoid intake of 
individuals in different settings is also key to further understanding the health effects of 
flavonoids. Several studies were conducted to estimate dietary flavonoid intake for 
various populations. For example, the mean flavonoid intake in South Korea was 
estimated to be 107 ± 1.47 mg/d among 11, 474 healthy adults aged 19 years older, with 
women having a significantly higher intake than men (Kim, Park, Chang, & Kwon, 
2015). In another study, researchers estimated the Brazilian population to have a mean 
flavonoid intake of 138.92 mg/day (Correa, Tureck, Locateli, Peralta, & Koehnlein, 
2015). In an Australian study of 79 participants aged 60 to greater than 80 years old, 
researchers found the mean dietary intake of flavonoids to be 638 mg/day (Kent, 
Charlton, Russell, Mitchell, & Flood, 2015). Finally, researchers conducted a study of 
flavonoid intake among approximately 30,000 Europeans from 14 countries aged 18 to 
64 years and estimated their mean flavonoid intake to be 428 ± 49 mg/day (Vogiatzoglou 
et al., 2015). Although, it is important to note there is considerable variation in mean 
flavonoid intake among individual European countries assessed in this study. For 
instance, the UK, Ireland, and Germany are among the lowest consumers of flavonoids 
among European countries (Vogiatzoglou et al., 2015). In fact, the average flavonoid 
intake in the UK and Ireland was assessed in a separate study by researchers who 
estimated flavonoid intake to be 182 mg/day and 177 mg/day, respectively (Beking & 
Vieira, 2011). Similarly, the mean flavonoid intake in Germany was found to be 181 
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mg/day, but this finding was greatly skewed, as the researchers noted the median was 
found to be 60-fold less at 3 mg/day (Vogiatzoglou et al., 2015). Ultimately, 
Vogiatzoglou et al. (2015) noted that their data was skewed because approximately half 
the population in Germany was found to consume negligible amounts of flavonoids.  
Beyond providing insight into the mean intake of dietary flavonoids among 
various populations within different countries, the results from the aforementioned 
studies also provide insight into demographic associations and leading sources of dietary 
flavonoids. For example, researchers found that gender is associated with flavonoid 
intake in some countries (Correa et al., 2015; Kim, Park, et al., 2015). Researchers 
reported that women consume greater quantities of flavonoids than men in South Korea, 
while men were found to have greater flavonoid intake than women in Brazil (Correa et 
al., 2015; Kim, Park, et al., 2015). Therefore, gender may be a significant factor to be 
considered when estimating flavonoid intake within any population. Also, dietary 
flavonoids appear to come from very different food sources in each of these countries. 
While South Koreans, Brazilians, Europeans, and Australians all obtain flavonoids from 
fruits and vegetables, the leading flavonoid food sources, such as kimchi, legumes, 
apples, oranges, and bananas, appear to vary based on availability within each country 
(Correa et al., 2015; Kent et al., 2015; Kim, Park, et al., 2015; Vogiatzoglou et al., 2015; 
Zamora-Ros et al., 2010; Zujko, Witkowska, Waśkiewicz, & Mirończuk-Chodakowska, 
2015). Among the Australian and European studies, tea was found to be the leading 
source of flavonoid intake in these countries (Kent et al., 2015; Vogiatzoglou et al., 2015; 
Zujko et al., 2015). Specifically, black tea accounted for 89% of flavonoid intake among 
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Australians (Kent et al., 2015). While South Koreans and Brazilians also consumed tea, 
but they did so to a lesser extent than Australians and Europeans. South Koreans and 
Brazilians obtain most of their flavonoid intake from other sources, such fruits and 
vegetables (Correa et al., 2015; Kim, Park, et al., 2015). Therefore, a lower intake of tea 
may partially explain the low flavonoid intake levels among South Koreans and 
Brazilians.  
Researchers have conducted several studies to assess flavonoid intake within the 
U.S. population with varying results for different time periods. For instance, results from 
an early study utilizing 24-hour dietary recall from the NHANES 1999-2002 and the 
2003 USDA Database for the Flavonoid Content of Select Food (DFCSF) indicated that 
the average flavonoid intake was 189.7 mg/day, with flavanols accounting for 83.5% of 
all flavonoids consumed (Chun, Chung, & Song, 2007). Results from a later study 
conducted to estimate the intake of flavonoids utilizing 24-hour dietary recall from 
NHANES 1988-1994 and the 2011 USDA DFCSF showed that average flavonoid intake 
among Americans was 344.83 ± 9.13 mg/day (Bai, Wang, & Ren, 2014). However, 
researchers who conducted a more recent study using the 2014 USDA DFCSF and data 
from NHANES 1999-2002 and 2007-2010 estimated that the average daily flavonoid 
intake of the U.S. population was 201.9 mg/day and 200.1 mg/day, respectively (Kim, 
Vance, & Chun, 2015). Despite changes in the estimated flavonoid intake within the U.S. 
from the aforementioned studies, the leading food sources contributing to flavonoid 
intake remained consistent across studies. In the US, tea was identified as the leading 
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contributor followed by wine, citrus juice, citrus fruits, and vegetables (Bai et al., 2014; 
Chun et al., 2007; Kim, Vance, & Chun, 2015).  
The proportional distribution of flavonoid intake across key demographic factors 
remained relatively constant across the 1988-1994, 1999-2002, and 2007-2010 NHANES 
populations. However, given the relevance of the findings from the 2007-2010 NHANES 
population to the current study, it is important to highlight the average daily flavonoid 
intake across gender, age, and race (Kim, Vance, & Chun, 2015). As such, men were 
found to have a slightly higher mean daily flavonoid intake (206.7 mg/day) than women 
(194.1 mg/day) in the 2007-2010 NHANES (Kim, Vance, & Chun, 2015). Additionally, 
mean daily flavonoid intake was highest among those aged 51-70 followed in descending 
order by those aged 31-50 years, 70 years and older, and 19-30 years (Kim, Vance, & 
Chun, 2015). Also, there are sharp contrasts in the estimated intake of daily flavonoid 
intake by race among participants in 2007-2010 NHANES (Kim, Vance, & Chun, 2015). 
Specifically, the mean daily energy-adjusted flavonoid intake for Whites, Blacks, 
Mexican-Americans, and Other are 218.6 mg/day, 157.6 mg/day, 123.5 mg/day, and 
185.2 mg/day, respectively (Kim, Vance, & Chun, 2015). Taken together, these findings 
indicate that age, gender, and race are be important demographic factors to consider when 
assessing mean daily flavonoid intake among participants in the 2007-2010 NHANES.  
Health benefits. Flavonoids are believed to promote good health through their 
high antioxidant capacity, as demonstrated in vitro and in vivo (Kumar, Mishra, & 
Pandey, 2013; Kumar & Pandey, 2013b). Flavonoids have been found to provide a wide 
variety of protective health effects across a broad range of chronic disease states related 
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to cardiovascular systems, neurology, urology, gastroenterology, metabolic disorders, and 
immunology among others (Andriantsitohaina et al., 2012; Can & Ozkay, 2012; Cote, 
Caillet, Doyon, Sylvain, & Lacroix, 2010; Hariprasath, Raman, & Nanjian, 2012; 
Nicolle, Souard, Faure, & Boumendjel, 2011; Peluso, Miglio, Morabito, Ioannone, & 
Serafini, 2015). These protective benefits are believed to result from antioxidant activity 
and the build-up of protective enzymes brought about through the mechanism of enzyme 
induction that follows flavonoid consumption (Hoensch &Oertel, 2015; Kumar & 
Pandey, 2013a).  
Reducing oxidative stress is a significant underlying mechanism contributing to 
protective effects of flavonoids against cardiovascular disease, which may also have 
implications for COPD (Kim et al., 2011; Kumar, Kant, Maurya, & Rizvi, 2012). 
Specifically, Kim et al. (2011) found that several flavonoids, such as epicatechin, 
avicularin, and quercitrin, derived from Lindera erythrocarpa protect cardiac muscle 
cells against cell death related to oxidative stress. Furthermore, in a study of hypertensive 
patients, researchers demonstrated that (-) epicatechin was found to have a significant (p 
< 0.001) protective effect against oxidative stress, which was induced by tert-butyl 
hydroperoxide on isolated erythrocytes (Kumar et al., 2012). The overall effect observed 
in this study was noted to be dose-dependent by the researchers (Kumar et al., 2012). 
Antioxidant properties of flavonoids also protect against the damaging effects of 
hyperglycemia while improving glucose metabolism (Nicolle et al., 2011; Qi, Liu, Su, & 
Yu, 2011; Tang et al., 2011; Zheng et al., 2011). For example, researchers conducting 
animal studies have demonstrated that flavonoid extracts from leaves of Boldoa 
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purpurascens and Phoenix dactylifera have produced anti-hyperglycemic activity in rats 
with alloxan-induced diabetes (Gonzalez Mosquera et al., 2013; Michael, Salib, & 
Eskander, 2013). Flavonoids also exhibit biochemical actions indicating anti-
inflammatory effects and the ability to influence the immune system (Peluso et al., 2015). 
The anti-inflammatory actions of flavonoids are suggested to result from several 
mechanisms of action, such as the inhibition of eicosanoid generating enzymes, the 
reduced production of pro-inflammatory molecules, and the modulation of pro-
inflammatory gene expression, which attenuates the inflammatory response (Garcia-
Lafuente, Guillamon, Villares, Rostagno, & Martinez, 2009). Flavanol-rich lychee fruit 
extract (FRLFE) supplementation, as part of a clinical trial, was found to be potentially 
protective against inflammation and tissue damage during extreme physical training 
(Nishizawa et al., 2011). The changes in serum IL-6 levels between pre-training and mid-
training among young healthy male athletes were found to be significantly lower in the 
FRLFE group compared to placebo (Nishizawa et al., 2011). Furthermore, results 
indicated that changes in transforming growth factor-β levels prior to training and after 
training were significantly greater among those in the FRLFE group compared to placebo 
(Nishizawa et al., 2011). In an animal study conducted to investigate the effect of icariin 
on the expression of Toll-like receptor 9, researchers found that icariin-induced the 
expression of Toll-like receptor 9 and its mRNA in murine macrophages (Li et al., 2011). 
Toll-like receptor 9 plays a pivotal role in the regulation of the innate immune response 
(Li et al., 2011). Additional findings from this study also showed that several systemic 
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immune response molecules, such as myeloid differentiation factor 88, TNF-α, and IL-6, 
were significantly modulated as a response to icariin stimulation (Li et al., 2011).  
These findings have implications for patients with COPD because major 
comorbid diseases associated with COPD are thought to result from increased systemic 
inflammation (Agusti & Faner, 2012; Divo et al., 2012; Smith & Wrobel, 2014). For 
example, cardiovascular disease, hypertension, and type-2 diabetes are the most common 
comorbidities associated with systemic inflammation among those with COPD (Miller et 
al., 2013). Flavonoids appear to reduce the risk of these and many other chronic diseases 
by attenuating various underlying inflammatory mechanisms and processes. For example, 
in an animal study using rats that were susceptible to stroke and spontaneous 
hypertension, researchers demonstrated that flavonoids could suppress age-related 
increases in blood pressure, decrease thrombotic tendency, and increase the production of 
NO metabolites in urine (Ikemura, Sasaki, Giddings, & Yamamoto, 2012). Also, 
flavonoids have been found to inhibit neuroinflammatory processes that contribute to the 
development of degenerative neurological disorders, such as Parkinson’s and 
Alzheimer’s disease  (Spencer, Vafeiadou, Williams, & Vauzour, 2012). For instance, 
methylalpinumisoflavone isolated from Cudrania tricuspidata was found to suppresses 
LPS-induced microglial activation and production of pro-inflammatory mediators by 
attenuating nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) 
signaling and by phosphorylation of mitogen-activated protein kinases (Lim, Hwang, 
Hwang, & Park, 2012). These findings are clinically significant because chronic brain 
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inflammation is ascribed to prolonged activation of microglial cells, which induce 
degenerative neurological events (Lim et al., 2012). 
The anti-inflammatory health benefits of flavonoids also extend to the 
genitourinary and gastrointestinal tracts. Researchers have reported that flavonoids have a 
positive effect on patients with prostatitis, urinary tract infections, and other similar 
events possibly through a reduction in inflammation (Cote et al., 2010; Katz, 2002; 
Theoharides, 2007). For example, a review of the flavonoids present in cranberries and 
cranberry juice has found anthocyanins, flavonols, the flavanols, proanthocyanidins, and 
phenolic acid derivatives work in a synergistic way to reduce inflammation and prevent 
bacterial infection within the urinary tract (Cote et al., 2010). The gastrointestinal 
benefits of flavonoids have been found to include the inhibition of gastric ulcers, 
intestinal inflammation, and inflammatory activity in human adenocarcinoma gastric cells 
(Hariprasath et al., 2012; Park, Ji, & Sung, 2012; Bulgari et al., 2012). In fact, researchers 
who conducted an animal study in mice found that dietary Kaempferol restricts 
inflammation of colitis in mice (Park et al., 2012). This finding is clinically significant 
because the reduction of inflammation is a key component in ulcerative colitis therapy 
(Park et al., 2012). Additionally, flavonoids demonstrated anti-inflammatory effects in 
human adenocarcinoma gastric cells during an in vitro study to determine if the anti-
inflammatory effects of chamomile infusion at the gastric level could be attributed to the 
inhibition of metalloproteinase-9 and elastase (Bulgari et al., 2012). Ultimately, results 
from this study indicated that the flavonoid-7-glycosides might account for the observed 
anti-inflammatory action of the chamomile infusion (Bulgari et al., 2012). Given these 
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and other findings related to the aforementioned comorbid diseases, increased flavonoid 
intake might potentially reduce the comorbidity burden associated with COPD.  
Flavonoids and COPD. Taken together, the health benefits of flavonoids appear 
to cover a broad gamut of disease states. Ultimately, it seems that many of these benefits 
are driven by the antioxidant and anti-inflammatory properties of flavonoids, as 
inflammation appears to be at the center of many chronic diseases, such as 
arteriosclerosis, obesity, diabetes, cancer, and others as described above (Garcia-Lafuente 
et al., 2009). COPD is also considered to be an inflammatory-based disease. In fact, 
chronic inflammatory and immune responses are established in the literature as leading 
contributors in the development and progression of COPD (Rovina et al., 2013). For 
example, COPD may be associated with systemic inflammation, given observed increases 
in levels of systemic inflammatory mediators among those with COPD (Augusti et al., 
2012). These biomarkers include white blood cells, CRP, IL-6, IL-8, TNF-α, and 
fibrinogen (Augusti et al., 2012). In the short-term, these inflammatory mediators 
facilitate the resolution of cell injury; however, if the cellular injury is repetitive or 
sustained, more inflammatory mediators are recruited, which cause added tissue damage 
and perpetuates the inflammation (Lago et al., 2014). Given the pathology of COPD, the 
antioxidant and anti-inflammatory structure activity of flavonoids has been purported to 
influence the development and progression of the disease (Lago et al., 2014). 
In vitro research. Many researchers conducting in vitro studies have explored the 
relationship between specific flavonoids and inflammatory cellular and molecular actions 
related to COPD. Researchers conducting in vitro research have documented the ability 
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of specific flavonoids or groups of flavonoids to inhibit or regulate the release of pro-
inflammatory enzymes, proteins, and genes in the cells of rodents and humans (Esposito 
et al., 2014; Ferlazzo, et al., 2015; Flores et al., 2012; Ganesan et al., 2010; Lixuan et al., 
2010; Weseler et al., 2009). For instance, researchers who conducted a study with four 
flavone C-glycosides from the neotropical blueberry, anthopterus wardii, found a dose-
dependent relationship with anti-inflammatory activity against IL-8 and with inhibiting 
matrix metalloproteinase (MMP)-1 expression in the small airway epithelial cells of 
humans (Flores et al., 2012). This finding is noteworthy because IL-8, like other 
cytokines, is a circulating inflammatory mediator associated with COPD-related 
inflammation and MMP-1, which are key contributors in the pathology of COPD (Flores 
et al., 2012). The inhibition of MMP-1 in human small airway epithelial cells is 
particularly significant because excess MMPs produced by inflamed epithelial cells in the 
lungs ultimately degrade the alveolar walls and lead to the development of emphysema 
(Lago et al., 2014). In an earlier study testing the impact of the flavonoid quercetin on 
cell cultures of murine alveolar macrophages, researchers found that quercetin also 
decreased the expression and activity of MMP-9 and MMP-12 by increasing expressions 
of the type III protein deacetylase Sirt-1 (Ganesan et al., 2010). Sirt-1 is a negative 
regulator of MMP transcription (Ganesan et al., 2010). This finding demonstrates that 
different subgroups of flavonoids exhibit similar cytoprotective and anti-inflammatory 
properties in vitro. 
In addition to inhibiting the expression of IL-8 and MMPs, research has also 
found that flavonoids can attenuate the expression of a much broader range of cytokines 
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associated with COPD progression and inflammation. For example, baicalin, a flavone 
obtained from the root of Scutellaria baicalensis Georgi, has exhibited the cytoprotective 
properties of flavonoids through documented in vitro inhibition of a range of cytokines 
(Li et al., 2012; Lixuan et al., 2010). In a study investigating the relationship between 
baicalin and COPD inflammation and mechanisms of anti-inflammatory effect, 
researchers noted that baicalin inhibited the pro-inflammatory expression of TNF-α, IL-6, 
IL-8, MMP-9, and NF-κB (Lixuan et al., 2010). In a later study investigating the effect of 
baicalin on respiratory inflammation of human lung adenocarcinoma epithelial cells, 
researchers also found that baicalin attenuates cigarette smoke-induced inflammation by 
reducing inflammatory cells and diminishing production of TNF-α, IL-8, and MMP-9 (Li 
et al., 2012). Furthermore, in an in vitro study of wild low bush blueberries, researchers 
found that polyphenol-rich, anthocyanin-rich, and proanthocyanidins-rich fractions of this 
blueberry’s crude extract were effective in suppressing interleukin 1 Beta (IL-1β), 
cyclooxygenase-2, and nitric oxide synthase in murine RAW 264.7 macrophage cells 
(Esposito et al., 2014). These findings demonstrate the capability of flavonoids to 
regulate the expression of pro-inflammatory genes and enzymes. These findings are 
significant because macrophages typically activate pro-inflammatory genes, such as IL-
1β, cyclooxygenase-2, and nitric oxide synthase, to up-regulate cytokine production in 
response to damage or infection (Esposito et al., 2014). Furthermore, researchers 
conducting a separate study showed that the flavonoids fisetin and tricetin, inhibitors of 
the nuclear enzyme poly(ADP-ribose) polymerase-1, could diminish lipopolysaccharide 
(LPS) induced increases in concentrations of TNFα and IL-6 in vitro using blood samples 
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from 10 male patients with COPD (Weseler et al., 2009). The authors attributed the 
attenuation of cytokine release to the poly(ADP-ribose) polymerase-1 inhibiting 
properties of fisetin and tricetin, which further demonstrates the range of pathways 
through which flavonoids can potentially disrupt the perpetual cycle of inflammation 
associated with the onset and progression of COPD.  
Flavonoids appear to further impact the pathophysiology of COPD through other 
mechanisms, such as the reduction of oxidative stress through free radical scavenging 
activity (Ferlazzo et al., Zhong et al., 2014). Specifically, researchers have demonstrated 
that the free radical scavenging activity of flavonoids can minimize the intracellular 
oxidative damage caused by reactive oxygen species, which are associated with 
inflammatory diseases, such as COPD (Ferlazzo et al., Zhong et al., 2014). For example, 
researchers who conducted an in vitro study to examine the effect of flavonoids from 
bergamot and orange juices on hydrogen peroxide-induced oxidative stress in human 
lung epithelial cells found that these flavonoids demonstrated antioxidant activities that 
may help reduce the damage caused by oxidative stress in the pathology of COPD 
(Ferlazzo et al., 2015). Specific results indicated that both juice extracts reduced the 
production of reactive oxygen species and membrane lipid peroxidation, which improved 
mitochondrial functionality and prevented DNA-oxidative damage in the A549 cells 
(Ferlazzo et al., 2015).  
Animal research. Animal studies have been conducted to reproduce the in vitro 
research described previously. Several in vivo animal studies have been conducted 
involving the administration of quercetin to mice and rats with acute lung inflammation 
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and acute lung injury (ALI) similar to that of COPD. Quercetin was found to suppress 
inflammation, oxidative stress, and mucus production and demonstrates overall 
therapeutic potential in the prevention of the disease (Ganesan et al., 2010; Huang et al., 
2015; Yang, Luo et al., 2012). Quercetin also suppressed inflammation, mucus cell 
hyperplasia, oxidative stress, epidermal growth factor receptor (EGFR) phosphorylation, 
and NF-κB signal pathway activation in a study to examine the protective effect of 
quercetin against cigarette smoke-induced mucin expression and inflammation in rats 
(Yang, Luo et al., 2012). These findings demonstrate that quercetin can attenuate mucus 
production and airway inflammation, which is consistent with the findings of other in 
vivo animal studies involving flavonoids (Lee et al., 2015; Xie, Dong, Wu, Yan, & Xie, 
2009). For example, an earlier study was conducted to investigate the effects of licorice 
flavonoids (LF) derived from the roots of Glycyrrhiza uralensis on lung inflammation in 
mice (Xie, Dong, Wu, Yan, & Xie, 2009). LF at doses of 3 mg/kg, 10 mg/kg, and 30 
mg/kg significantly decreased the production of inflammatory response cells in 
bronchoalveolar lavage fluid (BALF), such as neutrophils, macrophages, and 
lymphocytes (Xie et al., 2009). Additionally, LF was found to reduce neutrophil-
mediated oxidative injury by significantly increasing superoxide dismutase activity, 
which is the body’s primary antioxidant defense, while also significantly decreasing lung 
myeloperoxidase activity (Xie et al., 2009). Likewise, similar results were obtained from 
a study that explored the effect that casticin, a flavonoid extracted from Vitex Fructus, on 
cigarette smoke-induced acute lung inflammation in mice (Lee et al., 2015). Findings 
indicated that casticin significantly inhibits the amount of total cells, neutrophils, 
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macrophages, and lymphocytes while reducing the amount of pro-inflammatory 
cytokines and chemokines in BALF (Lee et al., 2015). Researchers conducting in vivo 
animal studies have shown that Quercetin can ameliorate LPS-induced ALI through 
suppression of inflammation and oxidative stress (Huang et al., 2015). For instance, in a 
study conducted to assess the effects of quercetin on LPS-induced ALI in rats, 
researchers found that quercetin significantly (p < 0.05) counteracted the four to five-fold 
rise in BALF levels of TNFα and IL-6 found in controls (Huang et al., 2015). 
Additionally, quercetin also significantly (p < 0.05) suppressed oxidative stress by 
increasing activities of superoxide dismutase, catalase, and glutathione peroxidase in the 
lungs of LPS-treated rats (Huang et al., 2015). Given these results, the researchers have 
asserted that quercetin might have therapeutic potential in the prevention of ALI, which 
has implications for COPD.  
Additional animal studies provide evidence that other flavonoids, in addition to 
quercetin, are also able to protect against LPS-induced ALI in vivo (Chen et al., 2013; 
Guan et al., 2012). For instance, researchers who conducted a study to investigate the 
therapeutic effects and mechanisms of Mosla scabra flavonoids (MF) on LPS-induced 
ALI in mice found that MF was protective against oxidative stress by lowering 
myeloperoxidase activity and total protein concentrations in the BALF (Chen et al., 
2013). Furthermore, was found to MF exhibit a protective effect against inflammation by 
reducing serum levels of NO, TNF-α, IL-1β and IL-6 in ALI model using mice (Chen et 
al., 2013). Comparable findings were identified in separate study exploring the beneficial 
effects of liqueritin apioside (LA), a main flavonoid component from Glycyrrhiza 
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uralensis, against lung epithelial cell injury in mice caused by cigarette smoke. Results 
from this study demonstrated that LA at doses of 3 mg/kg, 10 mg/kg, and 30 mg/kg 
inhibited pulmonary neutrophil and macrophage inflammation in a dose-dependent 
manner (Guan et al., 2012). Additionally, LA was found to reduce the pulmonary release 
of TGF- β and TNF-α, attenuate myeloperoxidase activity, and enhance superoxide 
dismutase activity (Guan et al., 2012). These results indicate that LA, like MF and 
quercetin, may protect against ALI related to COPD. 
In addition to effectively attenuating ALI and airway inflammation in vivo, 
researchers have also demonstrated that flavonoids have the potential to disrupt the 
progression of emphysema and chronic bronchitis in animal studies. For instance, in a 
study assessing the ability of quercetin to prevent the progression of emphysema in 
elastase/LPS-treated mice, researchers reported that quercetin effectively decreased lung 
inflammation, goblet cell metaplasia, mRNA expression of pro-inflammatory cytokines, 
the expression of MMP9 and MMP12, and levels of thiobarbituric acid reactive 
substances (Ganesan et al., 2010). The decrease in thiobarbituric acid reactive substances 
is significant because it is a measure of lipid peroxidation caused by oxidative stress 
(Ganesan et al., 2010). In this study, researchers reported that quercetin prevented the 
progression of emphysema in elastase/LPS-treated mice. A reduction in the progression 
of emphysema in mice during this study was marked by reduced oxidative stress and 
inflammation within the lungs. Additional markers of the attenuated progression of 
emphysema within mice during the study also included a reduction in the expression of 
MMP9 and MMP12. Similar findings were observed in studies assessing flavonoids 
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derived from Baccharis retusa, such as 5,6,7-Trihydroxy-4´-Methoxy-Flavanone (5,6,7-
FLA) and sakuranetin, in mice with emphysema (Pinheiro et al., 2012; Taguchi et al., 
2015). Findings from one study indicate that this flavanone significantly (p < 0.001) 
attenuated the total cells, macrophages, and lymphocytes in BALF while also 
significantly (p < 0.001) reducing collagen and elastic fibers contents in mice with 
emphysema as compared to controls not treated with 5,6,7-FLA (Pinheiro et al., 2012). 
Findings from a separate but similar study involving mice with emphysema indicated that 
sakuranetin also reduced the alveolar enlargement, collagen and elastic fiber deposition, 
and number of MMP9 and MMP12 cells (Taguchi et al., 2015). Additionally, findings 
from this study also indicated that administration of sakuranetin decreased inflammation 
and levels of TNF-α, IL-1β, and macrophage colony-stimulating factor in the BALF 
(Taguchi et al., 2015). These findings related to inflammation are consistent with findings 
from similar studies that have investigated other flavonoids, such as Baicalin and 
flavonoids derived from Broussonetia papyrifera (Ko, Oh, Jin, Son, & Kim, 2013; 
Lixuan et al., 2010). Baicalin was found to inhibit the pro-inflammatory effects of 
cigarette smoke exposure-induced COPD in rats by attenuating the release of IL-8, IL-6, 
and TNF-α (Lixuan et al., 2010). Additionally, a novel phytoformula containing 
Broussonetia papyrifera and Lonicera japonica was found to inhibit production of TNF-
α, interferon gamma, and IL-1β in mice with LPS-induced inflammation (Ko et al., 
2013). Furthermore, among mice with LPS-induced chronic bronchitis, Broussonetia 
papyrifera and Lonicera japonica significantly inhibited cell recruitment in BALF and 
reduced lung injury based on histological observation (Ko et al., 2013). Taken together, 
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the results from the studies described above demonstrate the ability of flavonoids to 
counteract lung remodeling, oxidative stress, and inflammation in vivo. These in vivo 
results also support the premise that flavonoids have a potential to interrupt the 
development and progression of COPD.  
 Human research. While interest in the therapeutic benefits of flavonoids is 
growing, human studies examining the potential association between dietary flavonoid 
intake and the development of COPD are lacking. However, the researchers that have 
conducted studies in humans suggest a potential relationship exists between flavonoid 
intake and COPD. A Turkish case-control study involving 40 male smokers diagnosed 
with COPD (Group-I) and 36 healthy male smokers without COPD (Group-II) was 
conducted to investigate whether nutritional risk factors were inversely associated with 
the development of COPD in male smokers (Celik & Topcu, 2006). The researchers 
noted that significant differences were observed between Group-I and Ggroup-II for the 
intake of black tea and fruits and vegetables (Celik & Topcu, 2006). Additionally, 
significant differences were also observed between Group-I and Group-II for breakfast 
habits and eating salty dietary constituents (Celik & Topcu, 2006). Also, the area under 
the receiver-operating characteristic (ROC) curve for black tea (0.898, 95% CI [0.819–
0.977]) and fruits and vegetables (0.833, 95% CI [0.727–0.938]) offered a significant 
degree of precision in distinguishing between the COPD group and the control group (p < 
0:001; Celik & Topcu, 2006). While flavonoid content in black tea and vegetables-fruits 
consumption was not directly measured, these foods were noted as having high 
concentrations of flavonoids (Celik & Topcu, 2006). The researchers suggested that the 
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high concentration of flavonoids may have been responsible for protecting male smokers 
in their study from developing COPD (Celik & Topcu, 2006). 
Researchers have also conducted several studies to assess the association of 
specific flavonoid intake and lung function, systemic inflammation, and symptoms 
related to COPD. Researchers who conducted the earliest cross-sectional studies found 
significant associations between flavonoids and COPD symptoms and lung function 
(Butland et al., 2000; Tabak et al., 2001). In a Dutch study of 13,651 adults aged 20 to 59 
years old, researchers found that increased consumption of catechins, flavonols, and 
flavones was associated with improved lung function, as measured by FEV1, and COPD 
symptoms, such as cough, phlegm production, and breathlessness (Tabak et al., 2001). A 
food frequency questionnaire was used to measure dietary intake of catechins, flavonols, 
and flavones among study participants. The estimated intake of these flavonoids was 
found to be 58 mg/day (SD = 46), with tea and apples identified as the main flavonoid 
food sources (Tabak et al., 2001). High dietary intake of these flavonoids was found to be 
beneficial against COPD symptoms and lung function measures. For example, dietary 
intake of catechins, flavonols, and flavones was found to have a protective significant 
associated with FEV1, chronic cough, and dyspnea (Tabak et al., 2001). Additionally, 
intake of catechins was independently associated with FEV1 (βQ5-Q1 = 130 ml, 95% CI 
[101-159]) and all COPD symptoms (OR Q5-Q1 = 0.74, 95% CI [0.58-0.94]) after 
researchers adjusted for potential confounding variables and the intake of flavonols and 
flavones. Flavonol and flavone intake was only independently associated with cough 
(Tabak et al., 2001). Similar results were later found by researchers who conducted a 
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cohort study of 63,257 Chinese men and women aged 45 to 74 years old to assess dietary 
factors impacting chronic respiratory symptoms, such as cough and phlegm (Butler et al., 
2004). Results showed that consumption of soy isoflavones significantly reduced new 
onset of cough and phlegm (OR = 0.67, ptrend = 0.001, 95% CI [0.53 – 0.86]; Butler et al., 
2004). A cross-sectional study using a prospective cohort of 2,512 Welshmen aged 45 to 
59 years old also yielded similar results related to lung function and the consumption of 
apples (Butland et al., 2000). Higher apple intake, consisting of five or more apples per 
week, was positively and significantly associated with FEV1 (Butland et al., 2000). 
Furthermore, the association between high apple intake and FEV1 was independent of 
other variables, such as consumption of vitamin E and vitamin C (Butland et al., 2000). 
The authors attributed this effect to the high quercetin content of apples, although 
quercetin content was not directly measured in this study (Butland et al., 2000).  
An association may also exist between flavonoid intake and measures of systemic 
inflammation. Researchers conducted a cross-sectional study of 2,115 women aged 43 to 
70 years to examine the relationship between intake of the six primary flavonoid 
subgroups and biomarkers of inflammation and endothelial dysfunction (Landberg et al., 
2011). Flavonoid intake was measured using a food frequency questionnaire, and 
inflammatory biomarkers were assessed using blood sample measurements of several 
biomarkers for inflammation, including CRP, IL-6, and IL-18  (Landberg et al., 2011). 
Multivariate-adjusted results indicated that mean plasma IL-8 levels were lower among 
participants grouped in the highest intake quintile for flavones, flavanones, and total 
flavonoids compared to participants grouped in the lowest intake quintiles (Landberg et 
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al., 2011). The difference in mean plasma IL-8 concentrations between the highest and 
lowest intake quintiles for each of the aforementioned flavonoid categories were “9% 
(Q1: 264 ng/L, Q5: 241 ng/L, ptrend = 0.019), 11% (Q1: 273 ng/L, Q5: 244 ng/L, ptrend = 
0.011), and 8% (Q1: 276 ng/L, Q5: 55 ng/L, ptrend = 0.034), respectively,” according to 
Landberg et al. (2011, p. 618). Overall, the results of this study demonstrated that various 
subgroups of flavonoids are associated with smaller amounts of systemic inflammatory 
biomarkers, which may have an effect on the chronic inflammation present in COPD. 
A relationship between dietary flavonoid intake and lung function has also been 
suggested, which may implications for COPD because declining lung function is a key 
characteristic of the disease. For instance, researchers conducted a cross-sectional study 
to assess the relationship between ventilator function and antioxidant components of 
1,232 Chileans aged 22-28 years found positive associations between lung function and 
flavonoid intake (Garcia-Larsen et al., 2015). Results indicated that total intake of 
catechins was positively correlated with FVC (regression coefficient of the highest versus 
lowest quintile of intake [RC Q5-Q1] = 0.07, 95% CI [0.01-0.15], ptrend = 0.006; Garcia-
Larsen et al., 2015). Additionally, total fruit intake was significantly associated with FVC 
(RC Q5-Q1 = 0.08, 95% CI [0.003-0.15], ptrend = 0.02; Garcia-Larsen et al., 2015). 
Furthermore, intake of omega 3 fatty acids was also found to be associated with higher 
FEV1 (RCQ5-Q1 = 0.08; 95% CI [0.01-0.15]; ptrend = 0.02) and with FVC (RC Q5-Q1 = 0.08, 
95% CI [0.001-0.16], ptrend = 0.04; Garcia-Larsen et al., 2015). The authors concluded 
that dietary constituents, such as fresh fruits, flavonoids, and omega 3 fatty acids might 
support and help to maintain overall lung function. Researchers reported similar results 
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when examining the association of curry intake and pulmonary function among 2,478 
Chinese adult smokers and non-smokers aged 55 and older (Ng, Niti, Yap, & Tan, 2012). 
Positive associations were present between curcumins, the flavonoids present in curry, 
and lung function (Ng et al., 2012). Consuming curry at least once per month was 
significantly associated with better FEV1 (b = 0.045 ± 60.018, p = 0.011) and FEV1/FVC 
(b = 1.146 ± 0.52, p = 0.029) in multivariate analysis (Ng et al., 2012). Additionally, 
increasing levels of curry intake were found to be associated with higher mean adjusted 
FEV1 (plinear trend = 0.001) and FEV1/FVC (plinear trend = 0.048; Ng et al., 2012). Also, 
significant effect modifications were identified for interaction between curry and 
smoking for FEV1 (p =0.028) and FEV1/FVC (p = 0.05; Ng. et al., 2012). Significant 
differences between FEV1 were also observed between curry consumption and non-
consumption among both current and former smokers (Ng. et al., 2012). In fact, 
consuming curry was associated with a 9.2% and 10.3% higher adjusted mean FEV1 
among current smokers and past smokers, respectively (Ng. et al., 2012). Similar findings 
were reported by researchers who conducted a longitudinal study examining the 
association of flavonoid intake and age-related lung function decline among 839 
participants from the Veterans Affairs Normative Aging Study (Mehta et al., 2016). In 
particular, Mehta et al. (2016) reported a slower decline in FEV1 by 22.5 mL/year (95% 
CI: 10.8, 34.2) for those who consumed two servings or more of anthocyanin-rich 
blueberries each week as compared to those who consumed less. Similarly, a slower 
decline in FVC by 37.9 mL/year was observed among those who consumed two servings 
or more of anthocyanin-rich blueberries weekly as compared to those who consumed less 
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(Mehta et al., 2016). Ultimately, the findings from Garcia et al. (2015), Ng. et al. (2012), 
and Mehta et al. are supportive of the findings noted in the earlier study by Tabak et al. 
(2001) regarding the association between flavonoid intake and lung function.  
Overall, findings from the in vitro, animal, and human studies reviewed above 
appear to provide support for the premise that a potential relationship may exist between 
dietary flavonoid intake and the development and progression of COPD. In particular, 
findings from human studies have demonstrated significant associations between dietary 
flavonoid intake and lung function, systemic inflammation, and COPD. Additionally, 
results from the in vitro and animal studies seem to provide support for the biological 
basis that a relationship may be present between dietary flavonoid intake and COPD 
outcomes.  
Measurement Tools 
 An accurate accounting of the types and quantity of food consumed is necessary 
to determine the relationship between diet and flavonoids. Additionally, and equally as 
important, a reliable source of data is necessary to estimate the total flavonoid content of 
the individual foods within a given diet. The combination of these two sources of data 
enables the assessment of flavonoid intake. However, the measurement tools for these 
data can vary, and some tools have limitations that must be considered. 
Dietary intake. Several measurement tools are available to measure dietary 
intake. Some of the more standard tools include 24-hour food recalls, food frequency 
questionnaires (FFQ), food screeners, and food record diaries covering multiple days. 
Each tool has specific strengths and limitations that are ideal under certain conditions and 
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when using specific study designs. For example, the 24-hour food recall allows for 
collection of detailed and quantified intake data, utilization among low-literacy 
populations, increased precision through multiple administrations, and utilization in 
large-scale cross-sectional studies (Castell, Serra-Majem, & Ribas-Barbara, 2015; Illner 
et al., 2012; Kirkpatrick et al., 2014). However, the limitations of this tool include the 
need for well-trained interviewers, multiple administrations to capture typical intake of 
foods, reliance on participant recall, and increased risk of random error (Castell et al., 
2015; Illner et al., 2012; Kirkpatrick et al., 2014). Also, if the 24-hour food recall is not 
administered at various times throughout the year, it may not account for foods that are 
eaten infrequently (Castell et al., 2015).  
Alternatively, the FFQ has strengths that include low administration costs, the 
ability to estimate individual intake in one administration, and the ability to capture 
dietary information for longer periods (Illner et al., 2012; Kirkpatrick et al., 2014; 
National Cancer Institute [NCI], n.d.). Because the FFQ captures dietary intake for longer 
periods, such as up to 1 month or 1 year, the FFQ may account for episodic or seasonal 
variations in dietary intake (Illner et al., 2012; Kirkpatrick et al., 2014). The FFQ is often 
used in retrospective case-control studies because it is a cost-effective method, typically 
involving one-time self-administration, for capturing past dietary intake data (Kirkpatrick 
et al., 2014; NCI, n.d). However, the FFQ is limited to a finite pre-specified food items 
list, which may not accurately represent all foods that an individual may have consumed, 
and this limitation can be a source of systemic measurement error (Illner et al., 2012; 
Kirkpatrick et al., 2014; NCI, n.d). Furthermore, the results captured by the FFQ are 
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prone to recall bias (Illner et al., 2012; Kirkpatrick et al., 2014; NCI, n.d). Other 
limitations of FFQs include lack of dietary details and limited quantification of portion 
sizes in some cases (Illner et al., 2012; Kirkpatrick et al., 2014; NCI, n.d.). Given these 
limitations, the use of an FFQ to describe the dietary intake of a population in cross-
sectional studies is not recommended (NCI, n.d).  
 Food screeners are more limited in scope than FFQs because screeners are 
developed to collect data on very specific dietary components or behaviors. As a result, 
food screeners have more weaknesses than the FFQ. Given the limited pre-specified food 
items list of food screeners, they are not ideal for estimating typical dietary intake 
(Kirkpatrick et al., 2014; NCI, n.d.). However, food screeners can be used in cross-
sectional studies and retrospective case-control studies when the dietary scope, study 
resources, and study duration are limited (Kirkpatrick et al., 2014; NCI, n.d.). In contrast, 
the strengths of the food diary record seem to surpass those of the 24-hour recall and 
FFQ. The strengths of the food record diary include the ability to encompass a longer 
intake time frame than the 24-hour recall, obtain quantified and detailed intake data, and 
provide a real-time accounting of intake (Illner et al., 2012; Kirkpatrick et al., 2014). 
However, the food record diary is limited by high respondent and responder burden, 
reliance on participant literacy, decreased compliance over time, altered eating habits due 
to reactivity, and potential selection bias due to exclusion of participants with low literacy 
(Illner et al., 2012; Kirkpatrick et al., 2014; NCI, n.d.).  
Of these various dietary measurement tools, the 24-hour food recall appears to be 
the most widely utilized in studies purposed with capturing quantified and detailed data 
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on flavonoid intake, particularly for the U.S. population (Bai et al., 2014; Chun et al., 
2007; Chun, Lee, Wang, Vance, & Song, 2012; Kim, Vance, & Chun, 2015). The choice 
to utilize a 24-hour food recall as the primary instrument in these studies appears to be 
based on the accuracy of this instrument in providing precise portion quantities, which is 
essential to determining the flavonoid content of reported food items (Bai et al., 2014; 
Chun et al., 2007; Chun, Lee, Wang, Vance, & Song, 2012; Kim, Vance, & Chun, 2015). 
One study used an FFQ instead of the 24-hour food recall to successfully estimate 
flavonoid intake at midlife in relation to healthy aging (Samieri, Sun, Townsend, Rimm, 
& Grodstein, 2014). However, the FFQ utilized in this study contained a component for 
standard portion size, which allowed researchers to estimate the quantity of flavonoid 
content for foods listed on the FFQ (Samieri et al., 2014).  
It is recognized that a single 24-hour dietary recall may not adequately capture 
typical micronutrient intake. Micronutrient intake can fluctuate due to certain factors, like 
the day of the week and cultural beliefs, which can impact the intake of certain foods 
(Chun & Davis, 2012; Chun et al., 2007; Ma et al., 2009). Utilizing multiple 24-hour 
recalls when reporting nutrient intake can improve the measurement tool’s ability to 
reflect typical nutrient intake in relation to health outcomes (Beydoun et al., 2015; Ma et 
al., 2009). Among studies utilizing the 24-hour food recall to assess the flavonoid intake 
of Americans, researchers have obtained mean values from two non-consecutive 24-hour 
food recalls obtained from the NHANES (Bai et al., 2014; Chun et al., 2007; Chun, Lee, 
Wang, Vance, & Song, 2012; Kim, Vance, & Chun, 2015). Researchers averaged results 
from the two 24-hour food recalls within the NHANES datasets to account for typical 
74 
 
intake patterns to improve the limitation of using a single 24 hour food recall 
administration (Bai et al., 2014; Chun et al., 2007; Chun, Lee, Wang, Vance, & Song, 
2012; Kim, Vance, & Chun, 2015). Overall, it appears that accurately estimating typical 
flavonoid intake necessitates utilizing more than one 24-hour dietary recall, and the 
dietary components of the 2007-2010 NHANES includes two 24-hour dietary recalls. 
However, it is acknowledged that two 24-hour dietary recalls cannot fully account for 
within-individual variations in typical dietary intake, which is a known limitation given 
the cross-sectional design of this current study. 
NHANES. Several large-scale population-based health surveys that address 
nutrition and health outcomes are publicly available. For example, questions related to 
the diagnosis of COPD are found within National Health Interview Survey, the 
Behavioral Risk Factor Surveillance System, and the NHANES. However, the dietary 
collection tools along with other health outcome and diagnostic components make the 
NHANES datasets ideal for conducting comprehensive secondary analyses. For example, 
the NHANES is particularly relevant, as it collects information related to COPD 
diagnosis, spirometric diagnostic testing, comorbid chronic diseases, and biological 
laboratory testing (CDC, 2015a). In fact, studies have utilized spirometry values and self-
report of physician diagnosis obtained from the medical conditions and examination 
components of the NHANES to successfully estimate COPD prevalence for the United 
States (Doney, Hnizdo, & Halldin, 2014; Telert et al., 2013). Furthermore, researchers 
have also utilized medical conditions component of the NHANES to identify and 
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determine if relationships exist between COPD and other comorbid diseases (Putcha, 
Puhan, Hansel, Drummond, & Boyd, 2013; Schnell et al., 2012).  
The NHANES has long attempted to provide nationally representative data since 
it began in the early 1960s as a series of surveys focused on various population groups 
and health topics (CDC, 2015a). As of 1999, the survey has changed to become a 
continuous program conducted every 2 years to allow for increased flexibility with 
survey changes and adaptations to meet emerging needs (CDC, 2015a). While earlier 
versions of NHANES were limited in the ability to provide accurate estimates of certain 
measures, such as dietary intake, more recent changes in the NHANES measurement 
protocols have improved upon attempts at obtaining more accurate measures. For 
example, the improvements to measurement protocols for dietary intake include the using 
two days of recall, obtaining recall on weekends in addition to weekdays, utilizing the 
multi-pass approach, providing enhanced training to survey administrators, and 
improving quality controls (Archer, Hand, & Blair, 2013; McDowell, Briefel, Buzzard, 
Gardner, & Warren, 1989). Additionally, each version of the NHANES now involves 
approximately 5,000 participants from various counties across the United States, of 
which 15 counties remain the same each year (CDC, 2015a). The validity and reliability 
of the data collected in the NHANES are enhanced due to various internal quality checks 
and supplemental guidelines on how to interpret and analyze the collected survey data 
(CDC, 2015a). The process of participant selection, administration of surveys and 
questionnaires, diagnostic testing, and use guidelines are well documented and 
continuously reviewed by government and private experts (CDC, 2015a). 
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Flavonoid databases. There are very few resources available to aid in the 
determination of flavonoid content in a wide variety of foods for all six flavonoid 
subclasses. The USDA provides the most complete sources for flavonoid content in a 
broad spectrum of foods. For example, the USDA Database for Flavonoid Content of 
Select Foods (DFCSF), Release 3.2, contains flavonoid content for 506 food items 
(USDA, 2015). However, the USDA DFCSF only provides flavonoid content for five 
subclasses of flavonoids, which include flavonols, flavones, flavanones, flavan-3-ols, and 
anthocyanidins. The USDA maintains a separate database for the sixth flavonoid subclass 
known as isoflavones. The USDA Database for Isoflavone Content of Select Foods 
(DICSF), Release 2.1, contains the data on the isoflavone content of 560 food items 
(USDA, 2015). The expansion of the DFCSF and DICSF formed the basis for the 
Expanded Flavonoid Database for the Assessment of Dietary Intakes (FDB-EXP), 
Release 1.1, which has flavonoid content data for 2,926 food items. The flavonoid 
content profiles for the food items in the FDB-EXP were generated by applying the 
analytical values for the flavonoids identified for the 506 food items in the DFCSF and 
the flavonoids identified for the 560 food items in the DICSF (USDA, 2015). Together 
these databases provide the basis for the most comprehensive information on flavonoid 
content of foods currently available (USDA, 2015). Only data generated by acceptable 
analytical procedures resulting in good separation of flavonoid compounds are included 
in the USDA flavonoid databases to ensure quality reporting for specific flavonoid 
compounds (USDA, 2015). As such, the USDA flavonoid databases have been widely 
used in several large-scale studies within the United States and other countries, such as 
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Australia, Germany, the UK, and Ireland to quantify the flavonoid content of specific 
foods (Bai et al., 2014; Beking & Vieira, 2011; Chun et al., 2007; Chun et al., 2012; 
Filiberto et al., 2013; Kent et al., 2015; Kim, Vance, & Chun, 2015; McCullough et al., 
2012; Samieri et al., 2014; Vogiatzoglou et al., 2013).  
As the most comprehensive source for flavonoid content of select foods, the 
USDA flavonoid databases have enabled researchers to make more accurate estimates of 
flavonoid intake (Chun et al., 2012). For example, studies utilizing other sources to 
quantify flavonoid content of select foods prior the release of the DFCSF have reported 
lower estimates of flavonoid intake due lack of complete data for all flavonoid subclasses 
(Chun et al., 2012). For example, estimates of flavonoid intake using food tables from the 
Department of Nutrition at Harvard School of Public Health for postmenopausal women 
and middle-aged and older women were 24.6 mg/day and 21.2 mg/day, respectively (Lin 
et al., 2007; Sesso, Gaziano, Liu, & Buring, 2003). The food tables provided only 
flavonol and flavone content for several foods based on data initially produced in the 
Netherlands, but updated to include American foods (Sesso et al., 2003). Ultimately, the 
estimates of flavonoid intake by the aforementioned studies were likely underreported 
because only two subclasses of flavonoids, flavonols and flavones, were included due to 
the limitations of the flavonoid measurement tools that were used. These estimates were 
approximately ten times less than a more accurate estimate of 268 mg/day for men and 
women of similar age calculated using the DFCSF and DICSF, which included a broader 
and more comprehensive range of flavonoid subclasses (McCullough et al., 2012). 
Therefore, it is apparent that utilizing a current and comprehensive source for flavonoid 
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content in foods is essential to calculating accurate estimates of flavonoid intake, and the 
DFCSF and DICSF are appropriate sources in this regard. 
Summary and Conclusions 
COPD represents a significant disease burden and a major public health concern 
within the United States and around the world. In addition to the individual toll that 
COPD can take on those with the disease, this condition also has economic disadvantages 
manifested as losses in productivity and increases in medical expenditures. A wide range 
of research indicates that overall diet and the intake of specific foods can affect the onset 
and progression of COPD. However, it is still uncertain what specific dietary components 
and mechanisms of action are responsible for these effects. Research has suggested that 
there may be a relationship between high flavonoid intake and COPD outcomes. 
Furthermore, many of the foods found to have significant associations with COPD are 
noted to contain a high quantity of flavonoids, which adds further support to the 
suggested relationship between flavonoids and COPD. In general, no studies have been 
conducted that directly examined the potential relationship between dietary intake of 
flavonoids and COPD diagnosis, COPD severity, systemic inflammation, and 
comorbidity burden within the U.S. population. 
The NHANES and USDA flavonoid databases presented a novel opportunity to 
address this gap in the literature. The data from the NHANES allows for an accurate 
assessment of diet, COPD diagnosis and severity, systemic inflammation, and associated 
comorbidities within the general population. The combination of the NHANES data with 
that of the USDA flavonoid databases enabled the quantification of flavonoid intake as it 
79 
 
relates to specific COPD outcomes. Therefore, my aim with this study was to examine 
the potential relationship between total daily flavonoid intake and COPD. The design and 
methodological approach that I used in this study are described in the following chapter. 
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Chapter 3: Research Method 
Introduction 
This chapter includes a review of the study design and rationale I used to explore 
the potential effects of dietary flavonoid intake on the diagnosis, severity, and 
comorbidity of COPD among a sample of the U.S. population aged 30 years and older. I 
also present the methodology for this study, including a description of the population and 
sampling procedures used in the 2007-2010 NHANES. Furthermore, the methods for 
dietary and COPD data collection are reviewed, and the operationalization of variables 
are discussed in this chapter. Similarly, I describe the methodology for determining 
flavonoid content of selected foods using the USDA flavonoid databases, and provide a 
comprehensive explanation of the data analyses and statistical procedures employed to 
test the study hypotheses. Finally, I discuss the ethical considerations in this research 
study.  
Research Design and Rationale 
This was a quantitative, cross-sectional study using data from the 2007-2008 and 
2009-2010 iterations of NHANES in conjunction with expanded flavonoid data from the 
USDA’s DFCSF, Release 3.2 (September 2015, Slightly revised November 2015) and 
DICSF, Release 2.1 to test the association between dietary flavonoid intake and COPD. I 
selected these NHANES datasets because they provide comprehensive data using a large-
scale sample of participants who are representative of the population of the United States. 
Also, these specific iterations of the NHANES are the most current surveys that include 
laboratory testing and reporting of CRP, which was a key variable in the assessment of 
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systemic inflammation for this study. The USDA’s flavonoid databases were the most 
robust databases available for the flavonoid content of foods. The use of these flavonoid 
databases and the NHANES dataset together allowed for the appropriate assessment of 
the research questions for this study. 
Cohort, case-control, and cross-sectional non-interventional study designs are all 
appropriate for use when the units of observation are individuals, and the research 
questions are designed to identify associations with health outcomes rather than establish 
causation (Szklo & Nieto, 2014). I selected a cross-sectional design for this study because 
this design is well aligned with the quantitative nature of the research questions. Cohort 
and case-control studies require multiple measurements for study outcomes over a long 
period of time and significant resources, which are prohibitive constraints for a large 
population-based study (Szklo & Nieto, 2014). In contrast, cross-sectional study designs 
only require data to be captured at one point in time and also provide the opportunity to 
assess exposure and outcome associations (Szklo & Nieto, 2014). However, it is not 
possible to identify temporal relationships and trends or establish causation when using a 
cross-sectional study design. Despite these limitations, a cross-sectional design was the 
most appropriate for this study based on feasibility, logistics, and efficiency, as compared 
to other viable non-experimental designs. 
Methodology 
Population 
The subjects included in this study were participants in the 2007-2010 NHANES, 
and their data were obtained from the publicly available 2007-2010 NHANES datasets 
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(CDC, 2015b; CDC, 2015c). The 2007-2010 year range encapsulates two distinct 
NHANES datasets, those from 2007-2008 and 2009-2010. The sample size for the 2007-
2008 NHANES was 10,149, and the sample size for the 2009-2010 NHANES was 
10,537. Taken together, the total sample size for the 2007-2010 NHANES was 20,686. 
The NHANES aims to include a sample population that is representative of the non-
institutionalized U.S. population. Therefore, the NHANES includes participants ranging 
in age from less than 1 year old to 80 years or older from various races and ethnicities 
(CDC, 2015b; CDC, 2015c). In this cross-sectional analysis, the sample population 
excluded participants aged 29 years and younger, as COPD is a progressive disease with 
symptoms manifesting later in life. While the majority of COPD cases are diagnosed at 
40 years and older, the inclusion of participants 30-39 years old in the current study was 
relevant because COPD is found among younger patients within this age range (Wheaton 
et al., 2015). 
Sampling Procedures 
The 2007-2010 NHANES used a complex probability sampling design consisting 
of multiple stages to select study participants who are reflective of the non-
institutionalized, civilian population of the United States (CDC, 2013b). The NHANES 
sampling procedures consisted of a four-stage process starting with the selection of 
primary sampling units (PSUs), which included individual counties or clusters of 
adjoining counties. The PSUs were segmented into smaller area groupings of households 
from which a sample was randomly drawn (CDC, 2013). One or more individuals from 
these households were selected at random to participate. During this process certain 
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demographic groups, such as those identifying as Hispanic, non-Hispanic Black, low-
income White, and people aged 80 years and older were oversampled to provide 
dependable and precise estimates of health status indicators that assist with public health 
measures of relevance for these subgroups (CDC, 2013b). Therefore, each participant 
was assigned a sample weight to produce unbiased national estimates. This complex 
sampling strategy was well validated, justified, and documented for all iterations of the 
NHANES, including the 2007-2010 iterations (CDC, 2013b). 
I included as many participants from the 2007-2010 NHANES datasets as 
possible to ensure an appropriate sample size. Participants were included in this study if 
they performed spirometry testing to determine the presence of COPD, had responded 
negatively to having a diagnosis of asthma, and had complete dietary data to assess 
flavonoid intake. Participants without acceptable measures for FEV1 and FVC and CRP 
measurements were excluded from the severity analyses and systemic inflammation 
analyses, respectively. Those patients without an affirmative or negative response when 
providing a self-report of cardiovascular disease, diabetes, and hypertension were 
excluded from the comorbidity analysis. In Chapter 4 I provide further details regarding 
the composition of the final study sample, given the application of exclusion criteria. 
Data collection. The data from the 2007-2010 NHANES, as in other iterations of 
this national survey, were collected from participants through interviews, diagnostic 
testing, and medical health examinations. Interviews were conducted in participants’ 
homes by trained interviewers who administered all questionnaires for the household 
interview component, which included screener, family, and sample person interview 
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questionnaires (CDC, 2015a). The screener questionnaire was used to determine 
household eligibility and the relationships between all household residents. The family 
questionnaire was used to obtain family and household-level demographic information. 
The sample person questionnaire was used to obtain self-reported individual-level 
information on various health outcomes and behaviors, such as oral health, physical 
activity, and medical conditions (CDC, 2015a). Following completion of the household 
interview, study participants were asked to visit a mobile examination center (MEC). 
During the visit to the MEC, interviewers administered a 24-hour dietary recall 
questionnaire. Interviewers also administered additional questionnaires to collect data on 
more sensitive topics, such as reproductive health, drug use, and depression (CDC, 
2015a). Data collected throughout the interview process was obtained using a mostly 
electronic system that incorporated technology, such as touch-screen computers, a 
computer-assisted personal interview (CAPI) system, a computer-assisted self-interview 
system, and electronic questionnaires. All diagnostic testing and medical health 
examinations took up to 4 hours for each participant and were conducted in the MECs, 
which allowed for a standardized environment for all participants (CDC, 2015a). The 
MEC staff consisted of trained and certified physicians, dietary interviewers, medical 
technologists, phlebotomists, two interviewers, and computer managers (CDC, 2015a). 
The MECs had automated collection procedures with diagnostic components being 
recorded directly into the study database.  
All NHANES staff were trained in obtaining informed consent for all aspects of 
the survey and associated examinations, and in maintaining the privacy and 
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confidentiality of participants (CDC, 2015a). The 2007-2010 NHANES data files were 
made available for free public access on the CDC website. Because the data collected 
during the NHANES were intended for public use and participants provided consent for 
future use of their data, additional permission to use the data was not necessary. 
Therefore, I downloaded the data files for this study from CDC website for analysis 
following receipt of Walden University’s IRB approval. 
Constructing weights. To ensure that the sum of the weights matched the survey 
population, I had to weight the combined sampling data from the 2007-2008 and 2009-
2010 NHANES datasets. The weights that I used in this cross-sectional analysis included 
the 2-year examination weight with the variable name WTMEC2YR, and the 4-year 
examination weight with the variable name WTMEC4YR. The WTMEC2YR variable 
was included in the 2007-2010 NHANES datasets, and was used to construct the 4-year 
weight using the following formula: If SDDSRVYR in (5,6), then WTMEC4YR = 1/2 * 
WTMEC2YR (CDC, 2013a). The term SDDSRVYR represents the survey cycle 
variable, with the value of 5 representing 2007-2008 and the value of 6 representing 
2009-2010 (CDC, 2013a).  
Power analysis. The sample size for this study was calculated using G*Power 3.1 
(Faul, Erdfelder, & Buchner, 2007). To address the research questions in this study, 
multivariate analyses using multiple linear and logistic regression were required. These 
statistical procedures would require sufficient sample sizes to achieve 80% statistical 
probability of rejecting a false null hypothesis. In the absence of other studies with 
analyses directly matching this study, I made an approximation of the anticipated effect 
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size for changes in CRP and FEV1% predicted based on effect sizes found in the 
literature. The effect size for CRP in this study was based on the change in CRP predicted 
by total fruit intake (β = -0.100) in a study exploring the association between dietary 
constituents and serum CRP (Corley, Kyle, Starr, McNeill, & Deary, 2015)). Therefore, 
the sample size calculation using G*Power 3.1 included an effect size of 0.100 mg/dL 
change in CRP, alpha of .05, power of 80%, and nine predictors. The resulting sample 
size estimate for multiple linear regression analysis involving CRP was 166 participants. 
I estimated the effect size for FEV1% predicted based on the effect sizes found in a study 
by Schünemann et al. (2002) assessing the association between FEV1% predicted and 
lutein/zeaxanthin (β = 0.997), vitamin C (β = 1.04), and vitamin E (β = 1.601). Therefore, 
the sample size calculation using G*Power 3.1 was based on an estimated effect size of 
1% change in the FEV1% predicted, an alpha of .05, power of 80%, and nine predictors. 
The resulting sample size estimate for multiple linear regression analysis involving 
FEV1% predicted was 26 participants. Taken together, the total sample size needed to 
accommodate multiple linear regression for CRP and FEV1% predicted was estimated to 
be 166. 
Using G*Power 3.1, the calculation for logistic regression, based on a two-tailed 
test with an alpha of .05, power of 80%, and an odds ratio of 0.7-1.3, yielded a sample 
size ranging between 395 and 721. I selected this 30% range to account for both positive 
and negative effects of increased flavonoid intake between participants with COPD and 
those without. Additionally, 30% appears to be a moderate indicator of likely effect, as 
similar odds ratios of were observed in studies of flavonoid intake and outcomes, such as 
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COPD-related symptoms and various cancers (Fink et al., 2007; Tabak et al., 2001; Woo 
& Kim, 2013). Therefore, to accommodate multiple logistic regression analysis, the 
overall sample size required for this study was 721.  
Instrumentation 
The overall data collection instruments researchers used to obtain data for this 
study included survey questionnaires and diagnostic equipment. I obtained data from the 
2007-2010 NHANES datasets that were related to the variables of interest my study 
including medical, dietary, demographic, and health outcome assessments. Trained health 
technicians obtained this information from participants during interviews, examinations, 
and laboratory sample collections. 
Dietary Measurement 
During the 2007-2010 NHANES, CDC interviewers obtained a 24-hour food 
recall from participants at two different time points. The food recalls were used by CDC 
interviewers to collect data on the individual foods and portion sizes consumed by each 
participant within the previous 24-hour period. To more accurately reflect daily flavonoid 
intake for this study, I averaged the dietary data derived from the two non-consecutive 
24-hour food recalls obtained during the 2007-2010 NHANES. The first 24-hour food 
recall was obtained from participants through an in-person interview conducted while 
visiting a MEC. The second 24-hour food recall was obtained three to 10 days later by 
phone interview. All 24-hour dietary recalls were administered by trained dietary 
interviewers who were guided by an automated dietary interview program designed to aid 
in executing the multiple-pass method. The multiple-pass method is designed to enhance 
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the accuracy of short-term dietary habits elicited from participants (Raper, Perloff, 
Ingwersen, Steinfeldt, & Anand, 2004; Steinfeldt, Anand, & Murayi, 2013). The USDA’s 
computer-based automated multi-pass method (AMPM) program was used to prompt the 
interviewers to ask participants standardized questions about the foods and beverages that 
each participant consumed in the past 24-hours (CDC, 2015b; CDC, 2015c). The validity 
of the USDA’s AMPM has been confirmed by researchers in several studies to improve 
estimates of total energy and nutrient intake (Blanton, Moshfegh, Baer, & Kretsch, 2006; 
Moshfegh et al., 2008; Rhodes et al., 2013).  
This USDA’s AMPM involves five steps that ensure participants are provided 
with structured and unstructured opportunities to report the foods they consume. During 
administration of the 24-hour recall, the first step of the AMPM required each participant 
to provide a quick list of foods and beverages consumed within the past 24 hours. During 
the second step, the interviewer probed each participant for foods they may have 
forgotten to report during the first step. The interviewer probed for forgotten foods by 
bringing common food categories to each participant’s attention, such as non-alcoholic 
beverages, savory snacks, fruits, vegetables, and cheeses (CDC, 2015b; CDC, 2015c). 
The third step required the interviewer to ask each participant to identify the time and 
occasion that each food was consumed. Next, the interviewer placed all participant-
reported foods into chronological order and grouped those foods by eating occasion. 
During the fourth step, the interviewer asked each participant to provide detailed 
information regarding each reported food item, such as the amount consumed, where it 
was obtained, and where it was consumed (CDC, 2015b; CDC, 2015c). Additionally, the 
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interviewer reviewed each eating occasion and the duration of time between each eating 
occasion with participants to help them identify additional foods that may have been 
forgotten. The fifth step entailed a final probe by the interviewer to aid the participant in 
recalling additional foods. The final probe involved encouraging participants to recall 
other occasions where food may have been consumed or small amounts of foods that 
might have been viewed as insignificant (CDC, 2015b; CDC, 2015c). The interviewers 
recorded all participants’ responses directly into the AMPM computer program. The 
interviewers provided all participants with identical measuring guides to aid them in 
accurately reporting the quantity of the foods and beverages they consumed. The 
measuring guides included three-dimensional tools, such as bowls, spoons, and cartons, 
and two-dimensional tools, such as pictures of chicken pieces and shapes (CDC, 2015b; 
CDC, 2015c). The duration of each dietary interview ranged between 15 and 30 minutes, 
depending on the amount and types of foods reported by the participants (CDC, 2015b; 
CDC, 2015c). At the end of each participant’s 24-hour dietary recall interview at the 
MEC, the interviewer provided each participant with a set of measurement guides to take 
with them for use during the subsequent telephone interview. The interviewer conducted 
the telephone interview using the AMPM dietary interview program and by following the 
same procedures as the initial MEC interview (CDC, 2015b; CDC, 2015c). 
Demographics and Diseases 
CDC interviewers collected data regarding the demographics and diagnosis of 
COPD, cardiovascular disease, diabetes, and hypertension from study participants during 
the conduct of the 2007-2010 NHANES using standard questionnaires. The 
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demographics data were collected using the Demographics Questionnaire (DMQ). The 
Medical Conditions Questionnaire (MCQ) was used to collect data on self-reported 
diagnosis of COPD and cardiovascular disease. Data on self-reported diagnoses for 
diabetes and hypertension were collected using the Diabetes Questionnaire (DIQ) and 
Blood Pressure and Cholesterol Questionnaire (BPQ), respectively. The DMQ, MCQ, 
DIQ, and BPQ, were designated as in-home questionnaires. These questionnaires were 
administered to participants using standard modes of administration. The standard 
method of administration involved the use of portable CAPI systems, which contained 
electronic versions of the DMQ, MCQ, and BPQ. While present in participants’ homes, 
trained interviewers asked all questions using the CAPI system. Interviewers read the 
questions provided by the CAPI system to each participant. All participants’ responses 
were recorded directly into the CAPI system by the interviewers. Quality assurance and 
control were maintained through the CAPI system because the system is programmed to 
perform consistency checks, which reduces data entry errors (CDC, 2015a). Furthermore, 
onscreen help menus provided interviewers with assistance in providing standardized 
definitions of key terms to participants (CDC, 2015a). 
Medical Examinations  
Examination data, including spirometry values, height and weight measurements, 
and blood samples were collected from study participants by trained health technicians in 
the MECs. The spirometry testing procedures used in NHANES were performed 
according to recommendations from the American Thoracic Society recommendations 
(CDC, 2015a; Miller et al., 2005). The spirometry testing procedures entailed coaching, 
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ensuring adequate duration of expiratory maneuvers, and ensuring acceptability of 
testing. Prior to initiating a spirometry test, the spirometry technician coached 
participants on how to perform the expiratory maneuvers by describing the actions 
participants would need to take. These actions included taking a deep breath to fill the 
lungs with air, placing the mouthpiece of the spirometer in the mouth, sealing the lips 
around the mouthpiece, and blasting air out as hard and fast as possible until prompted by 
the technician to stop (CDC, 2015a). Expiratory maneuvers performed by participants 
during spirometry testing were considered acceptable if they were free of hesitation or 
false starts when blowing into the mouthpiece (CDC, 2015a). Additional acceptability 
criteria for expiratory maneuvers included no coughing during the first second, no 
mouthpiece obstruction, an extrapolated volume of < 150 ml or 5% of the FVC, a visible 
plateau toward the end of the volume-time spirogram, and duration of 6 seconds (CDC, 
2015a). Participants were asked to repeat the expiratory maneuver if it was found to be 
unacceptable by the technicians, with a maximum of eight attempts allowed. To ensure 
the quality of spirometry administration and performance the respiratory division of the 
National Institute for Occupational Safety and Health (NIOSH) acted as the training 
consultant for spirometry technicians during the NHANES. Furthermore, the quality 
control division at NIOSH reviewed all spirometry data, and spirometry equipment was 
regularly calibrated by trained technicians and confirmed by supervisors (CDC, 2015a).  
Trained NHANES examiners calculated BMI using height and weight 
measurements obtained from participants. The examiners received their training from 
expert anthropometrists. All body measurements were collected in a standardized manner 
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by an examiner who was assisted by a recorder. The standardized process for obtaining a 
participant’s weight involved providing disrobing instructions to participant, positioning 
them on a digital scale, and entering their weight result directly into a computer 
integrated survey information system. Examiners instructed participants to disrobe, with 
the exception of their undergarments, and change into a standard exam gown. The 
standard gown consisted of a disposable shirt, pants, and slippers (CDC, 2015a). The 
examiner instructed the participants to step onto the center of a digital scale platform with 
their hands at their sides and facing the examiner (CDC, 2015a). All participants were 
expected to use the same digital scale type and model provided in the MEC. The digital 
scale could only provide accurate weight measurements up to a maximum of 440 pounds 
(CDC, 2015a). If a participant weighed greater than 440 pounds, then two portable digital 
scales were used to weigh the participant (CDC, 2015a). In this instance, the examiner 
provided the same instructions; however, the examiner would instruct the participant to 
place one foot on each scale. All weight measurements obtained by the examiner, 
regardless of the number of scales used, were entered into the computer-based survey 
information system (CDC, 2015a).  
The standard process used by NHANES examiners to obtaining a height 
measurement for each participant included positioning the participant on a standometer, 
adjusting the standometer head piece, and recording the height result. The examiners 
instructed each participant to stand on the standometer platform with their arms at their 
sides and heels together with toes apart (CDC, 2015a). Additionally, the examiner 
ensured that each participant was positioned with his or her back and head against the 
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backboard of the standometer (CDC, 2015a). With the participant in place, the examiners 
lowered the headpiece along the measurement column until it rested on the top of the 
participant’s head. The examiners would then recorded the height value into the 
computer-based survey information system. As an added measure to minimize variability, 
all measurement examination rooms within the MECs were designed to be identical. 
Also, all equipment used to collect body measurements were calibrated regularly by 
technicians and confirmed by supervisors. Trained health technicians obtained blood 
sample collections from participants while they visited the MEC in order to obtain CRP 
data. All blood samples obtained from participants were processed, stored, and shipped to 
the University of Washington in Seattle, WA using quality control and assurance 
procedures that meet the requirements of 1988 Clinical Laboratory Improvement Act 
(CDC, 2015a).  
Operationalization of Study Variables 
Independent Variable 
The independent variable for this study was total daily flavonoid intake, measured 
as the total amount of flavonoids consumed per day. I calculated the total flavonoid 
intake of each study participant by averaging the flavonoid content of the foods reported 
in two non-consecutive 24-hour dietary recalls by participants of the 2007-2010 
NHANES. For this study, the total daily flavonoid intake was measured as a continuous 
interval variable. Adjusting flavonoid intake by total energy intake in regression models 
yields more accurate results when conducting epidemiologic analysis related to disease 
outcomes (Willett, Howe, & Kushi. 1997). Nutrient intake among people tends to be 
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correlated with their overall caloric intake (Willett & Stamphfer, 1986). By adjusting for 
total energy intake, flavonoid intake can be interpreted as a function of dietary 
composition and constituency rather than that of total caloric intake. Therefore, I adjusted 
all values for total flavonoid intake used for regression analysis in this study for total 
energy intake using the residual method (Willett & Stamphfer, 1986). Total energy intake 
was defined as the total daily caloric intake for all participants measured in kilocalories 
(kcal). The residual method entailed calculating the total energy-adjusted flavonoid 
intake values as the residual values obtained from a logistic regression model with total 
energy intake and total flavonoid intake as the independent and dependent variables, 
respectively.  
I obtained the flavonoid values of foods reported by each participant in this study 
from the USDA Flavonoid Intake Data Files (FIDFs), which corresponds to the dietary 
component of the 2007-2010 NHANES (USDA, 2016). The USDA compiled the FIDFs 
by applying expanded analytical flavonoid values from the DFCSF, Release 3.2 and 
DICSF, Release 2.1 to the self-reported 24-hour dietary recall information from the 2007-
2010 NHANES (Sebastian, Enns, Goldman, Steinfeldt, Martin, & Moshfegh, 2016). The 
DFCSF, Release 3.2 and DICSF, Release 2.1 were the most recent versions of the 
flavonoid databases with expanded analytical values that were the most comprehensive 
source of flavonoid data available at the time of the present study. The expanded USDA 
flavonoid databases provide the flavonoid content for 2,926 specific foods and identify 
those foods using a nutrient databank (NDB) number (USDA, 2016). The USDA used the 
Food and Nutrient Database for Dietary Studies (FNDDS) revision 4.1 and 5.0 to link the 
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codes from the USDA flavonoid databases and the 24-hour dietary recalls for the 2007-
2008 and 2009-2010 NHANES iterations, respectively (Sebastian, Enns, Goldman, 
Steinfeldt, Martin, & Moshfegh, 2016). The USDA took this approach because the food 
codes from the NHANES 24-hour dietary recalls and NDB numbers referenced in the 
USDA flavonoid databases differ. The USDA FNDDS was used because it contains a 
translation table linking the food codes from the NHANES with the corresponding NDB 
numbers referenced in the USDA flavonoid databases (USDA, 2014). Each revision of 
the FNDDS corresponds directly to the dietary intake component of a specific iteration of 
the NHANES (USDA, 2014). Specifically, the FNDDS revision 4.1 corresponds to the 
2007-2008 NHANES and the FNDDS revision 5.0 corresponds to the 2009-2010 
NHANES. Ultimately, the FIDFs provided the total daily flavonoid intake for each 24-
hour dietary recall for each participant who reported dietary data in the 2007-2010 
NHANES. The combination of the FIDFs and the NHANES datasets enabled the 
calculation of average total daily flavonoid intake for this study.  
Dependent Variables 
The dependent variables for these analyses include COPD, FEV1% predicted, 
CRP, and Comorbidity burden. These variables represent COPD diagnosis, COPD 
severity, systemic inflammation, and the accumulation of inflammation-related comorbid 





Dependent Variable Characteristics 
Variable name Level of measurement 
Comorbidity burden Ordinal 
COPD Dichotomous 
FEV1% predicted Interval 
CRP Interval  
 
COPD Diagnosis. To minimize misclassification error due to potential recall 
bias, I decided that the diagnosis of COPD would be defined by spirometry 
measurements instead of participant self-reporting. Therefore, I defined the diagnosis of 
COPD for this study as having a post-bronchodilator FEV1/FVC ratio of < 70%, 
according to GOLD (2015) guidelines. Participants with a pre-bronchodilator or post-
bronchodilator FEV1/FVC ratio of ≥70% were noted as not having COPD.  
COPD Severity. I defined COPD severity as the FEV1% percentage of the 
predicted normal FEV1 using individual post-bronchodilator spirometry results obtained 
in the 2007-2010 NHANES, converted from milliliters to liters. FEV1% predicted values 
were used in this study as an indicator of COPD severity because there are gradual 
declines in FEV1 among COPD patients prior to reaching the threshold for inclusion in 
each COPD severity stage, as specified by the GOLD criteria (Lange et al., 2015; 
Tantucci & Modina, 2012). Therefore, FEV1% predicted values were treated as 
continuous interval measurements for all relevant analyses instead of being categorized 
into stages of severity. As such, the statistical precision for addressing RQ2 increased by 
accounting for incremental changes in FEV1% predicted. 
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Systemic inflammation. I used serum CRP values as a measure of systemic 
inflammation among the COPD population. In this regard, CRP served as an indicator for 
the mechanism of action between flavonoid intake and COPD. CRP values were obtained 
from laboratory testing of blood samples obtained from participants in the 2007-2010 
NHANES. The lower limit of detectability for serum CRP was 0.02 ng/mL. Any test 
results that were obtained below this detectable limit were assigned a notional value, 
which was reported as the detection limit divided by the square root of two (CDC, 2015b; 
CDC, 2015c). By dividing the limit of detection by the square root of two, laboratory 
technicians were able to provide an estimate of the undetectable value, which lies 
between zero and the detectible limit (Hornung & Reeed, 1990). Assigning a notional 
value for CRP results below the detectable limit avoided the need to assign a zero value 
or omit these data points. If undetectable data points are assigned a zero value or omitted, 
then the mean for CRP concentrations can be skewed too high. Therefore, to improve the 
accuracy of the overall results for the sample population, the NHANES technicians 
applied the notional value to CRP results below the detectable limit (CDC, 2015b; CDC, 
2015c; Hornung & Reeed, 1990). In general, the normal range for adult serum CRP level 
is < 10 mg/L, with results above this threshold indicating a serious acute infection or 
trauma (Pearson et al., 2003; Shivappa et al., 2014). For the purposes of the current study, 
CRP was analyzed as a continuous interval variable. 
Comorbidity. I defined the comorbidity burden of participants in the 2007-2010 
NHANES with COPD as the number of concurrent self-reports of cardiovascular disease, 
diabetes, and hypertension. The determination of whether or not participants had 
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cardiovascular disease was made based on responses to three questions found within the 
NHANES. The first question asked, “Has a doctor or other health professional ever told 
you that you had a stroke?”  The second question asked, “Has a doctor or other health 
professional ever told you that you had a heart attack?”  The third question asked, “Has a 
doctor or other health professional ever told you that you had congestive heart failure?”  
Participants who responded positively to at least one of these questions were noted as 
having cardiovascular disease. Participants who responded negatively to all three 
questions were noted as not having cardiovascular disease. The self-report of diabetes 
was based on the affirmative or negative response to the NHANES interview question 
that asked, “Have you ever been told by a doctor or other health professional that you had 
diabetes or sugar diabetes?”  Likewise, the self-report of hypertension was determined 
based on an affirmative or negative response to the NHANES interview question that 
asked, “Have you ever been told by a doctor or other health professional that you had 
hypertension, also called high blood pressure?” I created a comorbid disease burden score 
specifically for this study by summing the number of systemic inflammation-related 
comorbid diseases for each participant in the COPD population.  
Covariates 
Covariates recognized as potential confounders according to research findings 
included age, annual income group, BMI, dietary fiber intake, education level, gender, 
race/ethnicity, and smoking status (ALA, 2014; Beiko et al., 2015; Eisner et al., 2009; 
Fonseca Wald et al., 2014; Hooper et al., 2012; Marott & Lange, 2013; Pistelli et al. 
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2012; Sebastian, Enns, Goldman, Steinfeldt, & Moshfegh, 2016; Zhou et al., 2013). Table 
2 provides a description of the characteristics of these variables.  
Table 2 
Covariate Characteristics 
Variable name Level of measurement 
Age Interval 
Annual income group Nominal 
BMI Interval 
Dietary fiber intake Interval 
Education level Nominal 
Gender Nominal, Dichotomous 
Race/ethnicity Nominal 
Smoking status Nominal 
 
The variable for age was defined by NHANES researchers as the age of a 
participant at screening during the 2007-2010 NHANES and consisted of age values 
ranging from 30 to 80. The age value of 80 represents participants who were ≥ 80 years 
old at the time of screening. The individual age of participants who were ≥ 80 years old 
was not reported in the 2007-2010 NHANES, as this would introduce an identification 
disclosure risk (CDC, 2015b; CDC, 2015c). Annual income group was defined as self-
reported annual household income reported categorically because these data were 
collected as such in the 2007-2010 NHANES. Therefore, annual income group consisted 
of reported income that corresponded to one of 15 income categories that consist of $0-
$4,999, $5,000-$9,999, $10,000-$14,999, $15,000-$19,999, under $20,000, over 
$20,000, $20,000-$24,999, $25,000-$34,999, $35,000-$44,999, $45,000-$54,999, 
$55,000-$64,999, $65,000-$74,999, $75,000-$99,999, and $100,000 and over. BMI was 
calculated in units of kg/m2 based on the height and weight measurements for all 
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participants. Dietary fiber intake was defined by NHANES researchers as the dietary 
fiber intake for all participants measured in grams per day. I adjusted all values for 
dietary fiber used for regression analyses in this study for total energy intake using the 
residual method (Willett & Stamphfer, 1986). Total energy intake was defined by 
NHANES researchers as the total daily caloric intake for all participants measured in 
kilocalories (kcal). 
 NHANES researchers defined education level as the highest grade or level of 
school a participant reported based on their response to the NHANES survey question 
that asked, “What is the highest grade or level of school you have completed or the 
highest degree you have received?” The categories for education level included “less than 
9th grade,” “9th-11th grades,” “high school grad/GED or equivalent,” “some college or AA 
degree,” and “college graduate or above.” Gender had a binary value and was defined as 
either “male” or “female.”  
NHANES researchers defined race/ethnicity as participants reporting themselves 
to be Mexican American, other Hispanic, non-Hispanic White, Non-Hispanic Black, or 
other race/multiracial. Variables for race and ethnicity were not provided separately 
within the NHANES dataset. Instead, only one variable for combined race and ethnicity 
was made available within the NHANES datasets based on participants’ self-reported 
race and ethnicity. Participants who identified themselves as “Mexican American” were 
categorized as such regardless of their other racial identities (CDC, 2015b; CDC, 2015c). 
Participants who otherwise identified themselves as “Hispanic” ethnicity were 
categorized as “other Hispanic” (CDC, 2015b; CDC, 2015c). All other non-Hispanic 
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people were categorized according to their self-identified races, which included “non-
Hispanic White,” “Non-Hispanic Black,” or “other race/multiracial” (CDC, 2015b; CDC, 
2015c). For this study, the categories of “Mexican American” and “other Hispanic” were 
combined into a single category labeled as “Mexican or Hispanic” to align with the racial 
categories used to determine FEV1% predicted values (Hankison et al., 1999).  
I created three categories for smoking status, which include “nonsmoker,” 
“current smoker,” and “former smoker.”  Participants were assigned to a smoking status 
category based on their responses to two survey questions. The first question asked, 
“Have you smoked at least 100 cigarettes in your entire life?” The second question asked, 
“Do you now smoke cigarettes?” I defined nonsmokers as participants who smoked fewer 
than 100 cigarettes throughout their lifetime. Current smokers were defined as those 
participants who have smoked at least 100 cigarettes in their lifetime and currently smoke 
every day or some days. Former smokers were defined as those participants who smoked 
at least 100 cigarettes throughout their lifetime and did not currently smoke at all. 
Statistical Analysis 
I performed all analyses for this study using the statistical package for social 
sciences (SPSS) version 21. I extracted and organized the data used in this study 
appropriately to create a complete dataset that included all variables required for analysis. 
Subsequently, I assessed the final dataset to ensure that all assumptions were met for each 
statistical procedure utilized to test the study hypotheses. These assumptions are 




The initial step in preparing the dataset required me to the download and 
extraction of the data files for all relevant variables from the 2007-2010 NHANES. I 
generated frequencies for all variables in the study to ensure the correct number of 
records was successfully obtained for each variable. The data for all study variables were 
reviewed to identify values that required recoding, such as those indicating a participant 
refused to answer a question, had missing data, did not know the answer. All values 
indicating a participant refused to answer the question or didn’t know the answer were 
recoded as missing data. To confirm that the appropriate values were recoded, I generated 
frequencies again for all variables and compared them to the original NHANES data 
codebook to ensure the final record counts were accurate. 
Data preparation for the independent variable, total daily flavonoid intake, 
initially entailed downloading the FIDFs from the USDA website. The FIDFs included a 
separate file for each 24-hour recall and I imported both files into SPSS. Next, I used 
SPSS to compute the mean of two total daily flavonoid intake observations from both 24-
hour dietary recalls. Subsequently, I adjusted the average total daily flavonoid intake 
values to account for total energy intake using the residual method (Willett & Stamphfer, 
1986). Adjustment for total energy intake involved performing a linear regression with 
total energy intake as the independent variable and the average total daily flavonoid 
intake as the dependent variable. I saved the residual values from this linear regression in 
SPSS as the new energy-adjusted total daily flavonoid intake values. The residuals had a 
mean of zero and contain negative values. Therefore, I added a constant to the residuals 
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to removed negative values and a natural log transformation was performed to improve 
normality in accordance with the residual method (Willett & Stamphfer, 1986). 
Likewise, I created the dietary fiber intake variable in SPSS by averaging the 
dietary fiber intakes from both 24-hour dietary recalls. Subsequently, I adjusted the 
average dietary fiber intake values for total dietary intake using the residual method. 
Specifically, a linear regression was performed using total energy intake as the 
independent variable and dietary fiber intake as the dependent variable. I saved the 
residuals from this regression in SPSS as the energy-adjusted dietary fiber intake values. 
As with total daily flavonoid intake, I added a constant to the residuals to removed 
negative values. Subsequently, I performed a natural log transformation of the residual 
values to improve normality of the distribution. 
I created the dependent study variable, COPD, in SPSS by coding the FEV1/FVC 
ratio values to reflect a diagnosis of COPD or not, according to the spirometric definition 
provided earlier. The dichotomous COPD variable was coded as “0” to indicate that a 
participant did not have COPD and “1” to indicate a participant had COPD. Upon 
creation of the new variable, I generated frequencies to ensure the correct number of 
records was available.  
I combined three separate dichotomous variables to create the dependent variable 
for comorbidity burden. These three variables include cardiovascular disease, diabetes, 
and hypertension. Using SPSS, I summed the values for all three self-reported diseases to 
create a composite score for comorbidity burden for each participant. The composite 
score consisted of values ranging from “0” to “3.” Each score corresponded to the 
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number of comorbid diseases a participant had. A value of “0” indicate no comorbid 
disease was reported while a value of “1” indicates only one comorbid disease was 
reported. Likewise, a value of “2” indicates two comorbid diseases were reported and a 
value of “3” indicates all three comorbid diseases were reported. I categorized and 
labeled the composite scores as comorbidity burden level categories in SPSS. Scores of 
“0” and “1” were labeled as comorbidity burden “Level 0” and “Level 1” in SPSS, 
respectively. Those participants with a score of “3” were combined into the same 
category as those with a score of “2” because there were very few participants with 
scores of “3”. Therefore, the final combined category was labeled as comorbidity burden 
“Level 2 and 3” in SPSS.  
I computed the dependent variable for COPD severity, FEV1% predicted, by 
exporting all relevant variables for all patients with COPD from SPSS into an Excel 
spreadsheet. The variables included gender, age, race, height, and post-bronchodilator 
FEV1. These characteristics were used to identify the FEV1 for a person with comparable 
characteristics who does not have COPD. I calculated the FEV1% predicted value by 
dividing the FEV1 value by the predicted normal FEV1 reference value for a person of 
similar age, gender, race, and height (Hankinson, Odencrantz, & Fedan, 1999). The 
normal FEV1 reference values used as the denominator in COPD severity calculations 
were established using spirometric testing results from healthy participants in the 
NHANES 1988-1994 (Hankinson et al., 1999). I imported the FEV1% predicted values 




I provide a summary and review of the data in Chapter 4 using descriptive 
statistics to characterize the sample population. I generated frequencies for all categorical 
variables, including annual income group, cardiovascular disease, COPD, diabetes, 
education, gender, hypertension, race/ethnicity, and smoking status. I also generated 
measures of central tendency and dispersion for all continuous variables, including age, 
FEV1% predicted, CRP, dietary fiber intake, and total daily flavonoid intake. These 
descriptive statistics serve to describe the basic features of the data in this study. I 
evaluated the symmetry of the distributions for continuous data to determine if they were 
normally distributed. Variables that failed to meet assumptions of normality for a given 
statistical procedure are discussed in further detail in Chapter 4.  
Bivariate Analysis 
I conducted bivariate analyses to test for associations between all individual 
variables. These bivariate analyses enabled the assessment of potential associations 
between variables that may impact statistical analyses. The outcome of these bivariate 
analyses determined which variables were relevant potential confounding variables to be 
included in multivariate analyses. Specifically, only those potential confounding 
variables found to have a statistically significant association with both the independent 
and dependent variables, defined as having a p-value of < .15, were included in 
multivariate analyses. Table 3 shows all bivariate statistical tests used to analyze possible 
associations between the dependent variables and potential confounding variables. 
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Likewise, Table 4 shows all bivariate statistical tests used to analyze possible 





Statistical Tests for Dependent and Potentially Confounding Variables 
Dependent variable  Comparison variable 







COPD Dichotomous  Age Interval Independent t test 
   Annual income group Nominal Chi-square 
   BMI Nominal Chi-square 
   Education level Nominal Chi-square 
   Dietary fiber intake Interval Independent t test 
   Gender Dichotomous Chi-square 
   Race/ethnicity Nominal Chi-square 
   Smoking status Nominal Chi-square 
FEV1% 
predicted 
Interval  Age Interval Pearson correlation 
   Annual income group Nominal One-way ANOVA 
   BMI Interval Pearson correlation 
   Dietary fiber intake Interval Pearson correlation 
   Education level Nominal One-way ANOVA 
   Gender Dichotomous Independent t test 
   Race/ethnicity Nominal One-way ANOVA 
   Smoking status Nominal One-way ANOVA 
Comorbidity 
burden 
Ordinal  Age Interval Spearman correlation 
   Annual income group Nominal Chi-square 
   BMI Interval Spearman correlation 
   Dietary fiber intake Interval Spearman correlation 
   Education level Nominal Chi-square 
   Gender Dichotomous Chi-square 
   Race/ethnicity Nominal Chi-square 
   Smoking status Nominal Chi-square 
CRP Interval  Age Interval Pearson correlation 
   Annual income group Nominal One-way ANOVA 
   BMI Interval Pearson correlation 
   Dietary fiber intake Interval Pearson correlation 
   Education level Nominal One-way ANOVA 
   Gender Dichotomous Independent t test 
   Race/ethnicity Nominal One-way ANOVA 






Statistical Tests for Independent and Potentially Confounding Variables  
Variable  Comparison variable 







Flavonoid intake Interval  Age Interval Pearson correlation 
   Annual income group Nominal One-way ANOVA 
   BMI Interval Pearson correlation 
   Dietary fiber intake Interval Pearson correlation 
   Education level Nominal One-way ANOVA 
   Gender Dichotomous Independent t test 
   Race/ethnicity Nominal One-way ANOVA 
   Smoking status Nominal One-way ANOVA 
 
Analysis of Research Questions and Hypotheses 
The statistical analyses utilized to test the hypotheses associated with the study 
research questions are described below. Study analyses were restricted to only those 
participants from whom spirometry values and two dietary recalls were obtained. Study 
procedures were selected according to the level of measurement for each of the variables 
included. 
The first study research question and associated null and alternative hypotheses 
for this study included: 
RQ1. What is the relationship between total daily flavonoid intake and COPD 
among adults?   
H01: There is no statistically significant association between total daily flavonoid 
intake and spirometry-diagnosed COPD among adult participants of the 2007–
2010 NHANES, after adjusting for relevant confounders. 
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H11: There is a statistically significant association between total daily flavonoid 
intake and spirometry-diagnosed COPD among adult participants of the 2007–
2010 NHANES, after adjusting for relevant confounders. 
Two logistic regression models were used to test the null hypothesis for this research 
question. The first model consisted of a simple unadjusted logistic regression analysis 
between total daily flavonoid intake and COPD. The second model entailed utilizing a 
multiple logistic regression with total daily flavonoid intake and all relevant confounders 
as covariate predictors of COPD. Relevant confounding variables selected for inclusion 
in multivariate analysis were identified using bivariate analyses. Results from the 
multivariate analyses were interpreted according to p-values, odds ratios, and 
corresponding confidence intervals.  
The second study research question and associated null and alternative hypotheses 
for this study included: 
RQ2. What is the relationship between total daily flavonoid intake and COPD 
severity among adults?   
H02: There is no statistically significant association between total daily flavonoid 
intake and FEV1% predicted among adult participants of the 2007–2010 
NHANES, after adjusting for relevant confounders. 
H12: There is a statistically significant association between total daily flavonoid 
intake and FEV1% predicted among adult participants of the 2007–2010 
NHANES, after adjusting for relevant confounders. 
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Two linear regression models were used to test the null hypothesis for this 
research question. The first model consisted of a simple linear regression to analyze the 
potential association between total daily flavonoid intake and FEV1% predicted. The 
second model consisted of a multivariate linear regression that included total daily 
flavonoid intake as the independent variable and all relevant confounders as covariate 
predictors of FEV1% predicted. Relevant confounding variables selected for inclusion in 
multivariate analysis were identified using bivariate analyses. Results from the 
multivariate analyses were interpreted according to p-values, odds ratios, and 
corresponding confidence intervals.  
The third study research question and test hypotheses that were explored in this 
study included: 
RQ3. What is the relationship between total daily flavonoid intake and Systemic 
inflammation among adults with COPD?   
H03: There is no statistically significant association between total daily flavonoid 
intake and the CRP serum levels among adult participants of the 2007–2010 
NHANES with COPD, after adjusting for relevant confounders. 
H13: There is a statistically significant association between total daily flavonoid 
intake and the CRP serum levels among adult participants of the 2007–2010 
NHANES with COPD, after adjusting for relevant confounders. 
Two linear regression models were utilized to test the null hypothesis for this 
research question. The first model consisted of a simple linear regression with total daily 
flavonoid intake and CRP. The second model consisted of a multiple linear regression 
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that included total daily flavonoid intake and all relevant confounders as covariate 
predictors of CRP. Relevant confounding variables selected for inclusion in multivariate 
analysis were identified using bivariate analyses. Results from the multivariate analyses 
were interpreted according to β-values, p-values, and corresponding confidence intervals.  
The fourth study research question and test hypotheses that were explored in this 
study included: 
RQ4. What is the relationship between total daily flavonoid intake and 
comorbidity burden among adults with COPD?   
H04: There is no statistically significant association between total daily flavonoid 
intake and comorbidity burden among adult participants of the 2007–2010 
NHANES with COPD, after adjusting for relevant confounders. 
H14: There is a statistically significant association between total daily flavonoid 
intake and comorbidity burden among adult participants of the 2007–2010 
NHANES with COPD, after adjusting for relevant confounders. 
I planned to use two ordinal logistic regression models to test the null hypothesis for this 
research question. The first model entailed utilizing a simple ordinal logistic regression to 
test the association of the total daily flavonoid intake and comorbidity burden. The 
second model consisted of utilizing a multiple ordinal logistic regression with total daily 
flavonoid intake as the independent variable along with all relevant confounders as 
covariates predictors of comorbidity burden. Relevant confounding variables selected for 
inclusion in multivariate analysis were identified using bivariate analyses. Results from 
the multivariate analyses were to be interpreted according to β-values, p-values, and 
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corresponding confidence intervals. However, due to sample size limitations among the 
subset of participants who had COPD, the use of logistic regression was not possible as 
compared with RQ1. The scope of RQ1 included all participants in analysis dataset. 
However, the scope of RQ4 was limited to testing the association between total daily 
flavonoid intake and comorbidity burden only among the subset of participants with a 
COPD diagnosis. As such, there were an insufficient number of participants with COPD 
to achieve the desired statistical power to detect an odds ratio of 0.7-1.3, as described 
earlier. Therefore, I treated the variable for comorbidity burden as a nominal variable and 
tested the null hypothesis for this research question using a one-way ANOVA to explore 
the association with total daily flavonoid intake. Although a one-way ANOVA would not 
provide information on the predictive relationship between total daily flavonoid intake 
and comorbidity burden, this statistical procedure did provide insight into the differences 
in total daily flavonoid intake across different comorbidity burden levels. Specifically, I 
performed the one-way ANOVA to determine whether any statistically significant 
differences were present between the total daily flavonoid intake means for each 
comorbidity burden group (Level 0, Level 1, and Level 2 and 3). The one-way ANOVA 
is an omnibus test and cannot indicate which group means are significantly different from 
each other. Therefore, I performed a Games-Howell post hoc analysis to identify the 
specific comorbidity burden level groups with significantly different means for total daily 
flavonoid intake.  
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Threats to Validity 
The most significant threat to validity for this study was the limitation of the 24-
hour dietary recall to provide long-term dietary habits for each participant. While the 24-
hour dietary recall provides only short-term information, multiple administrations of 24-
hour dietary recalls are able to provide more accurate estimates of long-term dietary 
habits as compared to the FFQ (Carroll et al., 2012; Freedman, Schatzkin, Midthune, & 
Kipnis, 2011; Schatzkin et al., 2003; Shim, Oh, & Kim, 2014). Therefore, a key 
assumption for this study was that the participants’ current diet was reflective of long-
term dietary habits for fruit and vegetable intake spanning several decades. This 
assumption was supported by a study analyzing the changes in intake of fruits and 
vegetables and weight change among U.S. men and women participating in three 
prospective cohort studies who were followed for up to 24 years (Bertoia et al., 2015). 
Among 289,916 participants aged 25-75 the intake of fruits and vegetables from 1986 to 
2010 remained relatively constant with minor changes exceeding no more than 0.1 and 
0.2 servings per day of fruit and vegetables, respectively (Bertoia et al., 2015). Therefore, 
it was anticipated that the reported dietary intake based on the average of two 24-hour 
dietary recalls was sufficient to estimate long-term dietary habits with regard to fruit and 
vegetable intake.  
Another limitation linked to the use of the 24-hour recall for this study was the 
limited ability to fully account for day-to-day or seasonal variation in dietary intake for 
each participant. In particular, data obtained from a single 24-hour recall cannot fully 
account for individual variations, and intake is usually shown to have a lower distribution 
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slope, as participants with true low intakes may report higher intake and the inverse may 
apply for those with true high intakes (Ramachandran, 2006). Statistical methods, such as 
the Iowa State University (ISU) adjustment procedure and the ISU food (ISUF) method, 
have been proposed to estimate the usual intake distribution from multiple 24-hour recalls 
(Guenther, Kott, & Carriquiry, 1997; Nusser, Carriquiry, Dodd, & Fuller, 1996; Nusser, 
Fuller, W. A., & Guenther, 1995). The basic aim of these methods is to estimate usual 
intake distribution for a group by partitioning total variation present in 24-hour recall data 
into within-person and between-person components and estimating usual intake 
distribution by accounting for within-person variation. However, estimates of usual 
individual intake derived from only two 24-hour recalls can be unreliable when using the 
ISU and ISUF statistical methods (Carriquiry, 2003; Dodd et al., 2006). For example, 
using aforementioned methods with only two 24-hour recalls would yield three possible 
consumption probabilities consisting of zero, one-half, and one, which would not provide 
a smooth distribution of expected intake probabilities (Dodd et al., 2006). Also, while the 
intermediary values calculated using these statistical procedures are derived from the 
means of each individual, the intermediary values are not appropriate estimates of usual 
individual intake (Dodd et al., 2006). Specifically, the intermediary values are solely used 
for describing the distribution of usual intake for the overall sample (Dodd et al., 2006). 
Therefore, the ISU and ISUF statistical methods were not appropriate for this study. This 
study required measures of food items reported by each individual in order to determine 
flavonoid intake for each participant. As such, using the average of the dietary 
information from two 24-hour recalls for each individual in this study was considered to 
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be the most practical approach. However, it is acknowledged that utilizing data from two 
24-hour recalls from the 2007-2010 NHANES cannot fully account for the within-
individual variation for dietary intake.  
Another potential threat to validity was recall bias because the data for key 
variables, such as total daily flavonoid intake and comorbid diseases, were reliant upon 
participant self-report. However, recall bias among participants was minimized for the 
independent variable given the short 24-hour period for recall, which is found to produce 
data that are far more accurate than long-term recall periods (Carroll et al., 2012; 
Freedman et al., 2011). Also, recall bias was further minimized through the use of two 
non-consecutive 24-hour dietary recalls, which has been demonstrated to improve recall 
accuracy exceeding that which is achieved by the FFQ (Carroll et al., 2012; Freedman et 
al., 2011; Schatzkin et al., 2003). Recall bias related to participant self-reporting of 
comorbid diseases was expected to be minimal and with no impact to study results. 
Specifically, research has demonstrated that self-reporting diagnoses of COPD, 
cardiovascular disease, diabetes, and hypertension have proven to be accurate reflections 
of true diagnoses as confirmed by medical records (Barr, Herbstman, Speizer, & 
Camargo, 2002; Okura, Urban, Mahoney, Jacobsen, & Rodeheffer, 2004; Schneider, 
Pankow, Heiss, & Selvin, 2012; Van der Heyden, De Bacquer, Tafforeau, & Van Herck, 
2014). Therefore, recall bias was not anticipated to contribute to misclassification of 
comorbid diseases.  
Temporal bias can also pose a threat to validity in cross-sectional studies. 
Temporal bias occurs when researchers incorrectly infer the sequence of occurrence for 
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an exposure versus an outcome (Szklo & Nieto, 2014). A major limitation of cross-
sectional studies is the inability to establish causation, given the measurement of data at 
only one point in time (Szklo & Nieto, 2014). In this study, it was not be possible to 
determine if flavonoid intake caused COPD outcomes or if COPD outcomes caused 
changes in flavonoid intake. Therefore, the aim of this study was to identify any potential 
associations between independent and dependent variables rather than demonstrating 
causation through temporal inferences.  
Another threat to validity was the selection of a study sample that was not 
representative of the population of interest. The external validity of a study is threatened 
if the characteristics of the subjects included in the study are not reflective of the 
population being investigated (Frankfort-Nachmias & Nachmias, 2008). Specifically, a 
study lacking a representative sample will produce results that are specific only to the 
study sample and cannot be generalized to the broader population. As described earlier, 
the sample for this study was obtained using a complex, multistage, probability-sampling 
design to ensure it was representative of the national population of the United States 
(CDC, 2013b). Based on the sampling design for this study, the results were expected to 
be generalizable to the U.S. population. To ensure that this assumption held true, the 
demographics of the final study sample were compared to the broader U.S. population. 
The results of this assessment are provided in Chapter 4. 
Ethical Considerations 
There were no ethical concerns related to participant recruitment and data 
collection for this study. The NHANES datasets are freely available for public access, as 
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personal identifiers have been removed, and it is not possible to identify a participant by 
combining various parts of the data. Furthermore, the CDC adheres to all data privacy 
and confidentiality laws for the storage and protection of NHANES participant data. Such 
laws include the Public Health Service Act (42 USC 242k) and Section 308(d) of that law 
(42 USC 242m), the Privacy Act of 1974 (5 USC 552A), and the Confidential 
Information Protection and Statistical Efficiency Act (PL 107-347; CDC, 2015a). This 
study did not require the use of confidential or private participant data, and no additional 
sources were used in combination with NHANES data that could identify a specific 
participant. 
To further ensure the ethical conduct of this study, this research did not proceed 
before review and approval by the Walden University Institutional Review Board. The 
data used in this study will be maintained for at least 5 years following completion of the 
study. To ensure the security of the study data, all data files were stored in a password-
protected online cloud-based storage server.  
Summary and Conclusions 
A cross-sectional study design supported the examination of associations between 
flavonoid intake and COPD-related outcomes. I used dietary, socioeconomic, 
demographic, and diagnostic data from the 2007-2010 NHANES and flavonoid data from 
the USDA to assess the previously mentioned associations among study participants from 
these iterations of the NHANES. The data collection instruments and methods of 
administration used in the collection of data during the 2007-2010 NHANES minimized 
potential threats to validity.  
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In Chapter 4, I provide an overview of the study results. I will also characterize 
the study population and data using descriptive statistics. Additionally, I will describe the 
statistical analyses conducted to address each the hypotheses for each research question 




Chapter 4: Results 
The purpose of this study was to explore the potential association between total 
daily flavonoid intake and COPD, COPD severity, systemic inflammation, and 
comorbidity burden among U.S. adults aged 30 years and older. This chapter includes the 
results from the statistical analyses of data from the 2007–2010 NHANES and the USDA 
Flavonoid Databases that I used to address the study research questions. As such, the 
chapter includes a description of the methods I used to create the final study dataset, the 
rationale for the manipulations and modifications I made to the data, an overview of 
descriptive statistics for study cases, and a review of findings from bivariate analyses and 
multivariate analyses. This chapter ends with a summary of statistical results related to 
each research question.  
The initial study design included participant self-reported diagnosis of COPD and 
COPD severity categorized into stages according to the GOLD criteria. However, I 
changed the study design to include a spirometry diagnosis of COPD to classify 
participants as having COPD or not, because diagnostic measures are more reliable than 
participant recall. Additionally, COPD severity changed from a categorical measure of 
the percentage of the predicted FEV1 value (FEV1% predicted) to a continuous measure 
of FEV1% predicted. Given the modifications to the operational definition of the study 
variable for COPD and COPD severity, it was necessary to slightly update the research 
questions and associated hypotheses accordingly. The research questions and hypotheses 
for the statistical analyses for this study were as follows: 
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RQ1: What is the relationship between total daily flavonoid intake and COPD 
among adults? 
H01: There is no statistically significant association between total daily flavonoid 
intake and spirometry-diagnosed COPD among adult participants of the 2007–2010 
NHANES after adjusting for relevant confounders. 
H11: There is a statistically significant association between total daily flavonoid 
intake and spirometry-diagnosed COPD among adult participants of the 2007–2010 
NHANES after adjusting for relevant confounders. 
RQ2: What is the relationship between total daily flavonoid intake and COPD 
severity among adults? 
H02: There is no statistically significant association between total daily flavonoid 
intake and FEV1 percent predicted among adult participants of the 2007–2010 NHANES 
after adjusting for relevant confounders. 
H12: There is a statistically significant association between total daily flavonoid 
intake and FEV1 percent predicted among adult participants of the 2007–2010 NHANES 
after adjusting for relevant confounders. 
RQ3: What is the relationship between total daily flavonoid intake and systemic 
inflammation among adults with COPD? 
H03: There is no statistically significant association between total daily flavonoid 
intake and the CRP serum levels among adult participants of the 2007–2010 NHANES 
with COPD after adjusting for relevant confounders. 
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H13: There is a statistically significant association between total daily flavonoid 
intake and the CRP serum levels among adult participants of the 2007–2010 NHANES 
with COPD after adjusting for relevant confounders. 
RQ4: What is the relationship between total daily flavonoid intake and 
comorbidity burden among adults with COPD?  
HΩ4: There is no statistically significant association between total daily flavonoid 
intake and comorbidity burden among adult participants of the 2007–2010 NHANES 
with COPD after adjusting for relevant confounders. 
H14: There is a statistically significant association between total daily flavonoid 
intake and comorbidity burden among adult participants of the 2007–2010 NHANES 
with COPD after adjusting for relevant confounders. 
Dataset Preparation 
This study received approval from the Walden University IRB (#10-04-16-
0370817) prior to the collection of any data for analysis. Following IRB approval, I he 
downloaded and compiled datasets from the 2007-2010 NHANES. Obtaining the 
flavonoid intake data involved downloading the publicly available USDA FIDFs for the 
dietary component of the 2007–2010 NHANES (USDA, 2016). Analysts at the USDA 
compiled these intake files using the methods outlined in Chapter 3, which entailed 
applying the flavonoid values found in the flavonoid databases to the participant self-
reported 24-hour dietary recall information from the 2007–2010 NHANES. The 
flavonoid intake data from the USDA FIDFs and the prepared 2007–2010 NHANES 
dataset formed a complete dataset for the study, as described in Chapter 3.  
122 
 
The initial combined 2007-2010 NHANES study dataset included 20,686 
participants, which consisted of 10,149 from the 2007-2008 NHANES dataset and 10,537 
from the 2009-2010 NHANES dataset. As shown in Figure 2, my removal of cases 
according to the exclusion criteria for this study reduced the study sample size to 5,172 to 
address RQ1. The sample was further restricted to 5.2% of participants (n = 270) who 
had a spirometry-confirmed diagnosis of COPD to address RQ2, RQ3, and RQ4.  
 
Figure 2. Cases available for analysis after applying exclusion criteria.  
Adjustments to Study Data 
I made several adjustments to the dataset after it was downloaded and reviewed. 
These changes included redefining COPD diagnosis, transforming the CRP variable, and 
removing annual income from study analyses. These adjustments were necessary to 
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minimize potential misclassification, meet statistical assumptions, and address missing 
data.  
For this study, I initially defined the diagnosis of COPD as a self-reporting of 
COPD by participants. However, the diagnosis of COPD based on diagnostic measures, 
such as spirometry, is more accurate than self-reported data because self-reported 
diagnoses often result in underreporting COPD (Murgia et al., 2014; Rycroft, Heyes, 
Lanza, & Becker, 2012). A cross-tabulation of the study dataset with participant self-
reported COPD against COPD diagnoses based on spirometry showed that 169 
participants incorrectly self-reported that they had COPD when they did not, and 251 
participants incorrectly self-reported that they did not have COPD when they did. 
Therefore, I changed the definition of COPD diagnosis for this study from participant 
self-reporting of COPD diagnosis to spirometry-diagnosed COPD to strengthen the 
internal validity of the study. The diagnosis of COPD in this study was based on pre- and 
post-bronchodilator spirometry values obtained during the 2007–2010 NHANES. 
Therefore, participants must have performed spirometry in order to be included in this 
study. Participants were classified as having COPD based on post-bronchodilator 
FEV1/FVC ratio values according to the GOLD criteria, as described in Chapter 3. 
The data for the CRP variable were right-skewed with steep kurtosis and did not 
meet the assumption of normality to address RQ3. The skewness and kurtosis values for 
the CRP variable were 6.25 and 46.11, respectively. Therefore, I performed a natural log 
transformation of the CRP variable to improve normality prior to performing linear 
regression analysis for RQ3. Following the natural log transformation, the normality of 
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the data for CRP improved considerably, with the new values for skewness and kurtosis 
reflected as 0.536 and 0.341, respectively.  
I used a missing values analysis to assess the quantity and nature of missing 
values among the 5,172 cases in the dataset, which led to a determination that the 
variable for annual income had the highest frequency of missing data, which affected 190 
cases. Because it is well documented that those with high income often do not report their 
annual income (Hurst & Pugsley, 2014; Moore & Welniak, 2000; Turrell, 2000), this 
variable could have been a source of error when conducting study analyses. My final 
decision was to remove the annual income group variable from the study analyses. The 
removal of annual income group likely did not limit the ability to incorporate the measure 
of socioeconomic status in multivariate analyses because the variable for education level 
served as a surrogate measure for annual income.  
Descriptive Characteristics 
I conducted univariate analyses to generate descriptive statistics for all 
participants in the study sample. The 4-year MEC sample weight was applied to the 
means and percentages for continuous and categorical variables, respectively. Most 
participants in this study were females (n = 2,646) and consisted of 50.9% of the study 
sample, while males accounted for 49.1% (n = 2,526). The average age of all participants 
was 49.9 (SD = 12.4) years old. Those identifying as non-Hispanic White were the largest 
racial segment of the study population and accounted for 72.2% (n = 2,494), followed by 
those identifying as Mexican or Hispanic at 12.9% (n = 1,551). Most participants were 
nonsmokers and accounted for 56.4% (n = 2, 863) of this group. Former smokers 
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consisted of 26.2% (n = 1,228) of participants, and current smokers accounted for 17.4% 
(n = 973).  
To assess if the study sample was representative of the general non-
institutionalized U.S. population, I compared the demographic proportions for the study 
sample against published data from the U.S. Census Bureau. While it was not possible to 
conduct statistical comparisons, the study sample appeared to reflect the general civilian 
non-institutionalized U.S. population. For example, among the general civilian non-
institutionalized U.S. population, 72.4%, 12.6%, 16.3%, and 9.1%, of people identify 
themselves as non-Hispanic White, non-Hispanic Black, Hispanic, and other races or 
multiracial, respectively (U.S. Census Bureau, 2011). These proportions aligned well 
with those of the participants in this study, with the exception of those who identified as 
Hispanic and other races or multiracial. People identified as Hispanic and other races or 
multiracial appeared to be slightly underrepresented by approximately 4%in this study, 
compared to the general U.S. population. The proportion of males and females in this 
study was also was similar to that of the U.S. non-institutionalized civilian population, 
which consisted of 49.2% males and 50.8% females (U.S. Census Bureau, 2011). 
Likewise, the proportion of current smokers in this study was similar to that of the 
general U.S. population, which is 19.3% (CDC, 2012b). Within the general U.S. non-
institutionalized population, the percentage of people who have attained the educational 
level of less than 9th grade, 9th-11th grade, high school grad/GED or equivalent, some 
college or AA degree, and college graduate or above is 5.2%, 7.6%, 31.2%, 26%, and 
29.9%, respectively (U.S. Census Bureau, 2011). In this study, those achieving an 
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education level of 9th-11th grade were overrepresented by 3.6%, while those with an 
education level of high school grad/GED or equivalent were underrepresented by 
approximately 8%. Despite slight discrepancies in education level, the proportional 
distributions in this study align with that of the broader U.S. population. Likewise, as 
shown in Table 5, the demographic parameters for the group of participants without 
COPD closely resembled that of the overall sample population. 
The group of participants with a spirometry-confirmed diagnosis of COPD 
consisted of 270 participants, which reflected a prevalence of 5.2%. The COPD 
prevalence among participants in this study was representative of the national COPD 
prevalence because 5% of U.S. adults are reported to have a diagnosis of COPD (CDC, 
2016). The majority of the participants with COPD were males (70.7%, n = 200), and 
females accounted for 29.3% (n = 70). The average age of participants in the COPD 
group was 58.6 (SD = 10.7) years old. Nonsmokers made up the minority of participants 
in the COPD subset at 24.8% (n = 59), while former smokers and current smokers 
accounted for the majority at 40.2% (n = 108) and 35.1% (n = 103), respectively. Table 5 
includes more detailed information on the distribution of demographic variables for the 





Demographic Data for Study Sample 




N = 5,172 
Non-COPD  
n = 4,902 
COPD  
n = 270 
p-value 
Age (years)     
Mean ± SD 49.9 ±12.4 49.4 ±12.3 58.6 ±10.7 < .001 
Min-max 30-79 30-79 30-79  
BMI     
Mean ± SD 29.1 ±6.4 29.2 ±6.5 27.1 ±4.8 < .001 
Min-max 13.2-81.3 14.2-81.3 13.2-46.2  
Education level (frequency [%])    < .001 
Less than 9th grade 613 (5.7) 593 (5.8) 20 (3.6)  
9-11th grade 786 (11.2) 741 (11.2) 45 (11.9)  
High school grad/GED or 
equivalent 
1174 (23) 1094 (22.6) 80 (30.2)  
Some college or AA degree 1400 (28.6) 1326 (28.6) 74 (28.7)  
College graduate or above 1192 (31.4) 1141 (31.8) 51 (25.7)  
Gender (frequency [%])    < .001 
Male 2526 (49.1) 2325 (47.8) 200 (70.7)  
Female 2646 (50.9) 2576 (52.2) 70 (29.3)  
Race/Ethnicity (frequency [%])    < .001 
Non-Hispanic White 2494 (72.2) 2300 (71.3) 194 (87.4)  
Non-Hispanic Black 944 (10) 905 (10.2) 39 (5.9)  
Mexican or Hispanic 1551 (12.9) 1521 (13.5) 30 (2.9)  
Other race or multiracial 183 (4.9) 176 (4.9) 7 (3.8)  
Smoking status (frequency [%])    < .001 
Nonsmoker 2863 (56.4) 2804 (58.2) 59 (24.8)  
Former smoker 1336 (26.2) 1228 (25.4) 108 (40.2)  
Current smoker 973 (17.4) 870 (16.4) 103 (35.1)  





To illustrate the dietary distribution for the sample, descriptive statistics for total 
daily flavonoid intake and dietary fiber intake are shown in Table 6 for all participants 
and among those with and without COPD. Table 6 includes weighted mean intake values, 
standard deviation, and minimum and maximum values to demonstrate the full scope of 
dietary variance for all cases and among those with and without COPD. The mean daily 
flavonoid and dietary fiber intake for all participants in the study sample was 249.3 
mg/day and 17.6 g/day, respectively. Among participants with COPD, the mean daily 
flavonoid and dietary fiber intake was 238.1 mg/day and 17.9 g/day. The data shown in 
Table 6 indicate that the flavonoid and dietary fiber intake among participants diagnosed 
with COPD differed significantly from participants who did not have COPD.  
Table 6 
Total Daily Flavonoid and Dietary Fiber Intake Data 
  Participant groups 
Variable 
All  




(n = 270) 
p-value 
Flavonoid intake (mg)      
      Mean ± SD 249.3 ± 393.8 249.9 ± 395.2 238.1 ± 369.7 < .001 
      Min-max .08-4938.60 .08-4938.60 1.0-4321.86  
Dietary fiber intake (g)     
      Mean ± SD 17.6 ± 8.7 17.6 ± 8.7 17.9 ± 9.1 < .001 
      Min-max .40-73.8 .40-73.8 2.3-64.2  
 
The main health outcome variables I assessed among participants with COPD 
included FEV1% predicted, CRP, and comorbidity burden. Therefore, descriptive 
statistics were generated to assess the distribution of these data within the COPD group. 
Table 7 shows frequencies and weighted percentages for comorbidity burden and values 
for measures of distribution for FEV1% predicted and CRP. As shown in Table 7, the 
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majority of participants (61.9%) in the COPD group had no comorbid diseases of interest 
in this study, while the rest of the participants (38.1%) in the COPD group had at least 
one comorbid disease.  
Table 7 
Comorbidity Burden, CRP, and FEV1% Predicted Data 
  Participant groups 
Variable 
All  




(n = 270) 
p-value 
Comorbidity burden (frequency [%])    < .001 
Level 0  3,158 (65.5%) 3,003 (65.7%) 155 (61.9%)  
Level 1 1,437 (26.6%) 1,358 (26.4%) 79 (29.4%)  
Level 2-3 577 (7.9%) 541 (7.9%) 36 (8.6%)  
CRP (mg/dL)     
Mean ± SD  .36 ± .69 .36 ± .69 .35 ± .77 < .001 
Min-max .01-18.01 .01-18.01  .01-6.73  
FEV1% predicted      
Mean ± SD .90 ± .15 .94 ± .12 .87 ± .16 < .001 
Min-max .30-1.29 .5-1.29 .30-1.29  
 
Descriptive statistics were generated to further explore the distribution of 
demographic parameters across comorbidity burden levels within the COPD group. As 
seen in Table 8, the average age of participants within each comorbidity burden level is 
higher for groups with a greater number of comorbid diseases. Specifically, the mean age 
among participants in comorbidity burden Level 0, Level 1, and Level 2-3 was found to 
be 55.4, 61.5, and 71.1 years old, respectively. Additional details regarding the 
distribution of other demographic parameters across comorbidity burden levels are shown 
in Table 8. Results related to the statistical significance of associations between each 
outcome variable and demographic parameters are presented in a review of bivariate 




Demographic Data Across Comorbidity Burden Levels 
 Comorbidity burden levels    
Variable 
Level 0 
(n = 155) 
Level 1  
(n = 79) 
Level 2-3 







Age (years)       
Mean ± SD 55.4 ±9.2 61.5 ±11.1 71.1 ±5.1 .418  < .001 
Min-max 30-79 33-79 59-79    
BMI       
Mean ± SD 26.3 ±4.5 28.0 ±4.7 28.4 ±4.7 .201  < .001 
Min-max 13.2-40.8 18.2-45.2 20.4-42.6    
Dietary fiber intake 
(g) 
      
       Mean ± SD 18.22 ±9.6 17.9 ±8.4 15.9 ±7.7 -.054  < .001 
       Min-max 2.3-64.2 2.6-41.1 2.4-33.1    
Education level 
(frequency [%]) 
    1647662.10 
(8) 
< .001 
Less than 9th 
grade 
11 (2.8) 4 (3.6) 4 (8.3)    




47 (33.7) 24 (24.5) 9 (28.3)    
Some college or 
AA degree 
46 (30.7) 20 (27.1) 6 (15.1)    
College graduate 
or above 
29 (24.6) 17 (29.8) 4 (21.8)    
Gender (frequency 
[%]) 
    140662.86  
(2) 
< .001 
Male 118 (73.5) 55 (65.1) 24 (74.5)    
Female 37 (26.5) 24 (34.9) 7 (25.5)    
Race/Ethnicity 
(frequency [%]) 





112 (87.6) 57 (88.8) 23 (82.8)    
Non-Hispanic 
Black 
18 (4.8) 14 (7.0) 5 (7.5)    
Mexican or 
Hispanic 
21 (3.4) 6 (1.8) 2 (2.7)    
Other race or 
multiracial 
4 (4.2) 2 (2.4) 1 (7.0)    
Smoking status 
(frequency [%]) 
    1415077.50 
(4) 
< .001 
Nonsmoker 33 (23.8) 18 (27.7) 7 (24.5)    
Former smoker 54 (37.1) 37 (43.7) 15 (49.5)    
Current smoker 68 (39.1) 24 (28.6) 9 (26.1)    
Note. Level 0 = no comorbid diseases, Level 1 = one comorbid disease, Level 2-3 = two or three 




I performed bivariate analyses between all potential confounding variables and 
each dependent variable for the study. I also performed bivariate analyses between all 
potential confounding variables and the independent variable for the study. As noted in 
Chapter 3, these bivariate analyses helped to determine if any potential confounding 
variables were significantly associated with both the independent and the dependent 
variables. All bivariate analyses involved using the 4-year MEC exam weight variable for 
the 2007-2010 NHANES dataset.  
Bivariate statistical procedures included chi-square tests, independent t tests, one-
way ANOVAs, Pearson correlations, and Spearman correlations. The assumptions for 
bivariate statistical analysis included random sampling from the population and 
independence of scores on variables between cases (Green & Salkind, 2011). Additional 
assumptions for chi-square included no expected empty cells, and independent t tests and 
ANOVAs also require normal distribution of data and homogeneity of variance (Green & 
Salkind, 2011). Results indicated variances might be unequal, which violated Levene’s 
tests for homogeneity. However, Levene’s test is sensitive to large sample sizes and 
identifies inconsequential differences in variances, and these statistical procedures show 
robustness even when the assumption is violated (Field, 2013; Green & Salkind, 2011; 
Lumley, Diehr, Emerson, & Chen, 2002). Therefore, I determined that proceeding with 
bivariate statistical procedures was acceptable.  
132 
 
Assessment of Potential Confounding Variables 
I assessed all potential confounding variables to determine if they were 
significantly associated with the independent variable (flavonoid intake) and the 
dependent variables (COPD, comorbidity burden, CRP and FEV1% predicted). I assessed 
associations between the potential confounding variables and COPD first. Next, I 
performed chi-square tests to assess the association between potential confounding 
categorical variables and COPD. All potential confounding categorical variables were 
significantly (p < .001) associated with COPD. I performed independent samples t-tests 
to determine the association between potential confounding continuous variables and 
COPD. The mean differences between participants with COPD and those without COPD 
were statistically significant (p < .001) for all potential confounding continuous variables. 
The details of these findings are presented in Table 5 and Table 6. 
Next, I assessed the association between FEV1% predicted and potential 
confounding variables using one-way ANOVAs and an independent samples t-test. One-
way ANOVAs were suitable to test the association between FEV1% predicted and 
potential confounding nominal variables with three or more categories. As shown in 
Table 9, results from the one-way ANOVAs indicated that education level, race/ethnicity, 
and smoking status were significantly (p < .001) associated with FEV1% predicted. 
Additionally, results of the independent samples t-test indicated that gender was also 




FEV1% Predicted and Potential Confounding Variables 





Age -.079    < .001 
BMI -.043    < .001 
Dietary fiber intake   .164    < .001 
Education level   94450.17  
(4, 2263483) 
 < .001 
Less than 9th grade  .90 (.14)    
9-11th grade  .87 (.19)    
High school grad/GED or 
equivalent 
 .88 (.16)    
Some college or AA degree  .90 (.15)    
College graduate or above  .94 (.12)    
Gender    157.51 
(8483173) 
< .001 
      Male  .90 (.15)    
      Female  .89 (.14)    
Race/ethnicity   69515.30  
(3, 975017) 
 < .001 
Non-Hispanic White  .90 (.15)    
Non-Hispanic Black  .87 (.15)    
Mexican or Hispanic  .95 (.14)    
Other race or multiracial  .98 (.15)    
Smoking status   537640.08  
(2, 6391513) 
 < .001 
Nonsmoker  .95 (.11)    
Former smoker  .90 (.15)    
Current smoker  .84 (.16)    
Note. N = 1572. 
 
I assessed the association between CRP and potential confounding variables using 
Pearson correlation tests, one-way ANOVAs, and an independent samples t-test. As 
shown in Table 10, results of the one-way ANOVAs indicated education level, 
race/ethnicity, and smoking status were significantly (p < .001) associated with CRP. 
Pearson correlation tests served to determine the association between potential 
confounding continuous variables and CRP. As seen in Table 10, results from the 
Pearson correlations indicated that age, BMI, and dietary fiber intake were significantly 
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(p < .001) associated with CRP. Likewise, results from the independent samples t-test 





CRP and Potential Confounding Variables 
Potential confounding 
variable 





Age -.004    < .001 
BMI .270    < .001 
Dietary fiber intake -.102    < .001 
Education level   166761.18  
(4, 25922321) 
 < .001 
Less than 9th grade  .47 (.81)    
9-11th grade  .45 (.91)    
High school grad/GED 
or equivalent 
 .38 (.71)    
Some college or AA 
degree 
 .37 (.68)    
College graduate or 
above 
 .29 (.56)    
Gender    816.05 
(96771400) 
< .001 
      Male  .30 (.69)    
      Female  .42 (.69)    
Race/ethnicity   172719.89  
(3, 13746286) 
 < .001 
Non-Hispanic White  .33 (.63)    
Non-Hispanic Black  .55 (.99)    
Mexican or Hispanic  .40 (.71)    
Other race or 
multiracial 
 .27 (.70)    
Smoking status   88497.75  
(2, 36642223) 
 < .001 
Nonsmoker  .34 (.62)    
Former smoker  .37 (.70)    
Current smoker  .43 (.87)    





Spearman correlation tests served to determine the association between potential 
confounding continuous variables and comorbidity burden. As seen in Table 8, results 
from the Spearman correlation tests indicated that age, BMI, and dietary fiber intake were 
significantly (p < .001) associated with comorbidity burden. I used chi-square tests to 
determine if a significant association was present between comorbidity burden and 
gender, education level, race/ethnicity, and smoking status. As shown in Table 8, results 
indicated that these variables were also significantly associated with comorbidity burden.  
I assessed the association between total daily flavonoid intake and potential 
confounding variables using Pearson correlation tests, one-way ANOVAs, and an 
independent samples t-test. As shown in Table 11, education level, race/ethnicity, and 
smoking status were significantly (p < .001) associated with total daily flavonoid intake. 
Pearson correlation tests served to determine the association between potential 
confounding continuous variables and total daily flavonoid intake. As seen in Table 11, 
age, BMI, and dietary fiber intake were also significantly (p < .001) associated with total 
daily flavonoid intake. Additionally, results from the independent samples t-test indicated 
that gender was significantly (p < .001) associated with total daily flavonoid intake as 
well.  
The results from all bivariate statistical procedures related to potential 
confounding variables indicated that all potential confounding variables were 
significantly associated with the independent variable and all dependent variables. The 
associations were statistically significant below the threshold of p < .15 for inclusion of 
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the confounding variables in multivariate analyses for hypothesis testing. Therefore, the 





Flavonoid Intake and Potentially Confounding Variables 
Potential confounding 
variable 





Age .027    < .001 
BMI -.026    < .001 
Dietary fiber intake .097    < .001 
Education level   512678.71 
(4, 30369183) 
 < .001 
Less than 9th grade  128.0 (234.1)    
9-11th grade  224.2 (412.9)    
High school grad/GED 
or equivalent 
 217.8 (362.1)    
Some college or AA 
degree 
 256.4 (409.8)    
College graduate or 
above 
 297.6 (410.2)    
Gender    158.77 
(97480558) 
< .001 
      Male  242.9 (416.3)    
      Female  255.4 (370.8)    
Race/ethnicity   984577.40 
(3, 16216058) 
 < .001 
Non-Hispanic White  268.6 (417.6)    
Non-Hispanic Black  187.2 (294.4)    
Mexican or Hispanic  143.5 (235.5)    
Other race or multiracial  369.1 (464.1)    
Smoking status   28550.53 
(2, 39731233) 
 < .001 
Nonsmoker  253.8 (378.1)    
Former smoker  234.8 (341.1)    
Current smoker  256.3 (502.1)    






Before proceeding with multivariate testing, I assessed total daily flavonoid intake 
and all confounding variables for collinearity using linear regression testing. The intent of 
the regression was to assess the collinearity statistics for tolerance and variance inflation 
factors (VIFs) for each variable. The utility of tolerance and VIF can be described using 

, which is used to represent the proportion of variance for the ith independent variable 
in relation to the other independent variables (Belsley, Kuh, & Welsch, 2005; O’Brien, 
2007). As such, the tolerance for each independent variable is determined by subtracting 
one from the proportion of variance shared with the other independent variables and is 
represented mathematically as 1-
. The resulting tolerance value is the proportion of 
variance for each independent variable that is unrelated to the other independent variables 
(Belsley et al., 2005; O’Brien, 2007). VIF is represented as 1/(1-
) because it is the 
reciprocal of tolerance (Belsley et al., 2005; O’Brien, 2007). Therefore, VIF is an 
indicator of the degree to which the estimated variance would be for the ith regression 
coefficient if the proportion of variance for the ith independent variable associated with 
the other independent variables was equal to zero (Belsley et al., 2005; O’Brien, 2007). 
More specifically, VIF indicates the inflation in the standard error of a given beta weight 
for a particular predictor variable that is attributable to collinearity. Taken together, 
tolerance and VIF provide a reasonable indication of collinearity among independent 
variables, with values greater than 10 for VIF or lower than .01 for tolerance indicating 
unacceptable degrees of collinearity (Belsley, 1991; Belsley et al., 2005; O’Brien, 2007; 
Hair, Anderson, Tatham, & Black, 1995; Tabachnick & Fidell, 2001). As shown in Table 
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12, all variables were below the threshold of concern for collinearity, with values greater 
than .01 for tolerance and less than 10 for VIF. Therefore, I included all predictor 
variables in the planned multivariate analyses, which included linear regression and 
logistic regression. All multivariate analyses included the 4-year MEC exam weight 
variable for the 2007-2010 NHANES dataset. 
Table 12 
Collinearity Statistics 
Variable Tolerance VIF 
BMI  .938 1.066 
Dietary fiber intake .859 1.165 
Education level    
9-11th grade .335 2.981 
High school grad/GED or equivalent .214 4.677 
Some college or AA degree .186 5.372 
College graduate or above .166 6.039 
Total daily flavonoid intake .946 1.057 
Gender .952 1.051 
Race/ethnicity   
Non-Hispanic Black .920 1.087 
Mexican or Hispanic .787 1.270 
Other race or multiracial .961 1.041 
Smoking status    
Former smoker .899 1.112 
Current smoker .799 1.252 
Note. VIF = variance inflation factor. 
 
RQ1 Results 
Testing the null hypothesis for RQ1 involved running two logistic regression 
models to assess the potential relationship between total daily flavonoid intake and an 
outcome of COPD. Model 1 consisted of conducting a simple logistic regression to 
investigate if total daily flavonoid intake was a significant predictor of COPD. This 
model explained little of the variance in COPD (Nagelkerke R2 = .0003), but correctly 
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classified 94.5% of cases. Total daily flavonoid intake was a statistically significant (p < 
.001) predictor of COPD in the logistic regression analysis. Results presented in Table 13 
indicate that for every 1% increase in total daily flavonoid intake, there was a 7.1% 
decrease (Exp [β] = 0.929, 95% CI [0.928, 0.930]) in the odds of having COPD. 
Table 13 
Logistic Regressions for Total Flavonoid Intake and COPD   
Model and predictors χ2 (df) R2 β (SE) OR (95% CI) p-value 
Model 1 107320.35 (8) .0003   < .001 
Total flavonoid intake   -.074 (.001) .929 (.928, .93) <.001 
Model 2 342302.12 (8) .2276    
Total flavonoid intake   -.061 (.001) .941 (.940, .943) <.001 
Age   .072 (< .001) 1.075 (1.075, 1.075) <.001 
BMI   -.071 (< .001) .931 (.930, .931) <.001 
Dietary fiber intake   .188 (.002) 1.207 (1.202, 1.211) <.001 
Education level      
Less than 9th grade   Ref.   
9-11th grade   .441 (.003) 1.554 (1.545, 1.562) <.001 
High school grad/GED or 
equivalent 
  .749 (.003) 2.116 (2.105, 2.127) <.001 
Some college or AA degree   536 (.003). 1.710 (1.701, .719) <.001 
College graduate or above   .335 (.003) 1.398 (1.390, 1.405) <.001 
Gender      
Female   Ref.   
Male   1.027 (.001) 2.794 (2.788, 2.80) <.001 
Race/ethnicity      
Non-Hispanic White   Ref.   
Non-Hispanic Black   -.712 (.002) .491 (.489, .493) <.001 
Mexican or Hispanic   -1.287 (.003) .276 (.275, .278) <.001 
Other Race or multiracial   -.248 (.002) .781 (.777, .784) <.001 
Smoking status      
Nonsmoker   Ref.   
Former smoker   .949 (.001) 2.584 (2.578, 2.590) <.001 
Current smoker   1.925(.001) 6.855 (6.837, 6.873) <.001 
Note. N = 270. 
 
Model 2 consisted of conducting a multiple logistic regression to control for 
confounding variables. Therefore, Model 2 was adjusted for potential confounding 
variables as previously described. The Hosmer-Lemeshow goodness-of-fit was 
significant (p < .05), which indicated that the model fit may not be ideal and the 
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interpretation should include some degree of caution. Results presented in Table 13 show 
that total daily flavonoid intake and all confounding predictor variables were statistically 
significant (p < .001) predictors of COPD. While controlling for all confounding 
variables in the logistic regression model, a 1% increase in total daily flavonoid intake 
resulted in a 5.9% decrease (Exp [β] = 0.941, 95% CI [0.940, 0.943]) in the odds of 
having COPD. Based on the results of both logistic regression models, the null 
hypothesis for RQ1 was rejected. 
RQ2 Results 
Analysis involved generating two linear regression models to investigate RQ2. 
Model 1 consisted of conducting a simple linear regression to investigate the potential 
relationship between total daily flavonoid intake and FEV1% predicted. As shown in 
Table 14, total daily flavonoid intake was significantly associated with COPD severity (β 
= .013, 95% CI [.013, .013], p < .001), such that for every 1% increase in total daily 
flavonoid intake, the FEV1% predicted increased by .00013. However, the model 
explained little of the variability (R2 = .002).  
Model 2 involved conducting a multiple linear regression to control for 
confounding variables. Therefore, Model 2 was adjusted for potential confounding 
variables as previously described. Results presented in Table 14 show that total daily 
flavonoid intake and all confounding predictor variables were statistically significant (p < 
.001) predictors of FEV1% predicted. The regression coefficient (β = .001, 95% CI [.001, 
.002], p < .001) associated with total daily flavonoid intake suggests that FEV1% 
predicted increases by .00001 for every 1% increase in total daily flavonoid intake. While 
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statistically significant, this regression coefficient was lower than that found in Model 1, 
which indicates a reduction in the utility of total daily flavonoid intake as a predictor of 
FEV1% predicted. Based on the results of both linear regression models, the null 
hypothesis for RQ2 was rejected.  
Table 14 
Linear Regressions for Total Flavonoid Intake and FEV1% Predicted 
Model and predictors R2 Β (SE) 95% CI  p-value 
Model 1 .002    
Total flavonoid intake  .013 (< .001) .013, .013 < .001 
Model 2 .214    
Total flavonoid intake  .001 (< .001) .001, .002 < .001 
Age  .0003 (< .001) .0003, .0003 < .001 
BMI  -.002 (< .001) -.002, -.002 < .001 
Dietary fiber intake  .087 (< .001) .086, .087 < .001 
Education level     
Less than 9th Grade  Ref.   
9-11th Grade  -.011 (< .001) -.012, -.010 < .001 
High school grad/GED or equivalent  .007 (< .001) .006, .007 < .001 
Some college or AA degree  .044 (< .001) .043, .044 < .001 
College graduate or above  .064 (< .001) .043, .044 < .001 
Gender     
Female  Ref.   
Male  .047 (< .001) .047, .047 < .001 
Race/ethnicity     
Non-Hispanic White  Ref.   
Non-Hispanic Black  -.003 (< .001) -.004, -.003 < .001 
Mexican or Hispanic  .024 (< .001) .024, .025 < .001 
Other race or multiracial  .024 (< .001) .023, .025 < .001 
Smoking status     
Nonsmoker  Ref.   
Former smoker  -.068 (< .001) -.068, -.068 < .001 
Current smoker  -.125 (< .001) -.126, -.125 < .001 
Note. N = 270. 
RQ3 Results 
Analysis also involved generating two linear regression models to investigate 
RQ3. Model 1 consisted of conducting a simple linear regression to investigate the 
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potential relationship between total daily flavonoid intake and CRP. Results presented in 
Table 15 show that total daily flavonoid intake was statistically significant (β = .036, 95% 
CI [.034, .038], p < .001) and indicated that a 1% increase in total daily flavonoid intake 
results in a 0.036% increase in CRP. However, the model explained little of the 
variability (R2 = .0003).  
Table 15 
Linear Regressions for Total Flavonoid Intake and CRP 
Model and predictors R2 Β (SE) 95% CI p-value 
Model 1 .0003    
Total flavonoid intake  .036 (.001) .034, .038 < .001 
Model 2 .186    
Total flavonoid intake  -.076 (.001) -.078, -.074 < .001 
Age  .012 (< .001) .012, .012 < .001 
BMI  .085 (< .001 .085, .085 < .001 
Dietary fiber intake  -.042 (.002) -.046, -.039 < .001 
Education level     
Less than 9th grade  Ref.   
9-11th grade  -.178 (.003) -.183, -.172 < .001 
High school grad/GED or equivalent  -.626 (.003) -.631, -.621 < .001 
Some college or AA degree  -.600 (.003) -.605, -.594 < .001 
College graduate or above  -.568 (.003) -.574, -.563 < .001 
Gender     
Female  Ref.   
Male  -.256 (.001) -.258, -.254 < .001 
Race/ethnicity     
Non-Hispanic White  Ref.   
Non-Hispanic Black  .225 (.002) .221, .229 < .001 
Mexican or Hispanic  .106 (.003) .101, .111 < .001 
Other race or multiracial  -.299 (.002) -.304, -.294 < .001 
Smoking status     
Nonsmoker  Ref.   
Former smoker  .147 (.001) .144, .149 < .001 
Current smoker  .526 (.001) .523, .529 < .001 
Note. N = 270. 
Model 2 consisted of conducting a multiple linear regression to control for 
confounding variables. Therefore, Model 2 was adjusted for potential confounding 
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variables as previously described. Results presented in Table 15 show that total daily 
flavonoid intake and all confounding predictor variables were statistically significant (p < 
.001) predictors of CRP. The regression coefficient (β = -.076, 95% CI [-.078, -.074], p < 
.001) associated with total daily flavonoid intake suggests a 1% increase in total daily 
flavonoid intake results in a 0.076% decrease in CRP. Also, by adjusting for the 
confounding variables, the direction of the association between total daily flavonoid 
intake and CRP changed from positive to negative. Based on the results of both linear 
regression models, the null hypothesis for RQ2 was rejected.  
RQ4 Results 
Investigating RQ4 involved performing a one-way ANOVA to determine if 
differences in total daily flavonoid intake were significant among participants in the 
COPD subset with different levels of comorbidity burden. Levene’s test for equality of 
variances indicated a violation of the assumption of homogeneity of variances (p < .05). 
Results from the one-way ANOVA indicated that total daily flavonoid intake was 
statistically significantly different for different levels of comorbidity burden, Welch's 
F(2, 1348601.11) = 55509.04, p < .001. Figure 3 shows the differences in mean flavonoid 
intake for the comorbidity burden Level 0 group (M = 201.7, SD = 308.5), Level 1 group 




Figure 3. Flavonoid intake across comorbidity burden levels.  
A Games-Howell post hoc analysis was suitable to explore the nature of the 
differences in total daily flavonoid intake between comorbidity burden levels. As seen in 
Table 16, results from the Games-Howell post hoc analysis revealed that the mean 
differences between each of the comorbidity burden levels were statistically significant (p 
< .001). Specifically, there was an increase in total daily flavonoid intake from the 
comorbidity burden Level 0 group to the Level 1 group. Additionally, a decrease in total 
daily flavonoid intake occurred from the comorbidity burden Level 0 group to the Level 2 
and 3 group. A decrease in total daily flavonoid intake also occurred from the 
comorbidity burden Level 1 group to the Level 2 and 3 group. Taken together, the results 
of the one-way ANOVA and associated post hoc analysis indicated that the group means 





Total Flavonoid Intake Between Comorbidity Burden Levels 
Comorbidity burden levels Mean difference SE 95% CI  p-value 
Level 0 and Level 1  130.31 .42 129.35, 131.30 < .001 
Level 0 and Level 2-3   -22.43 .39 -23.34, -21.52 < .001 
Level 1 and Level 2-3 -152.76 .52 -153.97, -151.54 < .001 
Note. N = 270. 
Summary 
This chapter included the results from the secondary analysis of data from the 
2007–2010 NHANES and USDA flavonoid databases. Preparation of the data for 
analysis resulted in several modifications and adjustments, which included revisions to 
the study inclusion criteria, key study variables, and planned statistical procedures used to 
test RQ4. Bivariate analyses indicated that all potentially confounding variables were true 
confounders, as they were each statistically significantly (p < .001) associated with total 
flavonoid intake and each dependent variable. Subsequently, I evaluated all confounding 
variables for collinearity. Results of collinearity testing revealed that all confounding 
variables were suitable for inclusion in multivariate analysis as covariates. 
The results from the multivariate analyses addressed RQ1, RQ2, and RQ3, and 
the result from a one-way ANOVA addressed RQ4. Results from the logistic regressions 
addressing RQ1 indicated that total flavonoid intake was a statistically significant 
predictor of COPD. Results from the linear regressions used to address RQ2 and RQ3 
indicated that total flavonoid intake was a significant (p < .001) predictor of FEV1% 
predicted and CRP, respectively. Results from the one-way ANOVA used to address 
RQ4 showed a significant (p < .001) difference in total daily flavonoid intake for 
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different levels of comorbidity burden among participants with COPD. Based on these 
results, I rejected the null hypothesis for all research questions. 
In Chapter 5, I provide an interpretation and comparison of the results from this 
study with those of other studies. I also include a review of the strengths and limitations 
of the current study, as well as recommendations for future research. Furthermore, the 
next chapter contains a discussion of the results of the study as they relate to influencing 





Chapter 5: Discussions, Conclusions, and Recommendations 
The purpose of this cross-sectional secondary analysis of the 2007-2010 
NHANES dataset was to explore the potential association between total daily flavonoid 
intake and COPD, COPD severity, CRP, and comorbidity among U.S adults aged 30 
years and older. These analyses indicated that total daily flavonoid intake was a 
significant predictor of COPD. Also, I determined that total daily flavonoid intake was a 
significant predictor of FEV1% predicted and CRP. The inclusion of confounding 
variables in multiple regression models was critical in identifying the true effect of total 
daily flavonoid intake on the dependent variables. In fact, results varied substantially 
between simple and multiple regression models. Also, total daily flavonoid intake was 
significantly associated with comorbidity burden level among participants in this study. 
This chapter includes an interpretation of these findings to further address each research 
question. Additionally, I review study limitations, offer recommendations for future 
research, discuss implications for social change, and provide conclusions.  
Interpretation of the Findings 
Flavonoid Intake and COPD 
My exploration of the relationship between total daily flavonoid intake and COPD 
in this study expanded upon the findings of other researchers. In this study, I examined 
total flavonoid intake, which was measured as the sum of six flavonoid subclasses, and 
spirometry-confirmed COPD diagnosis. Researchers who previously studied the 
association between flavonoid intake and COPD were restricted in the ability to use 
direct measures for flavonoids and COPD in a single study. Some researchers who 
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measured flavonoid content directly were limited to assessments of lung function and 
symptoms of COPD, while other researchers who directly measured COPD diagnosis 
were restricted to indirect surrogate assessments of flavonoid content (Butland et al., 
2000; Celik & Topcu, 2006; Tabak et al., 2001). Despite these limitations, the authors of 
previous studies consistently demonstrated that higher intake of flavonoids or foods high 
in flavonoid content was associated with not having COPD or with having favorable 
measures of lung function and decreased COPD symptoms (Butland et al., 2000; Celik & 
Topcu, 2006; Tabak et al., 2001). The results from my study support these findings by 
demonstrating that a statistically significant relationship is present between flavonoid 
intake and COPD. Specifically, results from the bivariate analysis in the present study 
indicated that those without COPD had a significantly higher average total daily 
flavonoid intake of 11.80 mg/day (p < .001) than those who had COPD.  
When examining the unadjusted simple logistic regression analysis of total daily 
flavonoid intake and COPD, I found that total daily flavonoid intake was a statistically 
significant (p < .001) predictor of COPD. When the regression model was adjusted to 
control for confounding variables, I found that total daily flavonoid intake remained a 
statistically significant (p < .001) predictor of COPD despite a slight reduction in the 
odds ratio from 7.1% to 5.9%. As such, I found that higher total daily flavonoid intake 
was significantly associated with lower odds of having COPD. Other researchers have 
also reported inverse associations between flavonoids or foods high in flavonoid content 
and COPD or COPD symptoms (Celik & Topcu, 2006; Tabak et al., 2001). For example, 
catechin, flavonol, and flavone intake is inversely associated with the odds of developing 
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chronic cough (ORQ5-Q1 = 0.80) and dyspnea (ORQ5-Q1 = 0.74), which are common 
symptoms of COPD (Tabak et al., 2001). Also, the intake of flavonoid-rich beverages 
and foods, such as black tea, fruits, and vegetables is significantly lower among male 
smokers with COPD compared to healthy male smokers without COPD (Celik & Topcu, 
2006). As previously mentioned, this is the first study to directly explore the relationship 
between total daily flavonoid intake and COPD, as diagnosed by spirometry, in a large 
sample of adult males and females within the United States. Therefore, results from the 
RQ1 analyses have served to further the understanding of this association.  
Flavonoid Intake and COPD Severity  
My examination of the association between total daily flavonoid intake and 
COPD severity, as measured by FEV1% predicted, showed a weak but significant 
positive correlation between total daily flavonoid intake and FEV1% predicted. This 
result aligns with findings from other researchers who reported positive associations 
between flavonoids or foods with high flavonoid content and measures of lung function 
(Butland et al., 2000; Tabak et al., 2001). For example, higher intake of catechins, 
flavonols, flavones, and apples, which are known to have high levels of the flavonoid 
quercetin, are associated with higher FEV1 (Butland et al., 2000; Tabak et al., 2001). 
However, these observations are derived from examining only a few flavonoid subclasses 
or surrogate measures of flavonoid intake and no direct assessment of FEV1% predicted. 
This is the first study to directly explore the correlation between total daily flavonoid 




I also found total daily flavonoid intake to be a significant (p < .001) predictor of 
FEV1% predicted in both simple and adjusted regression models. However, the 
regression coefficient (β = .001) from the multivariate model reflected a nearly zero 
effect. Specifically, a 1% increase in total daily flavonoid intake resulted in only a 
0.00001 increase in FEV1% predicted. Other antioxidant vitamins have also been found 
to be significant predictors of FEV1% predicted, with effect sizes larger than that found in 
this study (Ochs-Balcom et al., 2006; Schünemann et al., 2001; Schünemann et al., 2002). 
For example, lutein/zeaxanthin, vitamin C, and vitamin E are all significant predictors of 
FEV1% predicted, with linear regression coefficients of approximately 1.00 or greater 
(Ochs-Balcom et al., 2006; Schünemann et al., 2001; Schünemann et al., 2002). 
Additionally, beta-cryptoxanthin, beta-carotene, and lycopene are also significant 
predictors of FEV1% predicted, with linear regression coefficients of 5.16, 5.10, 6.33, and 
4.28, respectively (Ochs-Balcom et al., 2006). As such, total daily flavonoid intake may 
not be a meaningful predictor of FEV1% predicted. Nevertheless, despite the minimal 
effect size observed in this study for total flavonoid intake as a predictor of FEV1% 
predicted, this result still serves to address the gap in the literature regarding this topic. 
Flavonoid Intake and Systemic Inflammation  
Results from this study showed a significant negative correlation between total 
daily flavonoid intake and CRP. Furthermore, I found total daily flavonoid intake to be a 
significant (p < .001) predictor of CRP. The absolute magnitude of the effect size for total 
daily flavonoid intake increased considerably in the adjusted regression model (β = -
0.076) compared to the unadjusted model (β = 0.036). The association between total daily 
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flavonoid intake and systemic inflammation, as measured by CRP, within a COPD 
population is understudied. However, this finding from my study aligns well with 
observations reported by other researchers (Chun, Chung, Claycombe, & Song, 2008; 
Corely et al., 2015; Landberg et al. 2011). For instance, a negative linear trend in serum 
CRP concentrations has been identified between tertiles of flavonoid intake (Chun et al., 
2008). Likewise, higher intake of flavonoid rich-foods like grapefruit, total fruit, and 
apples is significantly associated with lower levels of serum CRP (Corely et al, 2015; 
Landberg et al., 2011). Furthermore, relatively large effect sizes have been reported for 
apples (β = -0.456) and total fruit (β = -0.100) as significant predictors of CRP (Corely et 
al., 2015). However, the magnitude of this effect may reflect the combined effect of other 
favorable compounds found in fruits, such as vitamin A, vitamin C, and fiber, but further 
studies are needed to confirm this assertion (Corely et al., 2015). Given these nuances, 
the effect size for the association between total daily flavonoid intake and CRP in the 
present study appears to be a more accurate measure of this relationship compared to 
surrogate measures using apples and total fruit.  
In contrast with previous findings, individual flavonoid sub-classes (Catechins, 
Flavanones, Flavones, Flavonols, and, Proanthocyanidins) have also been reported as 
non-significant predictors of CRP, but within a non-COPD population (Corley et al., 
2015). This conflicting finding is attributed to variations in estimates of flavonoid intake 
derived from the use of a UK flavonoid database (Kyle & Duthrie, 2006) having 
flavonoid values for only 386 food items (Corely et al., 2015). Therefore, it is possible 
that intake of these five flavonoid subclasses may have been underestimated. In contrast, 
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I used the USDA flavonoid database, which is the most comprehensive source of 
flavonoid values for over 2,900 food items (USDA, 2016). Therefore, this study may 
offer a more precise estimate of the relationship between total daily flavonoid intake and 
CRP, particularly among those with COPD. 
Other significant predictors of CRP include total fiber, insoluble fiber, total 
polyunsaturated fatty acids (PUFAs), and omega-6 PUFAs (Muka et al., 2015; Villaseñor 
et al., 2011). The effect sizes reported by researchers (Muka et al., 2015; Villaseñor et al., 
2011) for total fiber (β = -0.029), insoluble fiber (β = -0.039), PUFAs (β = -0.03), and 
omega-6 PUFAs (β = -0.03) were relatively small compared to the effect size I found in 
my study for total daily flavonoid intake (β = -0.076). As such, total daily flavonoid 
intake may be a stronger predictor of COPD than fiber or PUFAs. However, the reported 
effects of fiber and PUFAs on CRP were observed within a non-COPD population that 
included either female cancer patients (Villaseñor et al., 2011) or Dutch nationals aged 55 
years or older (Muka et al., 2015). Nevertheless, these findings in the literature (Muka et 
al., 2015; Villaseñor et al., 2011) align with the results of my study in supporting the 
premise that diet is associated with CRP. Ultimately, my study serves to clarify the 
relationship between total daily flavonoid intake and CRP among Americans with COPD. 
Given the limited research on this topic, further studies are needed to replicate and 
confirm these findings from my study.  
Flavonoid Intake and Comorbidity Burden 
Comorbidity among those with COPD is a common occurrence, with most COPD 
patients having at least one comorbid disease (Dal Negro, Bonadiman, & Turco, 2015; 
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Divo et al., 2012; Putcha et al., 2013). However, comorbid diseases occurring in those 
with COPD are posited to be an extension of the systemic inflammatory nature of COPD 
(Agusti & Faner, 2012; Divo et al., 2012; Smith & Wrobel, 2014). Therefore, I performed 
analyses for RQ4 to explore the relationship between total daily flavonoid intake and 
comorbidity burden consisting of an accumulation of cardiovascular disease, diabetes, 
and hypertension. Through these analyses, I found that the total daily flavonoid intake 
was significantly (p < .001) different for each comorbidity burden group. Furthermore, I 
found the mean flavonoid intake for the comorbidity burden Level 0 group to be 
significantly (p < .001) lower than that of the comorbidity burden Level 1 group. While 
this finding was unexpected, it may be reflective of dietary changes made after receiving 
counseling for self-care following diagnosis of any one of the comorbid diseases included 
in the current study. Current counseling recommendations for managing cardiovascular 
disease, diabetes, and hypertension call for increased dietary intake of fruits and 
vegetables as a core self-care component (American Association of Diabetes Educators, 
2009; Eckel et al., 2014; Evert et al., 2013; Weber et al., 2014). However, given the 
cross-sectional study design used in these analyses, identifying the direction of 
association between total daily flavonoid intake and the accumulation of comorbid 
diseases is not within the scope of this study. Longitudinal studies are recommended to 
further elucidate the nature of the association identified in this study. 
I also found that the mean flavonoid intake for those with two or three comorbid 
diseases was significantly (p < .001) lower than those with one or no comorbid disease. 
This particular discovery is consistent with previous findings by other researchers who 
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show higher fruit and vegetable intake is significantly associated with a lower risk of 
multimorbidity (Ruel et al., 2014; Wikström, Lindström, Harald, Peltonen, & 
Laatikainen, 2015). In fact, those having less than three to five servings of fruit and 
vegetables each week are more likely (HR = 1.75, 95% CI [1.16 – 2.66]) to develop two 
or more comorbid diseases within a 10-year period compared to those with higher fruit 
and vegetable intake (Wikström et al., 2015). As previously mentioned, this study is the 
first to examine the relationship between total daily flavonoid intake and the comorbidity 
burden of cardiovascular disease, diabetes, and hypertension among Americans with 
COPD. Therefore, the results from this study support previous work and broaden the 
literature with respect to populations with COPD. However, additional studies with larger 
samples of COPD participants are needed to further explore the relationship between total 
daily flavonoid intake and comorbidity burden using multivariate analysis. 
Theoretical Framework 
I used the advanced model of the epidemiology triangle as a guide to explore the 
relationship between total daily flavonoid intake and COPD, COPD severity, systemic 
inflammation, and comorbidity burden. The advanced model of the epidemiology triangle 
places emphasis on the interaction between multiple causative factors, the group or 
population and their characteristics, and the environment over time to bring about the 
onset of chronic diseases (Merrill, 2009). Using this theoretical framework as a guide, I 
carefully selected all study variables based on their relevance to the components of the 
model. Specifically, the variable for smoking status represented a causative factor, and 
the population’s characteristics were represented by socioeconomic and demographic 
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variables. Additionally, the environmental component of the model was represented 
indirectly by dietary fiber intake and total daily flavonoid intake. The advanced model of 
the epidemiology triangle was proven effective in my study because I found all 
covariates, which represented key components of the theoretical framework, to be 
statistically significant predictors during multivariate analyses. Furthermore, the inclusion 
of these variables increased the predictive utility of each multiple regression model 
considerably from nearly zero percent to 23%, 21.4%, and 18.6% for RQ1, RQ2, and 
RQ3, respectively. Ultimately, the advanced model of the epidemiology triangle proved 
effective in guiding my design and execution of this study and served to elucidate the 
relationships between total daily flavonoid intake and COPD, COPD severity measured 
by FEV1% predicted, CRP, and comorbidity burden.  
Limitations of the Study 
This research was subject to several limitations that have some bearing on the 
interpretation of study results. The primary limitation of this study was the lack of long-
term dietary information due to limitations of the 24-hour dietary recall instrument and 
the cross-sectional nature of the study design. Specifically, it is uncertain if dietary intake 
reported in the 24-hour dietary recall is reflective of dietary habits prior to the onset of 
COPD or if dietary changes were initiated after diagnosis. Therefore, I could not identify 
temporal relationships or make causal inferences because the study design was limited to 
observational identification of associations between variables of interest at a cross-section 
in time. However, it is plausible that flavonoid intake could be responsible for the 
variability in the dependent variables of the study because long-term dietary habits have 
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been found to be consistent with findings from the 24-hour dietary recalls (Bertoia et al., 
2015). Ultimately, the results of this study should be interpreted with caution, given the 
aforementioned limitation. 
Another limitation of this study was the lack of data for other measures of 
systemic inflammation, such as interleukins 6 (IL-6) and 8 (IL-8), and tumor necrosis 
factor-alpha (TNF-α) to more fully address RQ3. However, CRP has been well 
established as an acceptable measure of systemic inflammation among those with COPD 
(Baldrick et al., 2012). Furthermore, CRP can be used as a surrogate measure for IL-6 
because CRP is induced in the body by IL-6 through the involvement of mechanisms 
related to NF-κB (Agrawal, Samols, & Kushner, 2003; Maehira, Miyagi, & Eguchi, 
2003). However, regardless of this relationship, additional measures of systemic 
inflammation could not be directly assessed due to limitations of the available data within 
the 2007-2010 NHANES dataset. Therefore, the results of this study only serve to 
elucidate the relationship between total daily flavonoid intake and one measure of 
systemic inflammation. Furthermore, given this limitation, it was not possible to 
conclusively assert that there is a relationship between total daily flavonoid intake and 
systemic inflammation. 
Sample size in the COPD subgroup was also a limitation of the study with regard 
to fully addressing RQ4. As mentioned, it was not possible to perform logistic regression 
to explore the relationship between total daily flavonoid intake and comorbidity burden 
due to the small sample size of the COPD subgroup. Therefore, my investigation of the 
relationship between total daily flavonoid intake and comorbidity burden was limited to 
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bivariate analysis. The small sample size resulted in an insufficient number of 
participants who had three comorbid diseases. Therefore, I combined participants with 
three comorbid diseases into the same group as those who had two comorbid diseases. By 
combining these participants into the same group, it was not possible to assess 
associations with flavonoid intake among those with three comorbid diseases in relation 
to participants with other comorbidity burden levels. Although I found statistically 
significant differences in mean total daily flavonoid intake between the comorbidity 
burden level groups, it is unclear if a predictive relationship exists between these two 
variables. The inability to perform multivariate analyses restricted my further 
examination of the relationship between total daily flavonoid intake and comorbidity 
burden.  
While the USDA flavonoid databases are a robust source of flavonoid content, 
several limitations related to the composition of the flavonoid data within the database 
should be acknowledged. For instance, analytical values were not determined for all 
foods in the database. Instead, researchers at the USDA imputed flavonoid values for 
approximately 24% of the values in the database using flavonoid data from foods that 
were similar in botanical origin (USDA, 2016). Therefore, the volume of analytical 
values within the USDA flavonoid database was limited, and may affect the precision of 
the flavonoid content of some foods within the database. Also, USDA researchers 
assigned a zero value for isoflavone content in some foods for which a non-zero 
isoflavone value was available. Zero values were assigned only when the isoflavones in a 
food item was attributable to an ingredient that may or may not be present in a food type. 
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For example, USDA researchers noted that two different brands of hot dogs have the 
same FNDDS code, but one brand may include isoflavone ingredients, like soy, and the 
other brand does not (USDA, 2016). Therefore, all food items within a given food type, 
such as hot dogs, that met this criterion were assigned a zero isoflavone value. Taken 
together, the limitations attributed to the compilation of the USDA flavonoid database 
may have resulted in an underestimation of total daily flavonoid intake in the present 
study.  
Another limitation of this study was that I did not account for variations in the 
bioavailability of flavonoid intake attributable to interactions with other food 
components. The absorption of flavonoids can be affected by food matrix components, 
such as dietary fat, fiber, and protein (Lesser, Cermak, & Wolffram, 2014; Mullen et al., 
2009; Ortega, Reguant, Romero, Macià, & Motilva, 2009; Probert, Emmett, & Heaton, 
1995). Dietary fat may enhance the digestibility and absorption of flavonoids within the 
small intestine (Lesser et al., 2014; Ortega et al., 2009). This effect is attributed to 
physiological interactions between dietary fat and flavonoids that result in prolonged 
transit time within digestive tract (Rao, Lu, & Schulze-Delrieu, 1996). Dietary fiber also 
impacts the duration of transit time for flavonoids in the gut, with insoluble fiber 
decreasing transit time and soluble fiber increasing transit time (Probert et al., 1995). As 
such, a reduction in transit time within the digestive tract is thought to be associated with 
a lower bioavailability of flavonoids, as observed with various pharmaceuticals (Kimura 
& Higaki, 2002). Furthermore, fermentable fibers, such as inulin and fructo-
oligosaccharides, act as prebiotics in animals and humans by increasing the microbiota 
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fermentation of flavonoids, which enhances the bioavailability of flavonoid aglycones 
and metabolites (Larkin, Price, & Astheimer, 2007; Piazza et al., 2007; Tamura, 
Nakagawa, Tsushida, Hirayama, & Itoth, 2007; Uehara et al., 2001). Proteins, on the 
other hand, such as those found in milk, appear to reduce the bioavailability of flavonoids 
(Mullen et al., 2009; Roowi, Mullen, Edwards, & Crozier, 2009; Serafini et al., 2009). 
For instance, consuming cocoa with milk results in reduced plasma concentrations of the 
flavan-3-ols by 25% and increased urine concentration of the same by 50% compared 
with consuming cocoa with water (Mullen et al., 2009). Similar findings were observed 
for blueberries consumed with and without milk and when orange juice was consumed 
with and without yogurt (Roowi et al., 2009; Serafini et al., 2009). These effects are 
suggested to reflect flavonoid-protein interactions that form bonds and complexes, which 
inhibit the uptake of flavonoids in the digestive tract and reduce bioavailability (Upri-
Sarda et al., 2010). Despite these food matrix effects on flavonoid bioavailability, the 
assessment of individual flavonoid sub-classes and food matrix composition in relation to 
COPD outcomes were beyond the scope of this study. As such, it may be of interest to 
explore the impact of individual flavonoid subclasses on COPD outcomes in future 
studies, as some flavonoid sub-classes offer more bioavailability than others. 
Recommendations for Further Research 
Results obtained from this study support assertions found in the literature that diet 
is associated with COPD outcomes. This study adds to the body of knowledge about the 
relationship between total daily flavonoid intake and COPD, COPD severity as measured 
by FEV1% predicted, systemic inflammation as measured by CRP, and comorbidity 
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burden consisting of cardiovascular disease, diabetes, and hypertension. However, due to 
the limitations noted above, further research in this area is warranted.  
Given the significant associations between total daily flavonoid intake and COPD 
outcomes of interest in this study, I recommend the use of prospective longitudinal study 
designs for future research to determine temporal relationships between variables. 
Ideally, dietary intake should be monitored and recorded multiple times each year over 
approximately 20 years or longer before diagnosis of COPD. Such a study would increase 
the likelihood of potentially identifying a temporal relationship between total daily 
flavonoid intake and odds of having COPD. In parallel, a similar design should be 
utilized with an observational period beginning at the time of COPD diagnosis and 
lasting for 10 to 20 years or longer. This additional recommendation targets identification 
of a potentially temporal relationship between flavonoid intake and COPD severity, 
systemic inflammation, or comorbidity burden among those with COPD. In addition to 
multiple collections of dietary data each year, measurements for spirometry and serum 
biomarkers for systemic inflammation should also be collected at similar time points 
along with medical records to identify the onset of comorbid diseases. Ample participants 
with COPD must be enrolled in future studies to overcome the sample size limitations 
noted in this study. For instance, if this study is replicated, I recommended that three or 
more NHANES datasets be combined to create a larger sample size with an increased 
number of participants with COPD. As previously mentioned, the associations between 
total daily flavonoid intake and COPD outcomes are understudied, and further research 
involving those with COPD is warranted. 
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Alternative study design recommendations for future research would entail 
utilization of a case-control or retrospective cohort research methodology. Use of these 
research design methods would improve the ability to make temporal assessments 
regarding total daily flavonoid intake and COPD outcomes. Furthermore, utilization of 
these alternative study design methodologies for future research may be more cost-
effective and less time consuming compared to the longitudinal study design proposed 
earlier.  
Future research should also incorporate more extensive flavonoid content data for 
an even greater number of foods. Such an approach would serve to increase the precision 
of flavonoid estimates for the study population. While the USDA flavonoid databases are 
the most comprehensive source of flavonoid content data, they are not exhaustive. 
Therefore, future research should entail combining the USDA flavonoid databases with 
other flavonoid data sources to expand flavonoid content information beyond what was 
available in the present study. The European BioActive Substances in Food Information 
System (eBASIS) database may serve as a viable adjunct to the USDA flavonoid 
databases because it has been successfully utilized to provide flavonoid content for other 
research studies (Euorpean Food Information Resource, 2015; Pounis et al., 2015; 
Samieri et al., 2014). Future versions of the USDA flavonoid databases and the eBASIS 
database may provide increased flavonoid content to provide more accurate estimates of 
flavonoid intake for an even greater number of foods. Therefore, future research should 
include the use of the most current version of these or other available databases and to 
combine them when possible.  
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A final recommendation for future research is to further examine the effect of 
individual flavonoid subclasses on COPD, COPD severity, systemic inflammation, and 
comorbidity. Individual flavonoid subclasses offer greater bioavailability than others, 
which reflect variations in the ability of each subclass to enact antioxidant and anti-
inflammatory properties throughout the body. Isoflavones seem to have the most 
bioavailability after being consumed, while flavan-3-ols and anthocyanidins are the most 
poorly absorbed (Barnes et al., 2011; Kumar & Pandey, 2013a; Manach, Williamson, 
Morand, Scalbert, & Remesy, 2005). As such, I recommended that considerations for the 
effects of dietary composition on the bioavailability of flavonoids are incorporated in 
future research. As described above, some dietary constituents increase the bioavailability 
of flavonoids while others reduce bioavailability. Therefore, it would be of interest to 
examine the potential relationship between each flavonoid subclass and COPD, COPD 
severity, systemic inflammation, and comorbidity burden to accounting for variations in 
bioavailability of each flavonoid subclass. Furthermore, it is recommended to stratify the 
study population by high and low intake of dietary fat, soluble and insoluble fiber, and 
proteins to account for potential effects on flavonoid bioavailability. Taken together, 
these recommendations are provided to further expand the understanding of the 
relationship between flavonoid intake and COPD, which can serve to inform public 
health policy and effect positive social change.  
Implications for Social Change 
The results obtained from this study offer some implications for social change by 
potentially improving population-based health outcomes. The literature indicates that a 
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healthy diet high in fruits and vegetables plays a substantial role in the development of a 
wide range of chronic diseases, including COPD (Boeing et al., 2012; Chiuve et al., 
2012; Li et al., 2014; Mekary, 2015). However, most Americans consume insufficient 
servings of fruits and vegetables to meet recommendations for maintaining a healthy diet 
(Slavin & Lloyd, 2012). Findings from this study show that higher intake of dietary 
flavonoids may have a substantial effect on COPD, systemic inflammation, and the 
accumulation of multiple comorbid diseases. These results can be used by public health 
advocates to inform public health policy and support recommendations and national goals 
for nutrition, such as the Healthy People 2020 objectives that call for greater fruit and 
vegetable intake (Healthy People, 2017). Also, it is likely that maintaining a healthy diet 
is also indicative of other positive lifestyle behaviors that improve overall health, such as 
abstaining from smoking or smoking cessation. Smoking is associated with several poor 
health outcomes in addition to COPD, such as lung cancer, heart disease, and stroke 
(Thun et al., 2013). In this study, I found that smoking status was the strongest predictor 
of COPD, COPD severity, and systemic inflammation, with non-smokers having more 
favorable outcomes than current and former smokers. Therefore, another implication for 
social change derived from the results of this study is the added scientific support for 
current initiatives that target smoking cessation and reductions in second-hand smoke 
exposure.  
COPD is the third leading cause of death within the United States and is 
responsible for millions of hospitalizations annually (ALA, 2014; CDC, 2012a). 
Therefore, COPD is a major public health concern within the United States that requires 
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evidence-based interventions informed by scientific research to reduce the mortality and 
morbidity associated with this disease. Ultimately, the results from this study have 
implications for effecting social change in this regard. Findings from this study can serve 
to inform public health policies that may help to reduce the morbidity and mortality of 
COPD and other comorbid diseases within the United States. 
Conclusions 
The results of this study further elucidated the relationship between dietary 
flavonoid intake and COPD among a broad sample of the US population. Results from 
multivariate regression analyses indicated that greater total daily flavonoid intake was 
associated with a reduced likelihood of COPD, a slight increase in FEV1% predicted, and 
decreased serum CRP concentrations. The relationship between total daily flavonoid 
intake and FEV1% predicted was very small, and not practically significant, given the 
small magnitude of change in FEV1% predicted that was observed in this study. Results 
from a one-way ANOVA indicated that statistically significant differences in mean total 
daily flavonoid intake were present between all comorbidity burden level groups. These 
results showed that the mean total daily flavonoid intake among those with two or three 
comorbid diseases was lower than among those with one comorbid disease or none. The 
findings from the present study have implications for promoting healthy dietary behavior 
and an overall healthy lifestyle among people in the United States. Subsequently, changes 
in dietary behavior and lifestyle choices can ultimately help to reduce the morbidity and 
mortality associated with COPD and other chronic diseases.  
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While this study has further elucidated the relationship between dietary flavonoid 
intake and FEV1% predicted, CRP, and comorbidity burden outcomes, identifying 
temporal relationships or causation outside the scope of this study because I used a cross-
sectional study design. Therefore, further research is recommended using prospective 
longitudinal study designs to fully explore the associations identified in this study and 
potentially identify temporal relationships and establish causation. Taken together, the 
results from this study, along with those of prior and future studies, can serve to inform 
public health policy and effect positive social change with regard to reducing the 
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